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ABBREVIATIONS
AB/PAS alcian blue/periodic acid Schiff
bp base pairs
BPV bovine papillomavirus
CLF cell loss factor
DDW deionised distilled water
DMSO dimethyl sulphoxide
DNA deoxyribose nucleic acid
E early viral gene
EDTA ethylene diamine tetra-acetate
EGTA ethylene glycol-bis-(B-amino ethyl
ether) N, N' tetra-acetate
G418 geneticin
GMEM Glasgow modification of minimum
eagles medium
HPV human papillomavirus





L late viral gene
mRNA messenger RNA
OD optical density
PBS phosphate buffered saline
PV papillomavirus
RNA ribonucleic acid
rpm revolutions per minute
6
SDS sodium dodecyl sulphate
SSC standard sodium citrate
SV4 0 Simian virus 40
TBE tris borate EDTA
TE tris EDTA
TGF transforming growth factor
TPA 12-O-Tetradecanoyl phorbol-13-
acetate
quantitative abbreviations (eg L, ml, M, uM
etc), chemical abbreviations (eg ATP, Ca2+, etc) , and
single letter amino acid code have also been used.
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ABSTRACT
The role of HPV genomes in human cervical neoplasia was
re-examined using a new, sensitive PCR-based assay. This
demonstrated increasing HPV prevalence with increasing
grade of histological abnormality in cervical neoplasia.
In contrast, HPV was not observed in histologically
normal epithelium from a control group of women defined
without reference to attendance at clinics for
gynaecological or sexually transmitted disease. HPV 16
was associated more with squamous cell carcinomas, and
HPV 18 with cancers showing glandular differentiation -
the histological type with a poorer prognosis. HPV 18
had higher CANCER/CIN prevalence ratios than HPV 16,
indicative of a more rapid transition from CIN to
carcinoma. Thus, HPV 18 appeared to be a more aggressive
type than HPV 16.
A rodent fibroblast model was developed to investigate
the effects of HPVs and the myc and ras oncogenes on
tumour cell apoptosis and growth rate. These genes were
introduced into immortalised fibroblasts, which were
studied both in vitro and in vivo. Regardless of the
introduced genes, fibroblast proliferation in vitro
differed little between the resulting cell lines. In
contrast, the rates of cell death (which was uniformly
effected by apoptosis) differed widely. Each tumour cell
line had a characteristic rate of apoptosis, which
determined large differences between the lines in their
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rates of population expansion in vitro . The tumours
produced by subcutaneous injection of these cells into
immune suppressed mice also showed large differences in
size, which demonstrated a consistent relationship to the
relative frequencies of mitosis and apoptosis. Thus,
apoptosis appeared to be a major determinant of tumour
growth in vitro and in vivo. The ratio of apoptosis to
mitosis appeared to be characterised by the genes
inserted into these cells. The c-myc oncogene and high
risk HPV genomes stimulated tumour cell apoptosis. HPV
18 was associated with lower levels of tumour cell
apoptosis than HPV 16. In contrast, the activated ras
oncogene suppressed apoptosis, either alone or in
combination with the other genes, contributing to the
faster growth of ras transfected fibroblasts.
The c-myc oncogene was associated with expression by
viable cells of one of the effector proteins involved in
apoptosis, the calcium-magnesium sensitive endonuclease.
In contrast, this enzyme was not expressed by viable
cells of the parent fibroblast cell line, or ras
transformed fibroblasts. These observations are
consistent with the hypothesis that apoptosis occurs in 2
distinct stages: priming - in which new effector
molecules appear within the cells; and triggering - in
which these molecules are activated to mediate apoptosis.
Priming for apoptosis by c-myc may explain the higher
intrinsic rates of apoptosis of c-myc transfectants, and
perhaps, the apoptotic rates associated with presence of
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high risk HPV genomes. Thus, differential genetic
regulation of apoptosis is reflected in net tumour growth
rates in. vitro and in vivo, and may partly explain the
more rapid transition from CIN to cancer, and the more
aggressive phenotype of cervical cancers containing HPV
18 compared to HPV 16.
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1. INTRODUCTION
It is axiomatic that the biological aggressiveness of a
tumour determines the prognosis for the patient. Yet,
tumour aggression is a poorly defined property, which
probably compounds many elements of tumour behaviour.
Rather little is known of what the essential elements
are, and less of the manner in which they are regulated.
The central theme of this thesis is that specific viral
and cellular oncogenes regulate two parameters which are
of fundamental significance for tumour aggression:
(1) progression of premalignant lesions to malignancy,
which is investigated in the human cervix/ and
(2) growth rate, which is studied using an experimental
fibroblast system.
More specifically, the possible contribution of HPVs to
progression of CIN to cervical cancer is addressed by
measuring the prevalence of viral genomes in these
lesions. To do this, without merely reiterating the
controversy which has surrounded the association of
papillomaviruses with cervical neoplasia, a new, highly
sensitive and specific, PCR-based assay was designed.
For practical reasons, it is difficult to study tumour
growth rate directly in patients. Net tumour growth rate
is determined by the balance of cell proliferation and
cell loss. Proliferation in tumours - both human and
experimental - has been investigated extensively, but
the contribution of cell loss to tumour growth and
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aggressiveness is less well understood. In the few
instances where quantitative data are available tumour
cell loss is considerable. This thesis examines the
proposition that tumour cell loss by the process of
apoptosis plays an important role in determining the
growth rate of tumours. Little is known about the genes
that regulate tumour cell apoptosis. Candidate genes
include those involved in modulating other aspects of
cell regulation, including proliferation and
differentiation, such as cellular and viral oncogenes.
The myc and ras oncogenes and the human papillomavirus
genomes were selected because of their known involvement
in human tumours. Their effects on tumour cell gain and
loss were investigated by manipulating their expression
in immortalized rodent fibroblasts.
To introduce this work, this chapter reviews four
subjects: tumour aggression and growth, apoptosis, myc
and ras oncogenes, and human papillomaviruses.
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1.1 TUMOUR AGGRESSION AND GROWTH
Human tumours derive from single cells and are thought to
evolve into malignant tumours by a series of stepwise
genetic changes (Nowell, 1976; Bernstein and Weinberg,
1985). Tumour cell variants develop, perhaps as a
manifestation of genetic instability, within the
expanding tumour cell population. Many of these variants
are probably eliminated because of growth disadvantage,
loss of key metabolic functions, immunological
destruction, or genetically determined cell loss.
However, occasionally variant cells may arise which have
a selective advantage over their parent cells, and expand
to form a new tumour subclone (Nowell, 1976). Many
malignant tumours studied have been found to be
heterogeneous, reflecting multiple subclones, in many
aspects of genotype and phenotype, including morphology,
ploidy, and proliferation (Shapiro et al, 1981; Fidler
and Hart, 1982; Moore, 1983; Carey et al, 1990; Hall et
al, 1990).
The probability of generating variant subclones with
greater aggression, depends on the overall rate of
population expansion of viable tumour cells, which is
determined by the balance of cell gain and loss.
Furthermore, the mechanism of cell loss may play a role




The concept that some tumours are more aggressive than
others is intuitively straightforward and clinically
important, yet tumour aggression is poorly understood and
correspondingly difficult to measure. In the absence of
more precise indices, clinico-pathological measurements
are often used, including death rates relative to the
tumour incidence rates, recurrence rates after therapy,
and survival rates at various times after diagnosis
(often 5 years). Histopathological measurements of tumour
aggression include tumour cell type, grading and staging
(Cotran et al, 1989) . These indices can obscure as well
as reveal differences in tumour aggression. A tumour with
large primary size and lymph node metastases may have
been present for only a short time prior to diagnosis, in
which case it is obviously aggressive; or it may be much
less aggressive, having achieved this status after more
than a decade of slow growth, all unnoticed by the
patient or physician. Underlying these differences are
poorly defined biological properties that determine the
tumour's capacity for expansion, infiltration and
metastasis (reviewed by Sobel, 1990) .
Cell surface receptors are required for attachment of
tumour cells to basement membranes or the extracellular
matrix, such as the laminin receptor (Liotta et al,
1988). Whereas, absence of other surface molecules (eg E-
cadherin) apparently promotes invasion (Birchmeier et al,
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1991). Secretion of degradative enzymes may clear a path
for invasion, for example collagenase type IV specific¬
ally cleaves collagen type IV in basement membranes
(Liotta et al, 1988). Induction of stromelysin 3 in
stromal cells by tumour, or induction of abnormal stromal
matrix components (eg tenascin) may generate new spaces
in basement membranes and tissue stroma. Autocrine
motility factors (eg AMF or scatter factor) are produced,
which promote movement of tumour cells into these spaces.
Some of these have been found to be associated with
activation of certain oncogenes, for example collagenase
type IV secretion and ras expression (Liotta et al,
1988). Still other factors (eg nm23, CD44) relate to poor
prognosis or to the frequency of metastasis, but for
obscure reasons (Birchmeier et al, 1991). It is clear
that the biology of tumour aggression is understood only
imperfectly at present.
Whatever else is involved, tumours behave as they do
because they contain cells, with properties essential for
the neoplastic phenotype. The generation of such cells,
including those with new properties, must therefore be
important. Autonomous cell proliferation is the
fundamental phenotypic change in neoplasia, and reflects
escape from normal growth control. The mechanism and
degree of growth deregulation is likely to influence the
net rate of growth of the tumour cell population.
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1.1.2 TUMOUR CELL PROLIFERATION
The molecular basis of autonomous tumour cell
proliferation is linked to two major groups of genes -
oncogenes, including those encoding growth factors, and
tumour suppressor genes. Mitogenic signalling pathways
mediate the normal functions of growth factors, and
oncogenes function at critical steps in these pathways.
Oncogenes encode growth factors (eg sis), growth factor
receptors (eg erb-Bl), post-receptor signalling molecules
such as tyrosine kinases (eg src) and G proteins (eg
ras) , and nuclear factors (eg myc) . Activation of
oncogenes, either by mutation or increased expression
through a variety of means, results in subversion of
signalling pathways in cancers (reviewed by Bishop,
1991) .
Growth factors are involved in entry into the cell cycle,
from GO to G1 - "competence factors" (eg EGF, PDGF, or
FGF), and progression from G1 to S phase - "progression
factors" (eg IGF-1, or insulin) . Oncogenes appear to
replace the actions of the former in tumours, but the
requirement for the latter may explain growth factor
dependence of many established cancer cell lines
(reviewed by Aaronson, 1991) . Growth factors also
influence tumour cell differentiation and non-tumour host
cells, such as those of the stroma and vasculature,
affecting overall tumour growth.
Tumour suppressor genes may act as a growth-restraining
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counterbalance to growth-promoting oncogenes, and
inactivation of them appears to liberate the cell from
such constraints. Many tumour suppressor genes were
identified by observation of loss of heterozygosity (eg
in retinoblastoma, or familial adenomatous polyposis
coli), and inherited mutation is associated with
congenital predisposition to specific cancers (reviewed
by Weinberg, 1991) . Their mechanisms of action are not
fully understood, although polypeptide homologies suggest
some similarities, for example between DCC and cell
adhesion molecules, and also between NF-1 and GTPase
activating proteins. Understanding of the regulatory
circuitry that governs tumour cell proliferation is
incomplete, but the early evidence points to important
interactions between growth factors, oncogenes and tumour
suppressors.
Cell proliferation has been studied extensively in many
tumour types and has often proved to be a very inaccurate
predictor of local growth rate (Quinn and Wright, 1990) .
This is presumably because net population expansion rate
is a balance of cell proliferation and cell loss. It is
the central hypothesis of this thesis that this balance
is significant in determining tumour aggression, and is
influenced by genes that regulate not only cell
proliferation, but also cell loss.
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1.1.3 TUMOUR CELL LOSS
Cells may be lost from tumour cell populations by a
variety of mechanisms. Cells may depart the primary
tumour site by natural exfoliation or cell migration.
They may leave the proliferating pool of cells by
terminal differentiation, or they may die (Cotran et al,
1989). Previous descriptions of tumour cell death have
often focussed on necrosis (Thomlinson and Gray, 1955;
Steel, 1977; Moore, 1983 and 1987; Tozer et al, 1990),
with less extensive study of apoptosis in tumours (Kerr
et al, 1972; Wyllie, 1985). Quantitative estimates of net
tumour cell loss have been made (Steel, 1977; Moore, 1983
and 1987).
It is possible to calculate the potential doubling time
(Tp) from estimates of tumour cell production rates
(mitotic indices, nucleotide incorporation or fraction of
cycling cells), and the actual doubling time (Td) from
measurements of tumour volume, and so derive the cell
loss factor (CLF = 1 - Tp/Td). The CLF approaches zero
with no cell loss, and unity if extensive loss makes the
actual doubling time unmeasurably large. In deriving
CLF s, errors can arise from several inevitable
assumptions, but in almost every tumour studied the CLF
is large. In rodent sarcomas and carcinomas CLFs of 0.65-
0.78, and in human bronchial and colorectal carcinomas
and a malignant melanoma CLFs of 0.73-0.96 were recorded
(Steel, 1977; Moore, 1983 and 1987; Kerr and Lamb, 1984) .
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The high level of tumour CLFs presumably explains the
poor correlation between measures of cell proliferation,
such as the thymidine labelling index, and the tumour
volume doubling times for a whole range of human tumours
(Steel, 1977) and points to the considerable importance
of tumour cell loss in determining tumour growth rate.
Thus, when the cell loss factor is large, it is likely to
act as a major regulator of the rate of tumour expansion
and probably determines the overall growth pattern in
terms of tumour enlargement, stasis or regression.
There is an unresolved question of whether the cell loss
factor is an intrinsic characteristic of a tumour cell
line, or is simply a manifestation of the growth
environment, in vivo or in vitro. The CLF has also been
shown to vary during enlargement of tumours over time
(Lala, 1972/ Steel, 1977/ Sarraf and Bowen, 1986).
Variations in the CLF with time may perhaps be explained
by elevated levels of cell death by necrosis, when tumour
cell populations outgrow their blood supply, or by
increased immune attack of tumour cells.
It is clear that cell loss occurs in tumours and that it
is relevant to the kinetics of tumour cell population
expansion, but there is surprisingly little direct
quantitative data on the relative contributions by
different mechanisms of cell migration, exfoliation,
differentiation, and death. It has been argued that cell
death is numerically the most significant form of cell
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loss from a growing tumour (Kerr et al, 1972; Wyllie,
1985; Bowen and Bowen, 1990). This may occur either by
necrosis or apoptosis. Although necrosis is often more
conspicuous histopathologically, due to its occurrence in
large, confluent zones, it does not occur in sufficient
quantities to explain the high tumour cell loss factors
observed, in contrast to the comparatively rapid and
inconspicuous cell death by apoptosis that occurs in a
scattered distribution (Wyllie, 1985; Bowen and Bowen,
1990). The ensuing sections of this chapter therefore
review the role of apoptosis in neoplasia, including its
incidence, morphology, mechanisms, and differentiation
from necrosis. All of these have a bearing on how and
why apoptosis may be triggered in growing tumours and
its quantitation both in vivo and in vitro.
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1.2 APOPTOSIS
Cell death plays a major role in the organisation of the
cell societies which we call tissues. Sometimes it is
conspicuous and clearly pathological, such as when sheets
of cells die in synchrony by necrosis (eg infarction).
Structurally, necrotic cells show critically damaged
organelles (eg mitochondria with 'high amplitude
swelling'), ruptured plasma membranes, and dispersal of
cytoplasmic elements into the extracellular space
(reviewed by Trump et al, 1981/ Wyllie, 1981). The
mechanisms are various, but do not depend upon continuing
synthetic activity. There is no evidence that specific
signalling pathways are involved. There is breakdown of
membrane homeostasis and net flow of water into the
necrotic cell, whose density falls. Intracellular calcium
rises uncontrollably to equilibrate with the millimolar
concentrations in the extracellular space. The process
results in an acute inflammatory reaction, perhaps
triggered by complement-activating factors emanating from
mitochondria which have escaped from the damaged cell
(Kagiyama et al, 1989) . Alternatively, leukotrienes and
other arachidonate chemotaxins may be generated from
partially degraded cell membranes (Denzlinger et al,
1985). The arrival of neutrophil polymorphs permits
digestion and phagocytosis of the constituents of the
necrotic cells, but brings with it the risk of further
tissue damage (Romson et al, 1983). In all these features
(incorporating incidence, morphology and mechanism), the
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cell biology of necrosis contrasts strongly with that of
apoptosis.
1.2.1 INCIDENCE OF APOPTOSIS
Apoptosis occurs frequently (though not exclusively) in
circumstances to which the term "programmed cell death"
has been applied (table 1.1) (reviewed by Kerr et al,
1972 / Wyllie et al, 1980 ; Wyllie, 1987a; Arends and
Wyllie, 1991). These include physiological states, such
as atrophy and normal embryonic development (Walker,
1987; Handyside et al, 1986), and pathological states,
for example inflammation and tumour growth. Amongst
these are the ontogeny and effector mechanisms of the
immune system. Apoptosis occurs in deletion of
autoreactive T-cell clones during thymic maturation, or
following stimulation of thymocytes by glucocorticoids or
ligand binding of the TCR/CD3 complex (Wyllie and Morris,
1982; Smith et al, 1989; Shi et al, 1989 and 1990) . It
occurs in B cell deletion in germinal centres in the
absence of antigen driven positive selection of
centrocytes (Liu et al, 1989) . Apoptosis is also found in
cells attacked by cytotoxic T lymphocytes (CTL) and
natural killer (NK) cells (Sanderson, 1981; Russell,
1983; Duvall and Wyllie, 1986; Martz and Howell, 1989;
Arends and Wyllie, 1991).
Apoptosis plays a critical role during resolution of
acute inflammation. Neutrophil polymorphs at the end of
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their physiological lifespan undergo apoptosis, with
subsequent phagocytosis by macrophages. This disposes of
them without causing further amplification of the
inflammatory response, which would occur if the
neutrophils died by necrosis, releasing their granule
contents into the tissues (Savill et al, 1989a and 1990) .
Apoptosis occurs in growing and regressing tumours (Kerr
et al, 1972/ Moore 1983 and 1987/ Wyllie 1985/ Sarraf and
Bowen, 1986/ Bowen et al, 1988/ Bowen and Bowen, 1991) .
It has often been observed as the mode of tumour cell
death following cytotoxic therapy (Searle et al, 1975)
and recently has been induced in experimental B and T
leukemic cells by treatment with monoclonal antibodies to
a specific surface epitope (APO-1) (Trauth et al, 1989/
Debatin et al, 1990) . APO-1 has been cloned, as has fas
another cell surface receptor capable of inducing
apoptosis, and these differ by only one non-essential
amino acid and share homology with the EGF receptor (Itoh
et al, 1991). In all these circumstances apoptosis is














































































































































































































1.2.2 MORPHOLOGY OF APOPTOSIS
The morphological changes of apoptosis occur in three
phases (Kerr et al, 1972; Wyllie et al, 1980; Wy11ie,
1987a and 1988; Walker et al, 1988b; Arends et al, 1990;
Arends and Wyllie, 1991). In the first, there is
reduction in nuclear size, condensation of chromatin into
toroids or crescentic caps at the nuclear periphery and
nucleolar disintegration with dissociation of the
transcriptional complexes from the fibrillar centre.
Cells dying by apoptosis detach themselves from their
neighbours and from culture substrata. There is loss of
specialised surface structures, such as microvilli and
contact regions. The cell adopts a smooth contour. Cell
volume shrinks, cytoplasmic organelles become compacted,
and the smooth endoplasmic reticulum dilates. The
dilated cisternae fuse with the cell membrane, giving
rise to a bubbling appearance at the surface.
Cytoskeletal filaments aggregate in side-to-side arrays,
often parallel to the cell surface, and ribosomal
particles clump in semi-crystalline formations, but
otherwise the organelles remain intact.
In contrast to necrosis, the other major type of cell
death (Trump et al, 1981), mitochondria do not show "high
amplitude swelling", the cell membrane does not become
permeable to vital dyes at this stage, and apoptotic
cells within tissues do not elicit an acute inflammatory
reaction (Wyllie, 1981).
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In phase 2 (which may overlap with the first), there is
blebbing at the cell surface and crenation of the nuclear
outline. Both nucleus and cytoplasm may split into
fragments of various sizes. Typically, the cell becomes
a cluster of round, smooth, membrane-bounded "apoptotic
bodies", some containing nuclear fragments, others
without. These bodies may be shed from epithelial
surfaces or phagocytosed by neighbouring cells or macro¬
phages. In glandular tissues in particular,
intraepithelial macrophages are prominent in this
activity (Walker, 1987/ Walker and Gobe, 1987).
In phase 3, there is progressive degeneration of residual
nuclear and cytoplasmic structures. In cultured cells,
this is manifested as membrane rupture producing
permeability to vital dyes. In tissues these changes
(sometimes termed "secondary necrosis") usually occur
within the phagosome of the ingesting cell. Eventually
membranes disappear, organelles become unrecognisable and
the appearance is that of a lysosomal residual body.
The majority of apoptotic bodies seen in tissues studied
with the light microscope are in this phase, and
sometimes the smooth outline of the ingesting phagosome
can be seen around them, but earlier phases can also be
recognised by their rounded contours and deeply
hyperchromat i c, often fragmented nuclei. The
histological appearance familiar to pathologists as
"melanosis coli" is the accumulation in the lamina
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propria of macrophages laden with apoptotic bodies
derived from mucosal cells (Walker et al, 1988a).
"Tingible body macrophages" in lymph node reactive
centres are similar, being laden with the apoptotic
residues of lymphocytes.
Time lapse cinematographic studies of apoptosis reveal
the sudden onset of cell shrinkage, with surface blebbing
and bubbling, as cells enter phase 1 and 2, after a
variable time from exposure to the lethal stimulus
(Sanderson, 1981; Russell, 1983). This initial response
lasts for only a few minutes, and generates small dense
apoptotic cells. If not phagocytosed immediately these
cellular particles undergo a gradual loss of cell density
(Wyllie, 1985), coinciding with loss of membrane
integrity, shown ultrastructurally and by failure to
exclude vital dyes. Apoptotic cells remain recognisable
within tissues for 4-9 hours, a time-course which
coincides with that of complete degradation of other
large biological structures within the phagosomes of
macrophages. This relatively short period ensures that
high rates of apoptosis produce only small increases in
the proportion of apoptotic cells observed in tissue
sections. Very simple calculations show, for example,
that if a tissue were to undergo involution to half its
cell number over 3 days, by a steady rate of apoptosis,
each apoptotic body remaining recognisable for 6 h, then
the proportion of apoptotic cells evident on microscopy
would rise to just over 4% in the first 6h, and
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thereafter more slowly to just over 8% by the end of the
3rd day.
1.2.3 MECHANISMS OF APOPTOSIS
The biochemistry of apoptosis is less well defined than
its morphology, probably because this process
characteristically involves scattered single cells within
tissues, surrounded and outnumbered by viable neighbours.
Nonetheless, six major events are known.
1.2.3.1 CELL DENSITY INCREASE
The conspicuous volume reduction of apoptotic cells
initially led to this type of death being called
"shrinkage necrosis" (Kerr, 1971; Kerr et al, 1972). In
thymocytes this is associated with a pronounced single
step-wise increase in buoyant density, suggesting that a
proportion of intracellular water and ions are lost,
without corresponding loss of macromo1ecu1es or
organelles (Ohyama et al, 1981; Wyllie and Morris, 1982).
In apoptotic cells endoplasmic reticulum (ER) dilates
forming vesicles which fuse with the plasma membrane,
voiding their contents extracellularly (Morris et al,
1984). This rapid and selective export of fluid and
intracellular ions into the ER may be mediated by an
ionic transporter system. A sodium-potassium-chloride
cotransporter has been described, inhibition of which
leads to net loss of sodium and water from affected cells
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(Wilcock et al, 1988) . At this time, apoptotic cells show
no evidence of increased permeability to vital dyes or
increased loss of previously accumulated radioactive
chromium. At a more pragmatic level this density increase
allows purification of intact apoptotic cells by density
centrifugation for experimental purposes (Wyllie and
Morris, 1982).
1.2.3.2 INTRACELLULAR SIGNALLING PATHWAYS
Perception of physiological lethal stimuli is presumably
mediated by cell type- and stimulus-specific receptors.
Possible intracellular signalling mechanisms in the
initiation of apoptosis include ion fluxes,
phosphoinositide hydrolysis, changes in activity of
protein kinases and altered expression or activity of
oncogenes. Although there is shut-down of total protein
and RNA synthesis early in apoptosis (Wyllie and Morris,
1982) in some cell types initiation of the process
appears dependent upon protein synthesis and can be
abrogated by application of inhibitors such as
cycloheximide or actinomycin D, shortly after the lethal
stimulus (Wyllie et al, 1984b; Wyllie, 1985) .
An interesting example of cell-type and stage-specific
signal transduction is the response of T cells to CD3
ligand binding: whereas in post-thymic cells the response
is proliferation, in the immature intrathymic cells it is
apoptosis (Smith et al, 1989; McConkey et al, 1989b).
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Similar observations have been made in T cell clones,
where apoptosis is blocked by cyclosporin A and
inhibitors of protein and RNA synthesis (Shi et al,
1989). As in the apoptosis induced by glucocorticoid, the
response to CD3 binding is preceded by a sustained rise
in cytosolic Ca2+ (McConkey et al, 1989a and 1989b).
Apoptosis in thymocytes can also be induced using low
doses of calcium ionophore (Wyllie et al, 1984b).
Endonuclease activation (in intact cells or even in
isolated thymocyte nuclei incubated in Ca2+) is inhibited
by phorbol ester (TPA), an agent which stimulates
endogenous protein kinase C (PKC), and this can be
reversed by H-7, a supposedly specific PKC inhibitor
(McConkey et al, 1 9 8 9b and 1 9 8 9c) . Thus calcium
mobilisation without commensurate stimulation of PKC may
trigger apoptosis in suitably primed cells. Initial
reports of direct measurements of diacyl glycerol and
phosphoinositides in apoptotic thymocytes suggests that
the different responses of intrathymic and post-thymic
cells are not due to differences in these signalling
pathways (Conroy et al, 1991) .
In prostatic epithelium, castration initiates a cascade
of transcriptional activation involving c-fos., c-myc and
hsp-70 prior to the onset of apoptosis (Buttyan et al,
1988). Novel RNA transcripts and proteins have been
observed following apoptosis of prostatic epithelium and
thymocytes (Montpetit et al, 1986/ Colbert and Young,
1986) . Two such transcripts in thymocytes (RP-2 and RP-8)
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have been partially characterized: one has a
transmembrane sequence suggestive of a cell surface
protein, and the other has a zinc finger motif
suggestive of a DNA regulatory protein (Owens et al,
1991). Transcriptional activation of the TRPM-2 gene,
which has homology with sulphated glycoprotein-2 gene
(SGP-2 or clusterin) expressed in Sertoli and epididymal
cells, has been demonstrated following the onset of
apoptosis in prostatic epithelium after castration and
also in breast epithelium (Kyprianou et al, 1 9 90) .
Withdrawal of certain specific growth factors or
transducers (eg IL-2, or bcl-2 protein) from lymphoid
cell lines in culture initiates apoptosis, although the
factors themselves do not necessarily stimulate
proliferation (Duke and Cohen, 1986; Vaux et al, 1988) .
Apoptosis of rat chloroleukaemic cells was preceded by
repression of c-Ki-ras expression (Servomaa and Rytomaa,
1988). Wild type p53 activity induced apoptosis in a
myeloid leukaemic cell line, whereas switching the
temperature to effect the mutant p53 activity of the
temperature-sensitive p53 protein did not do so (Yonish-
Rouach et al, 1991). It appears likely that the oncogene
and growth factor-dependent signal transduction pathways,
for long interpreted rather single-mindedly in terms of
cell proliferation, will be shown to play additional
important roles in the regulation of cell survival and
death.
The genetic regulation of programmed cell death has been
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well characterised in the nematode Caenorhabditis
elegans. Analysis of mutations yielding abnormal cell
death phenotypes has identified three loci in particular:
ced-3, ced-4 and ced-9. Recessive mutations at the ced-3
and ced-4 loci block nearly all of the programmed cell
deaths that occur during C. elegans development (Ellis et
al, 1991). It has been suggested that these genes code
for specific functions required in the dying cell itself
(Yuan and Horvitz, 1990 ) . Some mutations of the ced-9
gene with recessive transmissibility exhibit an embryonic
lethal phenotype, consistent with constitutive1y
activated cell death. Other types of mutation of ced-9
exhibiting dominant transmissibility are phenotypically
similar to ced-3 and ced-4 mutations. These observations
suggest that the ced-9 product may act as a type of
master-switch able to positively or negatively regulate
the cell death pathway (Ellis et al, 1991) . These
incisive studies promise to shed much light on the genes
regulating death in general, including mammalian
apoptosis. Despite the species divergence many of the
structural features of programmed cell death in the
nematode are similar to those of apoptosis. So far,
however, no homologues to ced-3, ced-4, or ced-9 have
been identified in mammals.
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1.2.3.3 CHROMATIN CLEAVAGE
Internucleosomal chromatin cleavage is associated almost
exclusively with the morphology of apoptosis. This
association was first demonstrated in glucocorticoid-
treated rat thymocytes in 1980 (Wyllie). Cleavage of
internucleosomal linker DNA generates well organised
chains of oligonucleosomes, with DNA lengths which are
integer multiples of 180-200 bp - the size of DNA wrapped
around a single histone octamer - observed as a ladder on
gel electrophoresis (Hewish and Burgoyne, 1973) . The
typical "chromatin ladder" has now been reported along
with morphological chromatin condensation of apoptosis in
many cell systems (Rotello et al, 1989; Zeleznik et al,
1989; Vaux et al, 1988; Baxter et al, 1989). The only
known circumstances in which endogenous chromatin
cleavage is not accompanied by the complete morphology of
apoptosis are normoblast maturation and the
differentiation of lens epithelium (reviewed in Wyllie,
1 9 8 7 a) . In both of these, although some of the
cytoplasmic changes are atypical, nuclear chromatin
undergoes widespread condensation entirely similar to
that of apoptosis. In contrast, cell death by necrosis
is not associated with internucleosomal DNA cleavage
(Russell, 1983) .
It has recently been demonstrated that DNA cleavage in
apoptosis occurs selectively, without associated
chromatin proteolysis (Arends et al, 1990a). The nuclear
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matrix appears normal, in terms of structural
organisation and the presence of the most abundant
protein species. DNA cleavage is at widely dispersed
sites: the apoptotic nucleus has a normal content of
acid-precipitable DNA. Two classes of chromatin fragments
are generated (Arends et al, 1 9 90a) : 70% exists as
oligonucleosome fragments bound to the nucleus, whilst
30% is unattached. Although the bound chromatin includes
fragments as short as dinucleosomes, the majority are
long; in contrast, the free chromatin comprises mono- and
short oligonucleosome fragments only. This minority class
probably derives from chromatin in a transcriptionally
active configuration as the chromatin-bound proteins are
depleted of histone HI and enriched in high mobility
group (HMG) proteins 1 and 2 - changes associated with
active gene transcription (Tremethick and Malloy, 1988) .
Whereas inactive heterochromatin is thought to be
tightly wound in a solenoid (Finch and Klug, 1976),
transcriptionally active chromatin is not compacted in
this way, which would allow better access to enzymes in
the nucleoplasm, producing more complete digestion. The
pattern of chromatin digestion in apoptosis, therefore,
is consistent with activation of an endonuclease in
solution in the nucleoplasm, rather than a constituent of
the matrix itself.
Brief digestion of normal nuclei with a purified
exogenous endonuclease (micrococcal nuclease) in the
presence of protease inhibitors, reproduces the nuclear
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morphologic changes of apoptosis, in step with
generation of the typical DNA ladder (Arends et al,
1 9 90a) . Interestingly, these changes include those
observed in the apoptotic nucleolus: segregation and
dispersal of the dense fibrillar and granular components
with preservation of an intact fibrillar centre. These
may be explained in terms of cleavage of the
transcriptionally active ribosomal genes within the dense
fibrillar component, with conservation of the inactive
ribosomal DNA protected within the nuc1eo1in-rich
fibrillar centre.
Thus, there is good evidence that the characteristic
morphological condensation of chromatin in apoptosis is
due to DNA cleavage. It is more difficult to be certain
that DNA change in apoptosis is due to an endogenous
endonuc1ease. It has been suggested that in some
circumstances similar chromatin cleavage might be the
result of damage by reactive oxygen intermediates
(Balkwill et al, 1 989) . Three observations, however,
make this improbable. First, cells dying by necrosis (in
which there is at least as much precedent for generation
of reactive oxygen intermediates as in apoptosis) do not
show the characteristic "chromatin ladder" (Russell,
1983). Second, the DNA cleavage in apoptosis is
predominantly double-stranded, with no single-stranded
nicks or gaps detectable by incubation with SI nuclease
(Arends et al, 1990a), whereas free radical damage would
be expected to generate a high proportion of single
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strand breaks. Third, in thymocytes subjected to
ionizing radiation, where free radicals are known to
mediate many biological effects, the evolution of
apoptosis shows a different timescale from the ionization
events which generate free radicals (reviewed in Wyllie,
1985) . Within seconds of radiation exposure, cellular
DNA undergoes multiple sing1e-strand breaks, with
consequent relaxation of supercoiling, characteristic of
ionization damage (Filippovich et al, 1982). These
breaks are repaired within minutes, and at this stage
there is no apoptosis. About an hour later, however, the
cells begin to show morphological apoptosis, together
with internucleosomal double-strand chromatin cleavage,
processes which can be abrogated by treatment (after the
radiation) with inhibitors of protein synthesis (Yamada
and Ohyama, 1988).
Early experiments with thymocyte nuclei suggested that
they contained an enzyme capable of cleaving chromatin in
apoptosis. If incubated in neutral pH, together with both
calcium and magnesium, such nuclei quickly developed
multiple doub1e-strand DNA breaks, generating the
familiar "ladder" on electrophoresis (Duke et al, 1983;
Cohen and Duke 1984). This activity can be inhibited by
zinc ions (Flieger et al, 198 9) . Endonucleases with
suitable features are known to be present within the
nuclei of many cell types (Hewish and Burgoyne, 19 7 3;
Ishida et al, 1974; Nakamura et al, 1981; Liu et al,
1980) and it seemed plausible that the raised calcium
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levels within apoptotic cells might be sufficient to
activate this enzyme. Attempts to purify an enzyme with
properties of the thymocyte neutral nuclease have been
reported (Wyllie et al, 1986b; Dykes et al, 1987).
The thymocyte nuclease cleaves chromatin of a target
system (nuclei from cells labelled during growth with
tritiated thymidine) to release labelled
oligonucleosomes. This nuclease activity is optimum at
pH 7.5, in contrast to contaminating acid nucleases,
which also differ in cleaving DNA to much smaller (acid-
soluble) fragments. The neutral calcium-magnesium
endonuclease is maximally eluted from normal thymocyte
nuclei at 300mM NaCl, and appears to be an anionic
protein of molecular weight around 130kd (Wyllie,
unpublished observations). This is substantially larger
than other candidates reported previously (Compton and
Cidlowsky, 1987) and now disputed (Alnemri and Litwack,
I 98 9) , but is close to the size of one subunit of
topoisomerase II (Halligan et al, 1985) . Topoisomerase
II is known to be present in thymocytes and would be
capable of engendering double-stranded DNA cleavage under
appropriate conditions (eg low ATP) (Udvardy et al, 1986;
Chow and Ross, 1987). It is not clear, however, whether
the thymocyte Ca-Mg endonuclease is identical with
topoisomerase II, or indeed whether either is responsible
for the chromatin changes in apoptosis.
In thymocytes the Ca-Mg endonuclease is constitutively
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present (Alnemri and Litwack, 1989). Whereas it is absent
from certain human and murine lymphoid cell lines
(Alnemri and Litwack, 1990). When cells of these lines
underwent apoptosis in vitro in response to
glucocorticoid, however, the extractable Ca-Mg
endonuclease activity rose from low levels, peaking as
endogenous chromatin cleavage and the morphology of
apoptosis appeared (Wyllie et al, 1986a). None of these
changes occurred in sublines selected for glucocorticoid
resistance. Similar nuclease activity has been observed
in an entirely different cell system, the physiological
death of ovarian corpus luteum cells (Zeleznik et al,
1989). Thus, endogenous endonucleases remain interesting
candidates amongst the effectors of apoptosis, but their
induction can precede the event of apoptosis itself.
1.2.3.4 TRANSGLUTAMINASE ACTIVATION
Coincident with the onset of apoptosis during the
involution of liver hyperplasia and in glucocorticoid-
treated thymocytes, there is induction and activation of
tissue transglutaminase (Ca2+-dependent protein-glutamine
J-glutamyltransferase) (Fesus et al, 1 9 8 7) .
Transglutaminases cross-link proteins through g-(#-
glutamyl) lysine bonds and mediate both formation of
cornified envelopes by epidermal keratinocytes (Green,
1980), and cross-1inking of fibrin and 2-plasmin
inhibitor in the final stages of thrombus stabilisation
(Sakata and Aoki, 1 982) . In apoptosis there is an
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increase in transglutaminase mRNA and protein, enzyme
activity and protein-bound (^-glutamyl) lysine (Fesus et
al, 1987; Fesus et al, 1991) . The probable consequence
of transglutaminase activation is an extensive cross-
linking of cytoplasmic and membrane proteins. In fact
apoptotic cells contain protein shells insoluble in
detergents and chaotropic agents. These shells, which
are not extractable from normal cells, appear in scanning
EM as wrinkled, spherical structures with some
morphologic similarities to epidermal cornified envelopes
(Fesus et al, 1989). This action may limit escape of
potentially toxic intracellular contents (eg lysosomal
enzymes) that may otherwise excite an inflammatory
response (Fesus et al, 1991) .
1.2.3.5 CELL SURFACE ALTERATIONS
It is characteristic of apoptotic cells that they are
rapidly recognized and phagocytozed by their neighbours
or by macrophages. The recognition process has been
reproduced in vitro in two isologous systems. Macrophages
bound preferentially to apoptotic compared with normal
cells. Recognition of apoptotic mouse thymocytes was
mediated by a sugar-dependent mechanism, inhibited by N-
acetylglucosamine or its dimer, N, N'-diacetylchitobiose,
but not by mannose or fucose, and only to a slight extent
by other monosaccharides including galactose (Duvall et
al, 1985).
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A similar sugar-dependent binding was demonstrated in the
recognition of apoptotic, aging human neutrophils by
isogeneic macrophages, although here glucosamine, galac-
tosamine and mannosamine inhibited recognition, as did
the basic amino acids L-lysine and L-arginine, and the
inhibition reactions were pH-sensitive and localized to
the apoptotic neutrophil surface (Savill et al, 1989b).
This sugar inhibition pattern suggests a lectin-type
interaction of the apoptotic thymocyte with a receptor¬
like molecular complex on the surface of rodent
macrophages capable of recognizing exposed glycan groups
on the surface of apoptotic cells. GlcNAc, the sugar
recognized in rodent thymocyte apoptosis, is present only
in deep positions within glycan structures of mature
glycoproteins and glycolipids. Other sugars, including
galactose and charged sialyl groups, are added
superficially during processing in the golgi apparatus
(Kornfield and Kornfield, 1985) . There is independent
evidence that these superficial groups may be lost in
apoptosis, from the observed reduction in cell surface
charge density, measured by microelectrophoretic mobility
(Morris et al, 1984) .
Apoptotic cell surfaces lose existing cell membrane due
to surface blebbing and budding, with shedding of
microvilli, and gain new membrane through fusion of
vesicles of dilated ER (Wyllie et al, 1980/ Wyllie,
1987a). Although other mechanisms are possible including
the expression of specific cell surface receptors (Wyllie
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et al, 1984a), this membrane loss and replacement could
explain the change from the normal population of mature
surface glycan groups to one containing some immature
glycan groups, leading to focal exposure of sugars
normally found in the interior of glycan structures, such
as GlcNAc (Morris et al, 1984; Wyllie 1987a). Macrophages
and hepatocytes are also known to clear blood
glycoproteins (gp) which have lost terminal sugar
residues, either asialo-gp (galactose terminated) or
asialoagalacto-gp (GlcNAc terminated). In each case the
clearance was found to be mediated by specific cell
receptors on the phagocytic cells (Ashwell and Hartford,
1982; Drickamer, 1988).
Macrophage recognition and phagocytosis of apoptotic
human neutrophils and lymphocytes can also be inhibited
by the RGDS tetrapeptide (Arg-Gly-Asp-Ser), RGD bearing
proteins vitronectin and fibronectin, or monoclonal
antibodies specific for the vitronectin receptor
polypeptide subunits (Savill et al, 1 9 9 0) . The
inhibitory effect was localized to the macrophage cell
surface, from which the vitronectin receptor polypeptide
subunits were immunoprecipitated, demonstrating that
recognition of apoptotic cells involves the vitronectin
receptor (Savill et al, 1990), a member of the B3
cytoadhesin family of integrins (Hynes, 1987) .
Thus, it is likely that recognition of apoptotic cells by
macrophages or neighbouring cells involves existing
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specific receptors on acceptor cells binding to newly-
exposed ligands on apoptotic cells by integrin-peptide
and lectin-carbohydrate type interactions. It is not
known whether there is a direct interaction between
acceptor cell receptors and apoptotic cell ligands, or
whether adherence is mediated via a molecular bridge,
such as occurs during platelet aggregation in which
fibrinogen bridges GPIIbllla integrins on platelet
surfaces (Phillips et al, 1988). Molecular bridging would
be compatible with the inhibition data, as lectin-
carbohydrate interactions may occur between one end of
the bridge and the apoptotic cell surface, and integrin-
peptide interactions between the other end of the bridge
and the macrophage cell surface (Savill, 1990). It is
also not known whether single or multiple receptor-ligand
or receptor-bridge-ligand interactions are required for
recognition and adherence. Diverse mechanisms might be
expected, however, as apoptotic cells can be phagocytosed
by neighbouring parenchymal cells as well as macrophages.
There are precedents for multiple, and sometimes syner¬
gistic, receptor recognition mechanisms in other cell-
cell interactions mediated by integrins (Hynes, 1987;
Dransfield et al, 1990) .
1.2.4 A GENETIC PROGRAMME FOR APOPTOSIS
A coordinated but complex pattern of events, such as
those seen morphologically and biochemically in
apoptosis, indicates the existence of a genetic programme
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for cell death. This implies genetic regulation of the
programme, in order that it may be switched on or off
appropriately in time and space. However, little is known
of such putative controller genes. The role of apoptosis
in neoplasia and how it may be regulated by candidate
genes - in particular the ras and myc oncogenes and the
transforming genes of papillomaviruses - is the central
theme of this thesis.
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1.3 MYC AND RAS ONCOGENES
1.3.1 MYC ONCOGENES
1.3.1.1 MYC GENE STRUCTURE AND FAMILY
The c-myc oncogene was first identified as a cellular
homologue of the transforming sequence in the MC29 avian
retrovirus (reviewed by Varmus, 1984). However, only the
second and third exons of avian, mouse and human cellular
c-myc are homologous to the MC29 v-myc sequence, and
these contain the protein encoding sequences. The first
exon consists of a 400-500 bp untranslated segment,
without initiation codons and with stop codons in all
reading frames (Stanton et al, 1983), which is involved
in regulation of c-myc expression (Cole, 1986). There are
two small domains of 70 and 80 bp ("myc boxes")/
separated by 120-150 bp in the middle of the c-myc second
exon, which showed a high degree of homology to non-c-myc
sequences, which were used to identify other genes in the
myc family. Five related proto-oncogenes have been found
in this myc gene family: c-myc, N-myc (found to be
amplified in double minute and homogenously staining
chromosomal regions in neuroblastomas), L-myc (similar
amplification in variant small cell lung carcinomas), U-
myc (unknown function), and B-myc (only identified in the
mouse genome) (Cole, 1986).
45
1.3.1.2 MYC ONCOPROTEIN FUNCTION
The c-mvc oncoprotein sequence is highly conserved across
chordates (van Beneden et al, 1986), with 90% amino acid
identity between mice and men (Bernard et al, 1983) . The
protein product has a predicted molecular weight of 4 9kDa
(Colby et al, 1982), but on SDS-PAGE a doublet of either
62/64 or 64/66kDa is observed (Alitalo et al, 1983a). The
protein is post-1rans1 ationa11y modified by
phosphorylation on serine and threonine residues
(Eisenman, 1985) and contains many proline residues
(Abrams et al, 1982). Using cell lines, p62myc was
initially immunolocalised to the cell nucleus, excluding
nucleol i (Alitalo et al, 1987), and subsequently
reported to be detectable in nucleus or cytoplasm
depending on type and adequacy of tissue fixation (Loke
et al, 1988). More recently, in the human colon and
rectum, it has been immunolocalised to the cytoplasm of
carcinoma cells, with only infrequent nuclear staining,
but strong nuclear staining in adjacent normal
epithelium, using ideally fixed specimens of colorectal
carcinomas (Williams et al, 1990). In both transient and
stable expression conditions, c-myc protein has been
shown to bind heat shock protein 70 in the cytoplasm and
induce its translocation to the nucleus (Koskinen et al,
1991) .
The c-myc oncoprotein has a short half-life of 20-30
minutes, possesses DNA binding activity in vitro
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(Eisenman et al, 1985/ Evan and Hancock, 1985), and
dissociates from DNA during metaphase in vivo (Winqvist
et al, 1984) . The DNA binding and protein dimerisation
motifs, consisting of helix-loop-helix and leucine zipper
domains, are located in the carboxy terminus of the
protein, and myc forms dimers with another small nuclear
protein,max, that bind to a specific hexanucleotide DNA
sequence (Blackwood and Eisenman, 1991)
C-mvc can prime some cells for growth competence -
passage of cells from quiescence (GO) into the first
phase of the cell cycle (Gl) (Robertson, 1985) . The
levels of c-mvc RNA are very low in serurn-starved
fibroblasts, but increase forty-fold on addition of
mitogens, such as platelet derived growth factor (Kelly
et al, 1983). Levels of c-myc protein do not vary in a
cell-cycle dependent manner, but correlate with cell
proliferation (Thompson et al, 1985/ Hann et al, 1985).
The precise functions of myc proteins are essentially
unknown, but the available evidence points towards
activity as transcription factors (Collum and Alt, 1990/
Cole, 1991) .
1.3.1.3 MYC EXPRESSION AND ACTIVATION
Oncogenic activation of c-myc does not require mutation
or other structural changes within the gene. Hence,
attention has focussed on quantitative changes in myc
expression in tumours. There appears to be a complex
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pattern of regulation of my c mRNA at both the
transcriptional and posttranscriptional levels. The c-
myc promotor has two distinct transcription start sites
in the first exon, containing TATAA sequences separated
by 160 bp, designated PI and P2 (Bernard et al, 1 983) .
The second promotor is the target for stimulation by at
least the adenovirus Ela protein (Lipp et al, 1989), and
probably other cellular and viral transactivators . The
introduction of activated c-myc and v-mvc into a variety
of cells results in the suppression of endogenous c-myc
expression, and in rat fibroblasts this occurs at the
level of transcription initiation and is proportional to
the c-myc protein concentration, indicating a negative
autoregulatory mechanism (Penn et al, 1990). A repressor
protein (myc-PRF) , found in certain cell types, interacts
with a widely distributed protein, myc-CFl, and they both
bind to specific short sequences just upstream of the
first exon (Kakkis et al, 1989) .
Serum stimulation of quiescent fibroblasts results in a
transient 3-4 fold increase in c-myc transcription rate
over 2 hours - not sufficient to account for the 20 - 40
fold increase in c-myc mRNA levels (Kelly et al, 1983) .
This difference is due to posttranscriptional regulation,
thought to be mediated by the first exon (Cole, 1986).
The very short half-life of c-myc mRNA (10-30 minutes),
is due to its cytoplasmic instability. This instability
is determined by sequences within the first exon. The
rapid cytoplasmic turnover may be decreased by
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cycloheximide treatment (Cole, 1986). Transcripts lacking
the first exon are not affected by cycloheximide
treatment, but c-myc RNA with only the first and second
exons still have short half-lives, indicating involvement
in RNA turnover of another region, in the downstream
untranslated region or protein coding sequences. It is
therefore of considerable interest that in the 8:14
chromosomal translocations in Burkitt's lymphomas,
although the breakpoint in the c-myc containing region
of chromosome 8 is variable, the second and third coding
exons are separated from the first exon in a significant
number of cases, and c-myc mRNA levels are higher than in
equivalent quiescent cells (Cole, 1986/ Lenoir and
Bornkamm, 1987) .
1.3.1.4 CELL TRANSFORMATION BY MYC
Cell transformation by c-my c involves activation
producing increased levels of functional c-myc protein.
This usually results from elevated transcription (Cole,
1986). Mechanisms of activation include retroviral
transduction, adjacent insertion of proviral promotors,
chromosomal translocation resiting the gene to a region
of influence of novel transcriptional enhancers, and gene
amplification (Alitalo et al, 1987) . These may result in
either constitutive expression or elevation of
transcription of c-myc.
Land et al (1983) used primary rodent fibroblasts to
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demonstrate that c-myc had neither immortalising nor
transforming activity unless linked to a transcriptional
enhancer to drive its expression. Immortalisation of
primary cells was induced by c-myc activated in this way,
mimicking in. vitro establishment of cell lines.
Transfection of activated c-myc into established cell
lines induced the tumorigenic phenotype, TGF production
and anchorage-independent growth, with little apparent
alteration in morphological appearance (Keath et al,
1984/ Pragnell et al, 1985/ Spandidos, 1985). Malignant
transformation of rat fibroblasts, by chimaeras of myc
oncoprotein and steroid receptors, was shown to be
tightly oestrogen dependent and reversible on hormone
withdrawal, clearly demonstrating the direct oncogenic
effect of high levels of functional myc and the
requirement for continued expression of myc activity for
maintenance of the transformed phenotype (Eilers et al,
1989). Cells transformed by activated myc oncogenes
display loss of normal growth regulation by factors such
as PDGF in serum (Campisi et al, 1984). Some of the
phenotypic changes induced by c-myc activation appear to
be cell type specific.
1.3.1.5 MYC ACTIVATION IN TUMOURS
Activation of members of the myc oncogene family in
authentic human cancers occurs in a wide range of cell
lineages, including haematological, neuroendocrine,
mesenchymal and epithelial. These include the most common
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cancers worldwide (ie cancers of the stomach, lung,
liver, breast, colon, cervix, and oropharynx) (Cole,
1986/ Kato et al, 1990/ Field and Spandidos, 1990). Three
of the best studied examples are (1) Burkitt's lymphoma
(c-myc translocation to Ig loci), which illustrates mvc
activation as part of multifactorial carcinogenesis with
Epstein-Barr virus infection of patients in the African
malaria zone (Taub et al, 1982/ Cole, 1986/ Lenoir and
Bornkamm, 1987)/ (2) neuroblastoma (N-myc); and (3)
small cell lung cancer (L-myc and N-myc), in both of
which there is my c amplification and/or elevated
expression, which correlates with poor prognosis (Brodeur
et al, 1984/ Field and Spandidos, 1990) . However, there
are few tumours of any type in which myc expression is
not increased to some degree.
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1.3.2 RAS ONCOGENES
1.3.2.1 RAS GENE STRUCTURE AND FAMILY
The first human cellular oncogene to be cloned (c-Ha-rasl
from the T24 human bladder carcinoma cell line) was found
to be homologous to the transforming sequence of the
Harvey rat sarcoma retrovirus. Similarly c-Ki-ras.2 is
the cellular proto-oncogene homologous to the Kirsten rat
sarcoma retrovirus transforming gene. The ras oncogene
family includes a third functional proto-oncogene member,
N-ras. without a viral homologue. There are also two
pseudogenes (Ha-ras2, Ki-ras1) (Barbacid, 1987;
Spandidos, 1988) .
The ras genes span 4.5 kb (Ha-rasl) and 4 0 kb (Ki-ras2)
as a result of large differences in the sizes of their
introns, which are widely divergent in their sequence
composition. The Ha-ras1 gene contains one 5' non-coding
exon (la) and four coding exons (I - IV) which synthesise
a 1.2kb mRNA. Ki-ras.2 has a similar arrangement of one
non-coding and four coding exons, except that there are
two alternative fourth coding exons (IVa and IVb) and two
mRNAs are generated (3.8 and 5.5kb); although they vary
in their mode of membrane attachment, specific
differences in the function of the 2 alternative Ki-ras
proteins have not been identified. N-ras has one non-
coding, and six coding exons, with two alternative sixth
exons (Via and VIb), which result in 2.0 and 4.3kb mRNAs
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(Spandidos, 1 988) . Although each ras gene codes for
different sizes of mRNAs, they all produce the same size
protein (21 kDa). The ras gene promotor regions lack
TATA boxes and resemble promotors of constitutive1y
expressed genes. They are thought to be expressed at low
levels in most if not all cells, but in some
differentiated cells and some tumour cells they are
expressed at higher levels (Spandidos, 1988).
There are many ras-related genes in different eukaryotic
organisms, which have been detected by relaxed
hybridisation or specific oligonucleotide probes. These
encode similarly sized proteins with varying but lower
degrees of amino acid sequence homology to the ras
family, indicating the existence of a wider superfamily
of related genes. These include rho (present in humans
and yeast), R-ras (detected in humans and rodents), and
ral (in humans and primates) (Santos and Nebreda, 1989).
K-revl (also known as rapla, with the closely related
raplb and rap2) was discovered independently by induction
of reversion of Ki-ras transformed cells (Kitayama et al,
1989), and by low stringency hybrisation with the DRAS3
gene of Drosphila (Pizon et al, 1988) . There is a group
of at least four rab genes, with homologues in yeast
(YPT1), rat (BRL-ras.) , and humans (rab.2), and several
other ras-related genes (eg mel), which have not been
fully characterised in terms of function.
The ras family gene sequences are highly conserved across
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many species, human ras being able to support growth in
mutant yeast (DeFeo-Jones et al, 1985). Ras and ras-
related members of the superfamily, show a high degree of
conservation of four amino acid motifs involved in
guanine nucleotide binding. All ras genes also show
significant conservation in another region (AA 32-40),
called the "effector" region (see below), but this is
shared by only some of the ras-related genes, indicating
the relative functional importance of these for ras
activity (Santos and Nebreda, 1989).
1.3.2.2 RAS ONCOPROTEIN FUNCTION AND ACTIVATION
The ras genes encode 21 kDa proteins (p21) consisting of
188-189 amino acids, which are attached to the internal
surface of the cell membrane via covalently linked fatty
acids (Sefton et al, 1982) . Ras proteins have several
similarities to G proteins, in that they bind GTP/GDP,
and show GTPase activity. There is striking conservation
of structure and mechanism among different GTPases, which
include (a) p21ras oncoproteins, (b) GTPases used in
ribosomal protein synthesis (eg bacterial elongation
factor EF-Tu) , and (c) alpha subunits of the
heterotrimeric signal-transducing G-proteins (Bourne et
al, 1990 and 1991). The 3 classes mediate a common GTPase
cycle, that acts as a molecular switch for diverse cell
functions. This cycle consists of 3 conformational
states. (1) Release of bound GDP converts the "inactive"
state into a transient "empty" state (2), during which
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GTP is more likely to bind than GDP due to differences in
cytoplasmic concentration. (3) GTP binding converts it to
an "active" conformation, which reverts to the GDP-bound
inactive form following hydrolysis of GTP. Many GTPases
have low intrinsic rates of GDP release and GTP
hydrolysis, which are increased by guanine nucleotide
release proteins (GNRPs) and GTPase activating proteins
(GAPs) respectively. Crystalline structures of p21ras
proteins and the guanine nucleotide binding domain of EF-
Tu are remarkably similar, and demonstrate the
conformational changes (Jurnak et al, 1990) .
Five regions of the ras p21 proteins (G1-G5) delineate
the guanine nucleotide binding site and mediate specific
functions in the GTPase cycle. These were identified by
homology with G proteins and ras-related proteins,
mutagenesis of specific sites, and crystallographic data
(Santos and Nebreda, 1989/ Bourne et al, 1991) . Regions
G1 (amino acid positions 10 - 17), G2 (32 - 40), and G3
(53 - 62) interact with the phosphate groups. The G4
region (112 - 119) and G5 region (143 - 147), together
bind the guanine ring.
Interestingly, all activating mutations detected in vivo
are located around amino acids 12/13 and 59/61, and these
cause a significant decrease in the intrinsic GTPase
activity. Whilst ras genes with experimentally introduced
mutations at codons 116/119 have been shown to possess
transforming properties in vitro, such changes have not
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been found in vivo (Santos and Nebreda, 1989). Activation
of ras also occurs by overexpression due to increased
transcription or gene amplification, but this is less
common than point mutation.
There is an important quantitative discrepancy between
decrease of GTPase activity and transforming potential of
mutated ras proteins (Barbacid, 1987). This apparent
paradox was resolved by the discovery of a GTPase
activating protein (GAP), which stimulates the GTPase
activity of normal ras by 100-fold with no effect on the
GTPase activity of mutated ras proteins (McCormick,
1989). Mutational analysis has revealed that ras binds
GAP through the "effector" region (G2 amino acids 32 -
40) of both normal and mutaionally activated ras. The
pl20 GAP protein is phosphorylated and membrane linked
when active, and when overexpressed it suppresses
transformation by normal ras but not by v-ras (Zhang et
al, 1990). Antigenic stimulation of T cells causes rapid
activation of p21ras by a mechanism involving a reduction
in GAP activity stimulated by protein kinase C (Downward
et al, 1990). These data suggest that GAP acts as an
upstream negative regulator of ras rather than a
downstream ras effector target.
Ras p21 protein requires membrane attachment for full
transforming activity. This occurs through a sequence of
post-translational modifications to its C-terminal
sequence Cys-A-A-X (Cys represents cysteine, A any
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aliphatic amino acid, and X any amino acid). First,
there is cleavage of the three C-terminal amino acids
(-A-A-X), followed by carboxymethylation and
polyisoprenylation (usually S-farnesylation of Ha-ras) of
the cysteine, which is now at the C-terminus.
Subsequently, there is palmitoylation of another
cysteine, between two and five residues away (Lowy and
Willumsen, 1989 / Hancock et a 1 , 1989). The major
expressed form of Ki-ras (exon 4B) does not have an
upstream cysteine residue, and is not palmitoylated.
Instead it has an adjacent string of six amino acids with
anionic side chains that form ionic bonds with membrane
head groups. Two related inhibitors of mevalonate and
polyisoprenoid synthesis, compactin and mevinolin, have
been shown to inhibit polyisoprenylation of Ha-ras, thus
preventing both membrane attachment and transformation
function (Schafer et al, 1989). The hypervariable
region is the only region displaying any significant
sequence variation between the three ras gene family
members, and across different species, and is likely to
be important in the manifestation of functional
differences between ras oncoproteins (Barbacid, 1987;
Santos and Nebreda, 1989).
The known biochemical properties of ras proteins (GTP/GDP
binding, guanosine triphosphatase activity and a degree
of sequence homology to G proteins), have led to the
suggestion that ras acts as a signal transducer of
information from cell surface receptors (Barbacid, 1987;
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Spandidos, 1988; Santos and Nebreda, 1989; Bourne et al,
1990 and 1991) . One model of ras function begins with
interaction of ligand and the extracellular component of
a transmembrane receptor causing a signal to be
transmitted by an unknown mechanism, perhaps
conformational change, to the intracellular component.
This in turn sets off a cascade of reactions. Initially,
the receptor (acting as a GNRP) mediates release of bound
GDP leading to formation of GTP-bound p21 - the "active"
state. This forms a complex with GAP, through its
"effector" G2 domain, and either "active" ras alone, or
together with GAP, pass on the signal to other molecules.
During the interaction of normal ras with GAP, there is
hydrolysis of bound GTP to GDP, returning ras to the
"inactive" state. Signal-receiving molecules may include
phosphoinositidases that hydrolyze phosphatidyl inositol
biphosphate to form diacy1g1ycero1 and inositol
triphosphate (Pichon et al, 1988; Alonso et al, 1988;
Spandidos, 1 9 8 8) . Both of these act as second
messengers, stimulating activation of protein kinase C
and calcium release from intracellular stores
respectively. Activated PRC increases intracellular pH
through the action of Na + /K +- activated adenosine
triphosphatase, and increased calcium and pH have been
associated with stimulation of DNA synthesis.
The function of ras varies with species and cell type. In
yeast, ras mediates survival (Katoaka et al, 1984) and
mating (Fukui et al, 1 9 8 6 ) . The precise molecular
58
functions of yeast ras proteins are unknown, but they
have been shown to influence growth by acting as positive
regulators of adenylate cyclase (Barbacid, 1987/ Tamanoi,
1988). In mammals the cellular effects of ras have been
related to differentiation in some cell lineages, eg the
rat phaeochromocytoma cell line PC12 which develops
neurite outgrowth and neuron-like morphology (Noda et al,
1985/ Bar-Sagi and Feramisco, 1985), and cell
proliferation in others (Mulcahy et al, 1985), for
example ras transcription increases in regenerating
liver cells (Goyette, et al, 1983) . Stimulation of the
antigen receptor of T lymphocytes, produces rapid
activation of p21ras via downregulation of GAP (Downward
et al, 1990).
1.3.2.3 CELL TRANSFORMATION BY RAS
Transformation of cells in. vitro by activated ras
oncogenes has been extensively studied (Barbacid, 1987) .
Transfection of mutated ras into immortalised rodent
cells induces transformation in a dominant fashion, with
higher levels of expression increasing the transforming
potency of the gene (Huang et al, 1981) . Non-mutated ras
proto-oncogenes, however, can transform primary rodent
cells only in co-operation with an oncogene of the
nuclear class (eg c-mvc), or if all the surrounding
normal cells have been eliminated (Spandidos and Wilkie,
1984/ Dotto et al, 1985/ Pozzatti et al, 1986) such as by
cytotoxic selection of transfectants. Activated ras
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oncogenes have immortalizing activity as well as activity
at later stages in transformation (Spandidos and Wilkie,
1984). Full tumorigenic conversion of primary cells
generally requires additional changes (Barbacid, 1987),
but can be achieved by high expression, via linkage to a
transcriptional enhancer, of a mutationally activated ras
(Spandidos and Wilkie, 1984). The ras oncogenes have been
strongly implicated as promoting tumour progression
(Vousden and Marshall, 1984) and their activation has
been related to increased aggressiveness of the
transformation phenotype (Marshall et al, 1985) .
The role of ras oncogenes in metastasis has been
correlated with the ability of ras-expressing cells to
escape from a primary tumour site rather than ability to
colonise a secondary site (Vousden et al, 1 986) . The
metastatic phenotype is expressed within a few cell
divisions of ras transfection (Muschel et al, 1985;
Thorgeirson et al, 1985) . One feature which might reduce
the effects of this altered phenotype is the increased
susceptibility of ras-transformants to NK cells (Johnson
et al, 1985) . Ras-transformed rodent cells demonstrate
the features of morphological transformation such as
growth of cells in foci, with overlapping of adjacent
cells, and a more spindle and retractile appearance
(Pragnell et al, 1985 ; Marshall et al, 1985) .
Overexpression of ras oncogenes also promotes anchorage-
independent growth and stimulates TGF production (Ozanne
et al, 1982; Anzano et al, 1985; Pragnell et al, 1985;
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Spandidos, 1985) . Ras oncogenes induce release of cells
from the requirement for trophic stimuli (Kasid et al,
1985; Zahn and Goldfarb, 1986), and ras-transformed
rodent cells have increased levels of expression of
endogenous c-fos and c-abl oncogenes (Wyllie et al,
1987); these are features which may plausibly contribute
to autonomous growth of tumour cells.
1.3.2.5 RAS ACTIVATION IN TUMOURS
Mutational activation of ras has been described in 10-20%
of human cancers studied (Williams et al, 1985; Barbacid,
1987), and in some there is over-expression of ras as
well (Slamon et al, 1984; Barbacid, 1987), including some
of the most common cancers, with correlation of ras
overexpression and poor prognosis in four (stomach,
breast, colorectum, and cervix, but not lung and
oropharynx) (Field and Spandidos, 1990) . Interestingly,
overexpression of cellular ras proto-oncogenes induces
only a weakly transformed phenotype in vitro (Pragnell et
al, 1985) .
In some human cancers (eg carcinoma of the cervix)
mutation of one ras allele is sometimes found with loss
of the other allele (Riou et al, 1988). In a mouse model
of skin cancer, in which carcinogen-induced initiation
occurs by Ha-ras mutation, followed by phorbol ester
stimulated promotion, the progression of invasive
squamous cell carcinoma to the more aggressive spindle
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cell cancer was associated with loss of normal ras
allele and imbalance of Ha-ras alleles (Quintanilla et
al, 1986; Buchmann et al, 1991). This suggests a possible
function for normal ras product as a competitor or
partial suppressor of the mutant protein, perhaps via
interactions with GAP or the downstream ras target.
Transforming ras oncogenes have been described in 70% of
chemically-induced tumours in various animal models
(Spandidos, 1985), and direct application of Harvey rat
sarcoma and BALB murine sarcoma virus v-ras genes
replaces the need for chemical carcinogens to initiate
two-stage mouse skin carcinogenesis (Brown et al, 1986;
Quintanilla et al, 1986) .
Activated mvc and ras oncogenes have synergistic effects
on the malignant transformation of primary cells (Land et
al, 1983). This is consistent with the requirement for
multiple viral oncogenes in DNA tumour virus mediated
transformation of primary cells, and is the basis of the
concept of separate classes of oncogenes - nuclear and
cytoplasmic - and of separate oncogenes for the different
stages of cell transformation (Weinberg, 1 985) .
Hypothetical schemes of shared transformation pathways
involving many oncogenes have been derived from blocking
experiments using antibodies or RNA antisense methods to
inhibit oncogene activities or using oncogene-revertants
(eg Krevl) (Herrlich and Ponta, 1 98 9) . Although the
situation is undoubtedly more complex than originally
envisaged, multiple genetic events are consistent with
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the multistep nature of carcinogenesis, and these may
include activation of cellular oncogenes, inactivation of
cellular tumour suppressor genes, and introduction of
viral transforming genes.
Ra s genes are known to cooperate with human
papillomaviruses in transforming primary cells (Crook et
al, 1988/ Storey et al, 1988), and have been found to be
activated in human cervical carcinomas containing these
viruses (Riou et al, 1984 and 1988) . The effects of ras
on the growth kinetics of transformed cells is to drive
rapid growth, both in vitro (Spandidos and Wilkie, 1984;
Spandidos, 1985) and in vivo (Wyllie et al, 1987) . For
these reasons, the ras oncogene represents an
interesting candidate that may have effects on tumour
cell apoptosis, either alone, in combination with another
oncogene of a different class such as the myc oncogene,
or with human papillomavirus transforming genes.
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1.4 HUMAN PAPILLOMAVIRUSES AND CERVICAL NEOPLASIA
Epidemiological studies of cervical neoplasia have
suggested a direct causal relationship with sexual
activity (Munoz et al, 1987 and 1991) . Early onset of
sexual activity and multiple sexual partners - apparently
acting as independent variables - are the principle risk
factors (Koss and Phillips, 1974/ Sebastian et al, 1978).
A further risk factor is exposure to the "high risk
male", characterised by a history of promiscuous sexual
activity and/or exposure to contraction of genital
neoplasia (Kessler, 1977; Graham et al, 1979; Cartwright
and Sinson, 1981) . Over the past twenty years the search
for venereally transmitted carcinogens has included
components of semen and various viruses (Vonka et al,
1984 and 1987). HPVs have emerged as the most promising
candidates.
Human papillomaviruses have been implicated in the
genesis of several benign and malignant tumours of the
cervix, vulva, and anogenital region (zur Hausen, 1977
and 1980; Pfister, 1984 and 1987; Arends et al, 1990b).
The inability to propagate papillomaviruses in cell
culture hampered research into their oncogenic potential
until the advent of molecular cloning of viral DNA in
the early 1980's. This allowed labelled viral DNA
probes to be used to investigate the prevalence of
viral DNA in various tumours and led to the cloning and
characterisation of new papillomavirus types. DNA
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sequencing of different viral types and manipulation of
whole viral genomes and subgenomic fragments in
experimental model systems has shed light on the
molecular biology of many viral functions including
malignant transformation.
Definitive investigations to prove a causal role for
this group of viruses in genital neoplasms are currently
lacking (anonymous Lancet editorial, 1985/ zur Hausen,
1989). There are, for example, insufficient long term
follow-up studies on matched case and control cohorts
using sensitive methods of detection of HPV. In this
section the association of HPVs with cervical neoplasia,
the biology of HPV infection, the genomic organization
and gene functions of papillomaviruses are reviewed. One
possible model of carcinogenesis is presented, which
accounts for clinical and experimental data. The
morphological basis of cervical neoplasia and the
involvement of HPVs are discussed in chapter 2, and cell
transformation by HPVs in chapter 3.
1.4.1 PAPILLOMAVIRUS TYPES
Papillomaviruses are membe;
and are composed of
circular double-stranded
in length (Pfister, 1984) .
host species infected and
hybridization in the li
s of the Papovaviridae family
capsids containing closed
DNA of approximately 8 kb
They are classified by the
by the degree of DNA cross
juid phase: designation of
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different types requires less than 50% cross
hybridization (Coggin and zur Hausen, 1979) . A change in
classification criteria was proposed at the 1991
International Papillomavirus Workshop to a system based
on sequence homology within specific viral genes. Over
60 types of HPV have been identified using existing
criteria, some being further divided into subtypes
(greater than 50% cross hybridization but with
differing restriction enzyme cleavage patterns, eg HPV
6a, 6b, 6c). Various types of HPV grouped according
to the sites of associated lesions and overall
sequence homology determined by hybridization are shown
in table 1.2 (Pfister et al, 1986/ Pfister, 1984, 1987a
and 1987b; deVilliers, 1989). A phylogenetic tree,
constructed from computer alignment of DNA sequences of
the highly conserved El C-terminal domain (Giri and
Danos, 1986), suggested three papillomavirus families:
genital, skin and fibropapi11omaviruses .
Fibropapi11omaviruses seemed to have evolved
separately from the other two families.
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TABLE 1.2
HUMAN PAPILLOMAVIRUS TYPES INFECT DISTINCT BITES
SITE GROUP HPV TYPE
Skin A I 1




EV B I 5*, 8*, 9, 12, 14, 15, 17,
19, 20-25, 36-38,46,47,49
B II 50
Mucosa C I 6, 11, 13, 44
C II 16*, 31(*)
C III 18*, 32, 42, 45(*)
C IV 30
C V 3 3 (*)
C VI 34
C VII 3 5 ( *)
C VIII 39 (*)
C IX 41
C X 43
Classification of the first 50 HPV types (except HPV 40
and 48) by site of infection and overall DNA sequence
homology, determined by cross hybridisation (data
modified from previous classifications by Pfister,
1987; deVilliers, 1989). The sites of viral infection
are: (A) skin, (B) skin of epidermodysplasia
verruciformis patients (EV), and (C) various mucosae
and specialised skin (cervix, vulva, anogenital
region, and restricted regions of the upper respiratory
tract) . HPV types strongly associated with
malignant tumours are indicated by * and those found in
premalignant and occasional malignant lesions by (*) .
Such a classification based on overall sequence
homology may be misleading, as different HPV types may
show similarity in some parts of the viral genome,
such as those encoding capsid proteins, but disparity
in other parts controlling important biological
functions including transformation.
67
1.4.2 BIOLOGY OF PAPILLOMAVIRUS INFECTION
The striking feature of different human
papillomavirus types is their predilection for
infection of squamous epithelia at specific sites
(table 1.2). Although such site specificity is not
fully understood, it may be explained by
attachment of viral capsid proteins to specific
surface receptors on epithelial cells. Alternatively,
there may be close linkage of the site-specific
epithelial differentiation programme with permissiveness
for viral replication, perhaps through cellular
regulatory proteins binding to viral DNA at
transcription control sequences.
Papillomavirus infection of squamous epithelia
produces epithelial proliferation with different
patterns of growth depending on the site and HPV type.
In benign infections the incubation period may vary from
a few weeks to several months (Rowson and Mahy, 1967).
Some lesions may regress spontaneously, whilst others
persist or progress.
It is thought that the virus primarily infects
epithelial basal cells at the site of a microabrasion
or by direct contact with exposed basal cells, such
as occurs at the transformation zone of the cervical
squamo-columnar junction (90% of HPV infections of the
cervix occur at this site) . The viral replication
cycle appears to be linked to the
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differentiation process of the epithelium (Bedell et
al, 1991) , and there is evidence that HPV can modify
keratinocyte maturation (Brescia et al, 1986). Early
viral genes are expressed in the lower epithelial
layers, and regulate viral DNA synthesis, whereas late
viral genes which encode capsid proteins are expressed in
the upper epithelial layers (Pfister, 1987; Galloway and
McDougall, 1989) . Following replication, viral DNA is
sufficiently abundant within nuclei in intermediate
and superficial layers that it can be demonstrated by
in situ hybridization. Similarly synthesis of
structural viral proteins in superficial epithelial
cells can be demonstrated by immunocytochemistry.
HPV infection of cervical, anogenital and other
epithelia often produces koilocytotic change in the
intermediate and superficial layers (Koss and Durfee,
1956). Koilocytosis is characterized by hyperchromatism
and crenation of nuclei with perinuclear clearing of
the cytoplasm, is often associated with multinucleation
of infected cells, and is considered to be an HPV-
induced cytopathogenic effect. Some but not all
koilocytes contain capsid antigens or virion particles
(Morin et al, 1981; Casas-Cordero et al, 1981), thus
the koilocyte represents a marker of HPV infection, but
not necessarily of complete viral maturation. Other
histological features sometimes associated with HPV
infection include individual cell keratinisation,
mu1tinuc1eation, parakeratosis, acanthosis, and
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papillomatosis (Meisels et al, 1982) .
1.4.3 PAPILLOMAVIRUSES AND THE CERVIX
Detail of the relationship between HPVs and cervical
neoplasia is given in the introduction to chapter 2, but
certain principles require mention here. Most information
relating to the oncogenic potential of HPVs has been
gained by investigating viral prevalence in neoplastic
lesions of the cervix. Low risk HPV types 6b and 11 are
associated with cervical condylomas and CIN 1, whereas
high risk HPV types 16 and 18 are found in up to 80% of
CIN 2 and CIN 3 lesions, and up to 100% of invasive
cervical cancers (Gissmann, 1984/ de Villiers et al,
1987/ Stanley, 1 990 / reviewed by Arends et al, 1 990) .
Small proportions of cervical neoplasms contain other
HPV types such as 30, 40, 42, 43, 44 and 58 in benign
lesions, and types 31, 33, 35, 39, 45, 51 and 52 in both
CIN and cancers (Lorincz et al, 1986, 1987a and 1987b/
Beaudenon et al, 1 98 6 and 1 987/ deVilliers, 1 98 9) .
However, HPVs are also detectable in control populations
(Toon et al, 1986/ de Villiers et al, 1987/ Melchers et
al, 1989), indicating that other events are required for
development of malignancy.
1.4.4 SYNERGISM OF PAPILLOMAVIRUSES WITH OTHER RISK
FACTORS
Zur Hausen (1982) suggested that in the development
of cervical neoplasia, papillomaviruses may act as
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promotor-1ike agents in synergism with carcinogenic
initiators such as cigarette smoke, or herpes simplex
virus (HSV). Several epidemiological studies have
revealed a low but consistent increase in relative risk
due to heavy or prolonged smoking, and a probable
increase in risk from prolonged use of combined oral
contraceptives (Vessey, 1986) . Access to cervical
epithelium by cigarette smoke products is indicated by
the presence in cervical mucus of tobacco metabolites,
which may be metabolised to carcinogens such as
nitrosamines (Sasson et al, 1985) .
HSV has been shown to possess mutagenic and
carcinogenic properties in infected cells (zur Hausen,
1982; Vonka et al, 1987) . Although HSV may have the
potential to act as a hit-and-run initiator, the lack
of persistent viral DNA, RNA or protein in most
neoplastic lesions and the equivocal findings in a
prospective study of HSV in cervical cancers (Vonka et
al, 1984) do not support a key pathogenic role for HSV
in genital neoplasia.
Studies on renal allograft recipients, treated with
immunosuppressants to inhibit graft rejection, have shown
a much higher incidence of CIN compared to controls,
and HPV 16 or 18 DNA has been demonstrated in most
lesions (Alloub et al, 1 9 8 9 ) . This supports the
hypothesis that immunosuppression may play a part in CIN
development.
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1.4.5 PAPILLOMAVIRUS GENOME ORGANIZATION AND FUNCTION
The pathology associated with HPV infection requires some
description of genome organization, gene functions, and
regulation.
A) . Genome Organization
The nucleotide sequences of the closed circular
double stranded DNA of all animal and human
papillomaviruses determined to date show a remarkably
similar colinear genome organization (Chen et al, 1982;
Schwar z et al, 1983; Seedorf et al, 1985; Matsukura et
al, 1986) (figure 1.1). All potential protein coding
sequences (open reading frames) occur in similar
positions on one DNA strand and are of approximately
similar lengths (Baker, 1 987 ) . There is an upstream
regulatory region (URR) containing the transcription
control sequences and origin of replication, followed by
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Figure 1.1
Genomic organisation of bovine papillomavirus 1 (Chen et
al, 1982) with aligned sequences of HPV 6b
(Schwar z et al, 1983) and HPV 16 (Seedorf et al,
1985) (incorporating the HPV 16 El sequence correction by
Matsukura et al, 1986). The boxes represent open reading
frames in the 3 possible translation frames; each open
reading frame is capable of coding for a polypeptide
uninterrupted by a stop codon. There is a translation
start codon (ATG) at or near the beginning of almost
all the coding sequences. The functions assigned to
BPV 1 coding sequences by genetic analysis are shown.
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B). Gene Functions
Study of cell transformation in vitro, and of viral warts
and cancers, has led to assignation of function to most
of the protein coding sequences of human and animal
papillomaviruses (figure 1.1). The late region genes (LI
and L2) code for structural capsid proteins (Pilacinski
et al, 1984) . Virion particle maturation is associated
with E4 (Doorbar et al, 1 98 6) . Cell transformation
functions map to the early region sequences E6 and E7
for HPV, and E6 and E5 for BPV (Schiller et al, 1984;
Yang et al, 1985; Munger et al, 1989a and 1989b; reviewed
by DiMaio, 1991): E6 binds to the p53 tumour suppressor
gene product, E7 to the retinoblastoma protein, and E5
activates the transforming activity of both epidermal and
platelet-derived growth factor receptors (Phelps et al,
1988; Martin et al, 1989; Munger et al, 1989b; Werness et
al, 1990; DiMaio, 1991). A detailed discussion of HPV
genes involved in cell transformation is provided in
chapter 3.
Episomal persistence maps to El (Lusky and Botchan,
1985). E2 encodes at least two regulatory proteins which
bind to specific sequence motifs in the URR ( Spalholz
et al, 1985; Lambert et al, 1987). Full length E2
protein upregulates transcription of other viral genes
by binding and activating a conditional enhancer in the
viral URR. This consists of at least two tandem repeats
of the ACCG-N4-CGGT palindrome, or sometimes the more
degenerate ACC-N6-GGT sequence (Phelps and Howley, 1987).
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The other E2 product is a transcriptional repressor
encoded by the carboxy half of the E2 gene (E2Tr),
which binds to the same sequence and competitively
inhibits the larger transactivator protein (Chin et al,
1988). The exact mechanism of control of early gene
transcription by E2 is not fully understood, but the
levels of the two competing proteins may determine
the overall effect (Ward et al, 1989). The usual
balance of E2 products causes repression in warts,
whereas disruption of the E2 gene by integration or
deletion at this site as occurs in cancers, would be
expected to abrogate repression and produce uncontrolled
expression of E6 and E7 (Ward et al, 198 9) . Fusion
products containing E2 sequences and regions of other
open reading frames may also contribute to regulation of
gene expression. It is theoretically possible that E2
products may also regulate expression of some host cell
genes with similar E2-responsive enhancer elements.
The URR also contains E2-independent enhancer elements
that are cell type-specific and glucocorticoid and
progesterone responsive (Cripe et al, 1987; Gloss et al,
1987 and 1989; Pater et al, 1988a; Gius et al, 1988; Chan
et al, 1989), implying complex control of expression of
viral early and late genes by cell type-specific,
hormonal and viral factors.
C) . Transcription of papillomaviruses
Different patterns of HPV gene expression are found in
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replicative infections compared with cancers. In
condylomas a complex pattern of RNA splicing occurs
(Pettersson et al, 1987) . Two or three main promoters
are used for initiation of transcription, one just before
the start of the E6 gene, and the others at or just after
the start of the El gene. There is a poly A addition
site at the end of the early region genes, and another at
the end of the late region genes. In replicative
infections, early region genes are expressed abundantly
in parabasal cells and in the middle of the epithelial
layer, whereas late gene expression is seen in the
superficial keratinocytes. Control of this change is not
due to a promoter switch mechanism, as seen with some
viruses, but rather to read-through of the early poly A
signal (Galloway and McDougall, 1989). In cancers, the
E6 and E7 sequences are the most abundantly expressed,
and are often the only viral genes to be expressed
(Schwar z et al, 1985/ Shirasawa et al, 1987/ Smotkin and
Wettstein, 1987). This reflects structural alterations to
the viral genome due to integration of HPV DNA in many
cancers, as described below.
1.4.6 PHYSICAL STATUS OF VIRAL DNA IN TUMOURS
Important differences in the physical status of HPV
DNA have been demonstrated in benign and malignant
tumours. HPV 6b and 11 are maintained as extrachromosomal
circular DNA episomes in benign cervical lesions,
whereas HPV 16 and 18 have been found to be
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integrated in most human cervical carcinomas and
carcinoma-derived cell lines (Lehn et al, 1985/ Pfister,
1987b; Choo et al, 1987). Integration occurred in 72% of
40 carcinomas containing HPV 16, and 100% of 23 cancers
containing HPV 18 (Cullen et al, 1991). In a series of
27 premalignant cervical lesions (CIN 1 to CIN 3), 66%
contained HPV 16 DNA; in mild dysplasias HPV 16 DNA was
found only as extrachromosomal episomes, but in all
higher grades of dysplasia integration of the viral
DNA was detected (Lehn et al, 1 98 8 ) . However, in
another study only 3 (all CIN 3) of 100 CIN biopsies
showed integration (Cullen et al, 1991) .
Carcinomas may contain one copy of integrated viral DNA
or multiple head-to-tail tandemly repeated copies,
sometimes at many host cell genome integration
sites with possible disruption of cellular genes at
those sites (Popescu et al, 1987; Shirasawa et al, 1987;
Popescu and DiPaolo, 1989 and 1990) . Some carcinomas have
both integrated and episomal viral DNA, some episomal
only, and some integrated only (Matsukura et al, 1989) .
As proof of integration Durst et al (1985) have cloned
DNA fragments of virus-host genome junctions. Viral
sequences are often amplified together with cellular
flanking sequences (Wagatsuma et al, 1990) .
The cause of viral integration is not known, but it
may be due to a carcinogen-induced recombination event
or perhaps an intrinsic property of certain virus
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types. Some analyses of integration sites in the host
genome have indicated that integration sometimes occurs
near cellular oncogenes or at fragile sites (Durst et
al, 1987a; Popescu and DiPaolo, 1989 and 1990) . However,
many studies show integration occurring randomly in the
genome (Smith et al, 1989). The pattern of viral DNA
integration into the host genome in carcinomas is
monoclonal suggesting that this occurs prior to
expansion of the malignant clone of cells.
Essentially similar findings derive from experimental
reconstructions. Human genital keratinocytes
immortalized in vitro by HPV types 16, 18, 31 or
33 contain integrated and transcriptionally active
viral genomes, whereas cells transfected with HPV
types 6b or 11, contain only episomal viral DNA and
have the same lifespan as nontransfected cells (Woodworth
et al, 1989). HPV 16 DNA integration frequently occurred
at fragile sites, at the junction of chromosome
translocations, at achromatic lesions, and within
homogenously staining regions and duplicated segments
(Popescu and DiPaolo, 1990). This was sometimes
associated with the induction of chromosome alterations,
such as marker chromosomes.
In both cervical carcinomas (Lehn et al, 1985; Choo et
al, 1987) and cell lines derived from them (Schwar z et
al, 1985; Pater and Pater, 1985; Shirasawa et al, 1987)
there is a consistent pattern of disruption of the
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circular viral DNA upon integration. The recombination
event frequently occurs within El or E2, and less
often L2, sometimes causing focal deletions (figure
1.2) (Schwar z et al, 1985; Pater and Pater, 1985; Choo
et al, 1987) . This pattern of DNA interruption provides
clues to the means whereby viral genes disturb growth
properties of host cells.
Viral integration by recombination within the El or
E2 genes leaves E6 and E7 directly coupled to the viral
enhancer and promotor sequences in the URR, thus
allowing their continued expression after integration.
Disruption of El or E2 during integration inactivates
or decouples the other early and late viral genes from
the viral promotor and enhancer sequences in the URR.
Viral genes and functions lost include El
(responsible for episomal persistence), E2 (producing
loss of both positive and negative control of viral
transcription), E5 (with possible changes in growth
modulation) and the late genes LI and L2 (stopping
synthesis of capsid proteins which might otherwise
present possible targets for immune recognition in
affected cells). A cervical carcinoma containing
episomal HPV 16 with a deletion of a large portion of
the URR has been described (Tidy et al, 1989c), which
also implicates alteration of viral gene expression as a
possible contributor to the neoplastic process.
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Figure 1.2
Pattern of integration of HPV 18 DNA in three cervical
carcinoma cell lines by disruption of the circular
viral genome at the E1-E2 region. The putative
transforming sequences E6 and E7 adjacent to the viral
promotors and enhancers in the upstream regulatory
region (URR) remain intact, whilst the other viral
coding sequences are either destroyed or decoupled
from the URR. Wavy lines represent host cell DNA. Data
redrawn from Schwar z et al (1985) .
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Another consequence of viral integration at the El
E2 region is the juxtaposition of HPV E6 - E7 DNA and
host cell DNA with uncoupling of the viral signals
that usually terminate transcription. Termination of
the integrated E6-E7 genes would then be achieved
through use of cryptic signals in the adjacent host DNA
(Durst et al, 1985) (figure 1.2). This leads to the
formation of RNA fusion transcripts (HPV E6-E7 encoded
RNA linked to RNA transcribed from adjacent host cell
DNA). Theoretically such fusion transcripts with changes
in the RNA secondary structure could have altered
stability producing increased half life or
trans1 atabi1ity of the E6 - E7 coding mRNA, with
increased or sustained E6 and E7 protein activity.
Schneider-Manoury et al (1987) studied a keratinocyte
cell line derived from a vulval Bowenoid papule, in which
HPV 16 DNA had integrated with disruption and deletion
within the E2-L2 sequences. Further, expression of
the E6 and E7 genes was demonstrated. The integration
event was shown to have occurred in the original
(premalignant) lesion. Thus, HPV DNA integration may
represent a critical event in the progression of
genital neoplasia, by inducing uncontrolled expression of
the viral genes E6 and E7, possibly in a continuous way.
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1.4.7 PAPILLOMAVIRUSES AND HOST CELL GENETIC CHANGES
The hypothesis that high risk HPVs play a contributory
role early on in cervical neoplasia, is supported by much
of the data presented in previous sections. However,
other genetic changes within the host cell appear to be
required for the full development of a malignant neoplasm
capable of invasion and metastasis. Several candidates
for such changes have been studied, and these will be
reviewed in the ensuing paragraphs. HPV E6 and E7
interact directly with the p53 and Rb tumour suppressor
proteins (Phelps et al, 1988/ Werness et al, 1990), and
perhaps other tumour suppressor genes may be involved. Of
the possible oncogenes which may become activated in
cervical cancer, myc and ras have been most extensively
studied. A different class of host genes appears to
regulate HPV gene expression. Such host cell genetic
changes may occur as mutations, alterations in gene
dosage, gene inactivation, or gene loss, and some of
these changes may be brought about by the development of
tumour cell aneuploidy.
Allele loss in cervical cancer has not been extensively
investigated. One preliminary study suggested that only a
small proportion of tumours lost alleles at those loci
that are most frequently lost or altered in other common
solid malignancies such as breast or colon (Busby-Earle,
personal communication). Neither loss nor rearrangement
of the p53 or Rbl loci were observed in a series of 50
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squamous cell carcinomas of the anus, of which 76% were
positive for HPV 16 DNA and 8% for HPV 18 DNA (Crook et
al, 1991). However, analysis of the p53 DNA sequence in 9
cases showed p53 mutations in 3 tumours negative for HPV,
and only wild type sequence in 6 HPV positive cancers.
This supports the hypothesis that loss of wild type p53
function is important in the development of anogenital
cancers, and that this may be brought about either by E6
complex formation with p53 protein in HPV containing
tumours, or by mutation in HPV negative cancers.
Most studies on oncogene activation in cervical cancers,
have focussed on myc and ras in established invasive
genital carcinomas and some carcinoma derived cell
lines. Resected specimens of human cervical carcinomas
containing HPV 16 or 18 DNA, show a correlation
between amplification of both c-mvc and c-Ha-ras1 and
advanced tumour stage (stages III and IV) (Riou et al,
1 984) . In early (stage I) invasive cervical
carcinomas c-mvc expression is closely correlated
with prognosis, with the 18 month relapse-free
survival rates of cases with normal myc expression
being 90% compared to 49% for those with high myc
expression (Riou et al, 1987). In a smaller study, Ocadiz
et al (1987) reported 49% cervical cancer cases had an
amplified c-myc gene, and that 43% presented with both
amplification and rearrangement of c-myc. In a series of
50 anal carcinomas, 15 (30%) showed amplification of c-
myc, of which 13 contained HPV 16, and 1 contained HPV 18
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(Crook et al, 1991) .
The WC12 human keratinocyte cell line, which generates
raft cultures histologically identical to CIN 1 and
contains episomal HPV 16 DNA, was compared with one of
its sublines with increased growth rate and resistance to
differentiation stimuli. The more aggressive subline had
increased c-myc expression due to amplification of the c-
myc locus resulting from chromosome 8q duplication (Crook
et al, 1990). Studies on the sites of integration of HPV
18 DNA into the host cell genomes of both HeLa and C4-
1 cervical carcinoma derived cell lines have revealed
that the virus is inserted at chromosome 8q24,
approximately 40 kb 5' proximal to the c-myc gene and
that the myc mRNA levels are increased in both lines,
suggesting cis-activation of mvc by adjacent insertion of
viral promotor/enhancer sequences (Durst et al, 1987).
Shirasawa et al (1987) found HPV 16 and 18 DNA
integrated in 5 cell lines derived from cervical
carcinomas in Japanese patients; all 5 cases contained
the URR and E6-E7 DNA sequences and expressed HPV
specific RNA. Three of the five cases expressed c-myc
and c-Ha-rasl at about 9 times the normal levels.
Elevated expression of the r a s p21 protein was
demonstrated in cervical neoplasms immunocytochemically,
and carcinomas had a higher staining intensity than
premalignant lesions (Agnantis et al, 1988). The c-Ha-
rasl locus on chromosome 11 was analysed in a series
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of cervical cancers, of which 90% contained HPV 16 or 18
DNA. One ras allele was lost in 36% of heterozygous
tumours and mutations in ras gene codon 12 were found in
2% of early cervical carcinomas (stages 1 and 2)
and 24% of advanced tumours (stages 3 and 4). 40% of
tumours with a ras mutation had also lost the other
allele (Riou et al, 1988). In the same series, the c-
myc gene was either overexpressed or amplified in 100%
of tumours containing mutations and 70% exhibiting a
deletion, supporting complementation between these
two oncogenes in tumour progression. Such
complementation was anticipated from experiments with
rodent cell fibroblasts (Land et al, 1983) .
The possibilty that cellular genes might control HPV
expression has been studied in HeLa cells, a long
established aneuploid cervical carcinoma cell line
expressing HPV 18. HeLa cells lose both
tumorigenicity in nude mice (Stanbridge et al, 1982)
and expression of HPV 18 i_n vivo (zur Hausen, 1986)
after fusion with normal fibroblasts. Such hybrid
cells progressively lose chromosomes; in
revertants which have lost chromosome 11, both
tumorigenicity and HPV 18 expression in vivo return.
Zur Hausen (1986) suggested that these data
support the existence of a host cell gene on chromosome
11 coding for a cellular interfering factor (CIF) . It
is postulated that CIF is activated when the hybridoma
is injected into nude mice and suppresses HPV expression
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and tumorigenicity. Presumably this suppression is
removed following loss of the CIF gene on chromosome 11.
HPV 16 enhancer/promotor sequences have also been shown
to function more strongly in del-11 cells - human
fibroblasts with a deleted segment of chromosome 11 (pll
to pl5) - than in normal diploid embryonic fibroblasts
(Smits et al, 1990) . Thus neoplastic progression could
be viewed as a consequence of the breakdown in host
cell control of persisting viral DNA.
Additional consequences of chromosome 11 loss may also
be important in tumorigenesis. First, c-Ha-ras1
(on chromosome lip) can be activated in a variety of
tumours and cell lines by mutation of one allele and
loss of the other (Spandidos, 1988; Spandidos and Field,
1990; Buchmann et al, 1991). The same pattern occurs
in cervical cancers containing HPV (Riou et al,
1988). Second, there are two candidate tumour
suppressor genes implicated in Wilm's tumour, on a region
of chromosome lip distinct from c-Ha-rasl (Koufos et
al, 1984) . Interestingly, when HPV 16 and mutated ras
were were transfected into primary human fibroblasts, the
resulting fast-growing, immortalized, but non-tumorigenic
cell line was found to have sustained a translocation
involving chromosomes 1 and 11 (Matlashewski et al,
1988). Aberrations of chromosomes 1, 3 and 5, as well as
generation of marker chromosomes have also been found
in cervical carcinomas (Atkin and Baker, 1984; Atkin,
1986; Teyssier, 1989; McDougall, 1990) .
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Changes in gene dosage or chromosomal loss occur
following the transition to aneuploidy, and this
represents one possible mechanism of CIF or tumour
suppressor gene inactivation, as well as contributing to
oncogene activation. A role for HPV in the genesis
of aneuploidy in cervical neoplasia is supported by
the association of abnormal mitoses with some HPV
infections (Crum et al, 1985), and the development of
aneuploidy in primary human cells by transfection of
HPV 16 or 18 DNA into genital keratinocytes (Durst et
al, 1987b; Pirisi et al, 1987 and 1988) and fibroblasts
( Ma11ashewski et al, 1 98 8) . The importance of
aneuploidy is uncertain, but it was found in 60 - 80%
of CIN 3 lesions, whereas diploid DNA content was
seen in 100% of normal/CIN 1 and 90% of CIN 2 biopsies
(Jakobsen et al, 1983; Hanselaar et al, 1988). The DNA
ploidy pattern of concomitant invasive cancers was
generally identical with adjacent CIN 3, suggesting that
the cancer developed from the CIN, and that aneuploidy
first occurred in the premalignant lesion (Hanselaar et
al, 1988) .
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1.4.8 PAPILLOMAVIRUSES AND CERVICAL CARCINOGENESIS
This section sets out a model of events which may-
occur during the transition of keratinocytes
manifesting HPV replication to neoplastic cells with
malignant potential (figure 1.3) . This emphasises the
coordinate or sequential participation of HPV and other
events such as oncogene activation. Such multistage
progression would explain several features of cervical
cancers. The small number of invasive carcinomas in
comparison with the high prevalence of HPV infection,
the monoclonality of cervical carcinomas, and the long
latent period required between HPV infection and
development of carcinoma.
The model envisages three major phases. First, there is
infection by a high risk HPV type. Various HPV types
differ in their oncogenic potential in the cervix. This
may be due to variations in the growth modulatory
activities of their E6 and E7 proteins, perhaps combined
with differences in their levels of expression.
Transcription factors may also be important, both through
viral proteins binding to host cell responsive DNA
elements, and host factors binding to viral transcription
control elements. Whatever the mechanisms, virally-
mediated growth advantages may increase the probability
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Possible events in tumour progression following HPV
infection of basal stem cells in cervical epithelium,
perhaps aided by immune suppression and exposure to
mutagens. High risk viruses (HPV 16 and 18) produce
high grade neoplastic cervical lesions in which viral
integration in combination with loss of HPV-cellular
inhibitory factor gene (CIF) activity cause
constitutive activation of viral E7 and E6
transforming sequences. There is associated
immortalisation and development of aneuploidy.
Oncogene activation and antioncogene inactivation may
be involved in conversion to invasive or metastatic
carcinoma.
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The second phase is viral integration. This has important
consequences for HPV genes E6 and E7, which are conserved
intact (Schwar z et al, 1985), and show evidence of
persistent and possibly elevated expression in
carcinomas (Shirasawa et al, 1987/ Smotkin and Wettstein,
1987). E6 and E7 have proven transforming activities,
and bind the p53 and Rb tumour suppressor proteins
respectively (Munger et al, 1988b; Werness et al, 1990) .
In vitro reconstructions demonstrate that E6 and E7
cooperate with activated ras to transform primary rodent
cells to malignancy (Storey et al, 1988; Crook et al,
1988) .
Integration of HPV DNA also occurs following experimental
introduction into human keratinocytes, and this results
in the development of a cluster of growth modulation
changes including reduced growth factor requirement
(growth in low serum), aneuploidy and immortalization
(rescue from senescence) (Woodworth et al, 1988 and
1989). These immortalized keratinocytes may be the
equivalent of CIN 2 or CIN 3 i_n vivo as raft cultures
formed by them show morphological features closely
similar to high grade intraepithelial neoplasia
(McDougall, 1990; Meyers and Laimins, 1992). This may
lead to an expansion of a population of aneuploid,
premalignant cells, promoting increased opportunity for
further genetic changes.
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The third phase includes progressive acquisition of host
cell genetic lesions including activation of oncogenes,
and inactivation of both tumour suppressor genes and
cellular genes controlling viral expression (eg the CIF
gene). Activation of the c-mvc and c-Ha-ras1 oncogenes
has been demonstrated in cervical carcinomas and cell
lines derived from them/ in some studies my c
activation appears to correlate with early stage tumours
and ras activation with late stage tumours (Riou et al,
1987 and 1988). Loss or inactivation of the putative
CIF would allow further deregulation of expression of
HPV E6 and E7 genes (zur Hausen, 1986) .
The credibility of this model would be strengthened if
two elements implied by it could be verified, and it is
the aim of this thesis to do this. First, it is important
to establish at what stage in the CIN-cancer sequence,
and how frequently, HPVs exert their effect. Although
much is already known of the prevalence of HPV in
cancers, controversy surrounds the levels of prevalence
in the normal population, and less is known about the
association with different grades of CIN. Thus, there is
a need for accurate information, which by neccesity must
often be derived from small tissue samples, requiring a
highly sensitive and specific HPV detection assay, as
described in chapter 2. Such data may also shed light on
the prognostic relevance of different HPV types, in terms
of progression from CIN to cancer and cancer cell type.
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Second, experimental reconstructions have demonstrated
oncogenic activity of HPV DNA in vitro, and this approach
provides an opportunity to investigate specific
phenotypic effects of interest. In chapter 3, rodent
fibroblasts transfected with HPVs, ras and myc, are used
to study genetic regulation of the rate of tumour cell
death by apoptosis, and how important this is in
influencing the overall rate of tumour growth.
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2.1.1 CERVICAL NEOPLASIA: EPIDEMIOLOGY AND PATHOLOGY
Cervical cancer is the second most common cancer
worldwide, and the most common in developing countries,
where screening programmes have been associated with 50%
- 60% decrease in mortality (The Walton Report, 1982;
WHO Meeting: control of cancer of the cervix uteri, 1986;
Cotran et al, 1989). Cervical cancer is presently ranked
eighth as a cause of cancer deaths in women in the
United States of America, with about 7000 deaths from an
estimated 13 000 new cases per year of invasive cancer,
and there are also 50 000 new cases per annum of
carcinoma in situ/CIN 3 (Silverberg and Lubera, 1989) .
Both the incidence and prevalence of CIN lesions in the
USA, has increased steadily over the past three decades,
particularly in teenagers and women under 30 (Berkowitz
et al, 1 979; Sadeghi et al, 1 984) . The incidence of
cervical cancer has also been gradually increasing from
1978 to 1987 in Scotland (Cancer Registration Statistics
Scotland, 1990).
The accessibility of the cervix has permitted extensive
study of both non-invasive neoplasms - cervical
intraepithelial neoplasia - and invasive cervical
carcinomas. From these investigations evidence has
accumulated to support the concept that cervical cancer
arises from precursor neoplastic lesions (Ferenczy and
Winkler, 1987 ; Richart, 1987) . A continuum of
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progressively more atypical changes of the cervical
epithelium has been described. Early changes involve the
appearance of atypical cells in the basal and lower
layers of the squamous epithelium, with persistence of
normal differentiation towards the prickle and
keratinizing layers. The atypical cells are pleomorphic,
show loss of polarity, changes in nucleocytoplasmic ratio
and increased mitotic figures, some above the basal
layer. More aggressive lesions in the continuum show
progressive involvement of more layers of the epithelium
with less surface differentiation. In the most advanced
lesions, the full thickness of the epithelium is replaced
by atypical cells. Lesions within this spectrum of
morphological change have been classified by three
systems.
(1) The classic terminology separates non-invasive
cervical epithelial lesions into two histologically
distinguishable groups: carcinoma i_n situ (CIS) and
dysplasia. Dysplasia is subdivided into mild, moderate or
severe according to the prorportion of the epithelium
involved by atypical cells; full thickness involvement is
known as carcinoma in situ (Weid, 1961).
(2) Cervical intraepithelial neoplasia (CIN) is a term
originally introduced to emphasize the continuous nature
of the change, and is subdivided into three grades
depending on the number of thirds of the epithelium
involved by atypical cells (Barron and Richart, 19 6 8;
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Richart, 1973) .
(3) The most recently introduced descriptive term is
squamous intraepithelial lesion (SIL), which may be
subdivided into high and low grades (National Cancer
Institute Workshop: The 1988 Bethesda System, 1 990) .
This system was designed primarily for use in reporting
cervical smears, and was intended to describe the
squamous cell precursors to invasive squamous carcinoma,
whilst incorporating and superceding CIN, dysplasia,
and CIS. The phrase "cellular changes associated with
human papillomavirus" was also suggested as a separate
diagnostic statement.
The fact that there have been three systems, over a
period of 30 years, for classification of a group of
common and readily studied lesions suggests an
incompletely understood but still developing concept of
the underlying biology and its correlation with
morphology. It may also reflect the practical
difficulties of consistently and reliably dividing into
two, three or four categories, what is perceived by many
pathologists to be a continuum, using morphological
criteria. However, there is no proof that this group of
lesions is a continuum, in terms of either the genetic
and viral changes that induce the lesions, or the
probability of developing malignancy.
The evolutionary potential of intraepithelial lesions has
been demonstrated by long term follow up studies. 50% of
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patients with CIN 1 lesions developed CIN 3 lesions over
9 years, whilst 28% either progressed to grade 2 or
remained at grade 1 (Richart and Barron, 1 9 6 9) . In
animals, cervical lesions also develop through
progressive stages of CIN 1 to CIN 3 and invasive
carcinoma (Rubio and Lagerlof, 1974). There is
variability in the progression rates, but the higher the
grade the shorter is the transition time to CIN 3;
regression also occurs but mostly in low grade lesions
(Richart and Barron, 1 9 6 9) . There is evidence that
strongly incriminates CIN 3 as a precursor of invasive
cancer. Foci of CIN 3 can often be found in the same
cervix as invasive carcinoma, usually at an adjacent
site. Invasive carcinoma developed in 60% to 70% of women
with carcinoma in. situ/CIN 3, followed over the long
term without treatment (Kottmeier, 1961/ Boyes et al,
1963), although a more recent review of several studies
attempting to define the natural history of carcinoma in
situ/CIN 3 suggested that only 20-30% of lesions
progress to invasive carcinoma within a period of 5-10
years (Chang, 1 990) . Most, but not all, new cases of
carcinoma occur in a population of women with previously
diagnosed CIN (Ferenczy and Winkler, 1987).
Progression to invasive cancer usually occurs at the
squamocolumnar junction of the transformation zone - at
the region of cervical ectopy (or ectropion). Previously,
80% - 90% of invasive carcinomas at this site were
believed to be squamous cell carcinomas, with
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adenocarcinomas accounting for most of the remainder. The
relatively recent use of mucin stains (Alcian
Blue/Periodic Acid Schiff or AB/PAS) has revealed that
only about 70% of cervical cancers are purely squamous,
and between 20% and 30% have to be reclassified as poorly
differentiated adenocarcinomas or as mixed adenosquamous
carcinomas (Yajima et a1, 1984/ Benda et a1, 1985;
Buckley et al, 1988) . There are three major categories
of cervical carcinomas, which have been redefined and
resubclassified recently (Buckley and Fox, 1989) .
(1) Squamous cell carcinomas are defined as neoplasms
"showing evidence of squamous differentiation, eg
keratinisation and/or intercellular bridge formation, and
not showing any evidence of glandular differentiation or
mucus secretion", and subdivided as well differentiated
(large cell tumours showing well marked differentiation) ,
moderately differentiated (large cell tumours showing
focal keratinisation), and poorly differentiated (large
or small cell tumours with minimal evidence of
keratinisation). Verrucous and papillary squamous
carcinomas are also separate entities.
(2) Adenocarcinomas can often be identified by their
obvious glandular differentiation, but the poorly
differentiated tumours may only be detected by
demonstration of mucus secretion using mucin stains.
Adenocarcinomas are defined as "neoplasms with no
evidence of squamous differentiation, but showing either
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formation of glandular structures or widespread mucus
secretion, ie in at least 75% of the tumour cells". Most
are recognisably of endocervical type, but a variety of
others are described (endometrioid, papillary serous,
clear cell, mesonephric, enteric) reflecting the capacity
of cells of Mullerian origin to differentiate along
alternative pathways, or undergo metaplastic change to
enteric type.
(3) Mixed adenosquamous carcinomas, contain both squamous
and adenocarcinomatous elements. These behave differently
from true squamous and true adenocarcinomatous tumours.
They were initially subdivided into "true" adenosquamous
carcinomas, with one third or more of tumour cells
secreting mucus, and "squamous carcinomas with mucus
secretion", in which only a small proportion of tumour
cells secrete mucus (mucoepidermoid carcinomas) (Buckley
et al, 1988). They behave in a biologically identical
manner, and the distinction is no longer justifiable
(Buckley and Fox, 1 98 9) . Glassy cell carcinomas and
adenoid cystic carcinomas are regarded as separate mixed
cell entities. It is thought that mixed cell tumours
arise from bipotential undifferentiated subcolumnar
endocervical "reserve" cells, capable of differentiation
to both squamous and glandular cells.
Only a small prortion of primary cervical carcinomas
cannot be classified into these three groups, and include
small cell carcinomas (neuroendocrine, basaloid, and
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subcolumnar reserve cell), and undifferentiated
carcinomas (Buckley and Fox, 1989). Metastatic carcinomas
at this site are very rare.
The two most important features of cervical carcinomas of
prognostic significance are the tumour size/extent of
local disease (local staging) and lymph node
metastasis, although there is considerable variability of
outcome within individual stages (Prempree et al, 1985;
Inoue et al, 1986; van Brommel et al, 1987). Of the
histological features, cell type, cytological grade and
lymphatic/vascular permeation all influence outcome.
Adenocarcinomas have poorer prognoses than squamous cell
carcinomas (Van Nagell et al, 1979; Moberg et al, 1986),
and mixed carcinomas have the highest levels of
association with nodal metastasis in early stage,
particularly the poorly differentiated adenosquamous
carcinomas detectable only with mucin stains (Ireland et
al, 1987; Buckley et al, 1988) . Cytological grading of
cervical squamous carcinomas is of little prognostic
value, as the nodal metastasis rate is identical for
well, moderately and poorly differentiated tumours, with
the exception of non-keratinising small cell squamous
carcinomas which are more likely to give rise to lymph
node metastases (Van Nagell et al, 1979; Buckley et al,
1988). Poorly differentiated adenocarcinomas have a lower
survival rate than well differentiated adenocarcinomas
(Prempree et al, 1985; Weiss and Lucas, 1986).
Lymphatic/vascular permeation by cancer cells correlates
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well with nodal metastases, and thus with poor prognosis
(Buckley et al, 1988/ Buckley and Fox, 1989) .
2.1.2 HUMAN PAPILLOMAVIRUSES IN CERVICAL NEOPLASIA
HPV infections have been categorised as clinical,
subclinical and latent (Schneider, 1990). Clinical HPV
infections, such as condylomas, either cause symptoms to
the patient, or are visible to the naked eye. Subclinical
HPV infections, such as intraepithelial neoplasia, may
not cause symptoms, but produce histologically
identifiable abnorma1ites. In contrast, latent HPV
infections can not be diagnosed clinically or
histologically, as the presence of the virus does not
cause any clinically or morphologically apparent
abnormalities. Clinical infection is often associated
with virion particle production, but it is not known
whether subclinical or latent infections are productive
or non-productive states. The majority of investigations
of subclinical and latent infections identified only HPV
DNA, and did not test for virion particles within the
lesions. Even in productive HPV infections the number of
virion particles is usually very low. Analysis of the
presence of koilocytes or dyskeratocytes in cervical
smears in routine screening programmes, detects a
prevalence of 0.7 - 3% (De Brux et al, 1983; Meisels and
Morin, 1986), whereas, of the cervical smears of STD
clinic attendants, 8 - 13% show these classical
cytological markers of HPV infection (Drake et al, 1987) .
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The prevalence of HPV, by detection of viral DNA, in the
normal population is controversial. Prevalence figures of
0% to 84% detected by PCR have been reported (Manos et
al, 1990/ Schneider, 1990). Some studies using DNA
hybridisation detected HPV in 10% - 12% of subjects (Toon
et al, 1986/ devilliers et al, 1987). Varying assay
sensitivities and target populations probably account for
the wide disparity of results. Since in the majority of
studies not all patients were colposcopica11y and
histologically examined for subclinical HPV infection,
some of the HPV positive patients may have been
subclinically infected and some latently infected with
HPV. A consensus figure, derived from published studies,
of approximately 10% of women with HPV DNA positive but
morphologically non-neoplastic cervices seems reasonable,
and this would provide an enormous pool for propagation
of HPV within the population. Transmission of HPV appears
to take place via the sexual and peripartal routes, and
there is evidence that immunosuppression and pregnancy
are risk factors for the acquisition or reactivation of
latent or subclinical HPV infection (Schneider, 1990).
However, many studies have used non-random, and possibly
non-normal control samples derived from patients
attending clinics, including those for sexually
transmitted diseases and other gynaecological diseases.
It is clear that accurate and reliable data for HPV
prevalence in a truly normal population are lacking.
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Broadly similar patterns of prevalence of HPV types
in cervical neoplasms have been found by many
workers, but some variation has been observed and
attributed to geographical differences, focal
heterogeneity of HPV replication within lesions
sampled, or variability in the sensitivity of the
assays employed. In genital warts and low
grade cervical intraepithelial neoplasia (CIN 1) the
commonest HPV types are 6b and 11, whereas HPV types 16
and 18 have been detected in association with up to
80% of high grade lesions (CIN 2 and CIN 3), and with up
to 100% of invasive cervical cancers (Gissmann, 1984
Brescia et al, 1986/ Syrjanen, 1986; Pater et al, 1986
Pfister, 1987b; deVilliers et al, 1987; Xiao et al, 1988
Stanley, 1990).
There is a progressive increase in positivity of HPV 16
or 18 in 4 groups of genital lesions: condylomas, all
grades of dysplasia, carcinoma in situ, and invasive
cancers (of cervix, vulva and penis); and a
complementary decrease in HPV types 6b and 11 in
these 4 groups, permitting categorization of HPVs into
high risk or low risk types (Gissmann, 1984) .
Amongst the high risk types, HPV 18 has been suggested to
be a more aggressive type than HPV 16, because it is
associated with (1) more glandular cancers, known to
have a poorer prognosis, in contrast to the predominance
of HPV 16 in squamous carcinomas (Wilczynski et al,
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1988), (2) more high grade tumours (Barnes et al, 1988),
and (3) a more rapid transition from CIN to cancer, at
least as indicated by the CANCER/CIN prevalence ratio.
HPV 18 has been associated with a higher CANCER/CIN
ratio of 7.3 (22%/3%), compared to 1.1 for HPV 16
(41%/37%) (Kurman et al, 1988).
Of the greater than 60 HPV types, many others infect the
cervix. Those HPVs associated only with benign lesions
include types 30, 40, 42, 43, 44 and 58. HPVs found in
either CIN or cancers include 31, 33, 35, 39, 45, 51 and
52 (Lorincz et al, 1986, 1987a and 1987b; Beaudenon et
al, 1986 and 1987; Naghashfar et al, 1987; deVilliers,
1989). Insufficient clinical information has accumulated
to authoritatively assign levels of clinical risk or
associated tumour aggression to these additional HPV
types. However, in vitro transfection of DNA from HPV
types 16, 18, 31 and 33 (but not 6b and 11) induced
immortalization and aneuploidy in normal human genital
keratinocytes, and transformation of primary rodent cells
with activated ras, suggesting a high oncogenic potential
for all these types (Storey et al, 1988; Crook et al,
1988; Woodworth et al, 1989) .
Nonetheless, a small proportion of cervical cancers
appear to remain negative for HPV DNA. Compared with HPV
positive carcinomas, these have a poorer prognosis in
terms of distant metastases and relapse, and may form a
biologically distinct subset of tumours (Riou et al,
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1990). It has not been possible in the past to determine
whether HPV is absent from these, present at copy
numbers below the level of detection, or represented by
some as yet uncharacterised HPV types. Some of these
problems may be overcome by use of the polymerase chain
reaction (PCR), which can detect a single target DNA
sequence amongst a million diploid cells (Saiki et
al, 1988). This technology has been used to identify as
few as 1-2 copies of an HPV genome integrated into a
cervical carcinoma cell line (SiHa), in a sample of only
10 cells (Shibata et al, 1988a). Using PCR-based
methods without optimisation of discrimination between
HPV types, viral DNA has been detected in cervical
smears from women with no history of cervical lesions
attending routine screening clinics (Melchers et al,
1989/ Young et al, 1989), and in substantial proportions
of women with CIN or cervical carcinomas (Melchers et
al, 1989; Young et al, 1989/ Shibata et al, 1988a and
1988b; Kiyabu et al, 1 989) . The detection rate often
exceeded that of non-PCR methods (Toon et al, 1986;
deVillers et al, 1987) .
To define more clearly the levels of association of HPV
with cervical neoplasia, a new assay was designed and
optimised for HPV detection. This used PCR to amplify
conserved DNA sequences within the E6 genes of 5 common
genital HPV types. The assay differed from previously
used PCR methods in several ways. Distinction between HPV
types was maximised by use of primers uniquely competent
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to amplify each virus type. The amplified DNA was
identified by hybridisation with HPV type specific
oligonucleotide probes, which were visualised by non¬
radioactive means. Stringent precautions were included
to avoid false positives secondary to sample
contamination.
106
2.2 MATERIALS AND METHODS
2.2.1 MATERIALS
Paraffin sections were taken from 1-2 yr old archival
blocks of forma 1dehyde-fixed cervical squamous
carcinomas. Frozen tissue was obtained from a colposcopy
clinic to which patients were referred as a result of
abnormal smears. HeLa and SiHa cervical carcinoma cell
lines and Raji lymphoblastoid cells were obtained from
the American Type Culture Collection. Oligonucleotide
primers and probes were synthesised on an Oswel Gene
Synthesiser (Dept. of Chemistry, University of Edinburgh,
UK) and were HPLC purified. Probes were biotinylated
during synthesis, by direct addition of a biotin moiety,
on a 15 carbon atom linker arm, to the 5' end of the
oligonucleotide probe. A 1 kilobase ladder marker (Gibco-
BRL) was used as the agarose gel electrophoresis
standard. HPV DNA sequences, derived from the EMBL
genetic sequence database, were analysed and
oligonucleotide sequences selected using the University
of Wisconsin (UW) Genetics Computer Group Software
(Cameron, 1988; Devereux et al, 1984) .
2.2.2 PARAFFIN SECTIONS
One 20um section was cut from paraffin-wax embedded
tissue blocks taken from uteri resected for cervical
carcinoma, and placed in a 1.5ml Eppendorf tube. Template
DNA was prepared by digestion with lOOul of 0.06mg/ml
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proteinase K in lOmM Tris, 0.ImM EDTA (pH8.0) at 48°C for
5 days (Jackson et al, 1990a and 1990b). Following
centrifugation at lOOg for 5 min, the supernatant was
twice extracted with an equal volume of
pheno1:ch1oroform:isoamy 1 alcohol (25:2 4:1) and
precipitated in 0.5 vol 7 . 5M ammonium acetate and 2.5 vol
ethanol at -20°C for 16 hours. After centrifugation at
lOOg for 15 min, the resulting DNA pellet was resuspended
at 20°C over 48 hours in lOOul lOmM Tris, 0.ImM EDTA
(pH8.0)(TE buffer). To lOul of this resuspended DNA was
added 90ul of PCR solution, and this was heated to 98°C
for 10 min prior to amplification.
2.2.3 FROZEN SECTIONS
Two 20um sections were cut from frozen tissue blocks of
punch biopsies of cervical intraepithelial neoplasia.
Prior to thawing, the frozen sections were placed on the
surface of frozen distilled water in a 1.5ml Eppendorf
tube. Concentrated PCR solution was added to give a final
volume of lOOul and this was heated to 98°C for 10 min
prior to amplification.
2.2.4 CULTURED CELLS
Up to 104 cultured cells, suspended in 25ul volume, were
prepared for PCR either by boiling in PCR buffer for 10
min (cell lysis procedure 1), or by lysis at 55°C for 60
min in PCR buffer with 0.45% NP40, 0.45% Tween and
108
0.06mg/ml proteinase K, followed by incubation at 98°C
for 10 min to inactivate the proteinase K enzyme (cell
lysis procedure 2). A further 75ul of PCR solution was
added prior to amplification.
2.2.5 POLYMERASE CHAIN REACTION
The PCR solution consisted of PCR buffer (50mM KC1, lOmM
Tris-HCl (pH8.3 at room temperature), 1.5mM MgCl2, 0.01%
gelatin), 200uM of each dNTP, 1.OuM of each primer, 2.5U
Taq Polymerase or Amplitaq (Perkin-Elmer-Cetus) and
template (tissue section, cell suspension or DNA
solution) in a total volume of lOOul overlaid with lOOul
mineral oil. Samples were subjected to 30 cycles of PCR
on an automated heating block (Hybaid), each cycle
consisting of DNA duplex denaturation at 94°C for 1 min,
primer annealing at 55°C for 2 min and DNA synthesis by
primer extension at 72°C for 3 min. During the final
cycle, the extension step lasted 10 min. 20ul of the
reaction product was electrophoresed on a 2% agarose (3:1
Nusieve GTG:Seakem) gel containing 2ug/ml ethidium
bromide and visualised under UV light. Amplified DNA
within the remaining 80ul reaction product was extracted
with an equal volume of phenol:chloroform:isoamyl alcohol
(25:24:1) and precipitated in 0.5 vol 7.5M ammonium
acetate and 2.5 vol ethanol. The resulting DNA pellet was
resuspended in 20ul lOmM Tris, 0.ImM EDTA (pH8.0)(TE
buffer) .
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Stringent precautions were taken to minimise the risk of
contamination of the PCR solution with HPV DNA from
unwanted sources (Kwok and Higuchi, 1 98 9) . Tissue
sections from different cases were cut using either
separate microtome blades or previously unused regions of
the same blade (when taking sections from small punch
biopsies). Sections cut from a block of tissue not
containing HPV (eg myocardium) were included when
appropriate, to investigate the possibility of transfer
of HPV DNA from case to case, during section cutting and
dewaxing. To reduce the chance of carryover of amplified
product three separate laboratories were utilised for (1)
preparation of the PCR solution, (2) amplification in the
automated heating block, and (3) analysis of the
amplified DNA by gel electrophoresis or dot blot
hybridisation. The components of the PCR solution were
prepared in small aliquots prior to use, and were added
to the reaction in a laminar air flow class II biological
safety cabinet, using positive displacement pipettes
exclusively dedicated to this purpose. Throughout this
the operator adopted a microbiological standard sterile
technique and wore disposable gloves. The PCR solutions
were added to the template solutions or sections in
another hood. Template solutions were transferred using
a separate set of dedicated pipettes, which were immersed
in 0 . 1M hydrochloric acid for 10 min and rinsed in
autoclaved distilled water prior to use. A template-free
negative control, exposed to the same preparative
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environment, was included in every assay in order to
detect contamination should it occur, as was a positive
control containing 5ng of the appropriate plasmid with
cloned HPV DNA to confirm successful PCRs.
2.2.6 DOT BLOT HYBRIDISATION
Nitrocellulose filters were pretreated with distilled
water followed by 15 x SSC (standard sodium citrate). The
amplified DNA was resuspended in 20ul TE buffer and
serially diluted ten- and one hundred-fold in 15 x SSC.
lOul of the original and the diluted samples, made up to
a final volume of lOOul in 15 x SSC, were subjected to
heat denaturation at 98°C for 5 min, and vacuum blotted
on to nitrocellulose filters, using "Hybridot" manifold
(Gibco-BRL). The sample wells were washed through with a
further lOOul 15 x SSC.
The filters were baked at 80°C for 2h in a vacuum oven
and prehybridised for 1 h at 42°C in 5 x SSC, 25mM
NaH2P04 (pH6.5), 5 x Denhardts solution, 0.1% sodium
dodecyl sulphate (SDS) and 200ug/ml denatured salmon
sperm DNA. The prehybridisation solution was replaced
with the hybridisation solution which contained the same
components, with the addition of 0.8uM biotinylated
oligonucleotide probe (heated to 98°C for 10 min before
use to denature any secondary structure), and differing
concentrations of deionised formamide optimised for the
different probes: 10% for HPV 11, 15% for HPV 16, 30% for
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HPV 18 and 0% for HPV 6b and 33 (Albretsen et al, 1988).
Filters were hybridised at 42°C for 16-20h, washed twice
at 20°C in 2 x SSC with 0.1% SDS, twice at 42°C in 0.5 x
SSC with 0.1% SDS and baked at 80°C for lh in a vacuum
oven.
Bound, biotinylated probe was detected using a
modification of the "Blugene" protocol (Gibco-BRL). Non¬
specific streptavidin binding sites were blocked by
incubating the filters for 20 min at 42°C in a solution
of 0.1M Tris-HCl (pH7.5), 0.1M NaCl, 2mM MgCl2, 0.05%
Triton X-100 (buffer 1) with bovine serum albumin added
to a final concentration of 3% (buffer 2). The filters
were baked under vacuum at 80°C for lh, rehydrated in
buffer 2 for 10 min, incubated at 20°C for 10 min in
2ug/ml streptavidin solution (Gibco-BRL), washed twice in
buffer 1, and incubated at 20°C in lug/ml biotinylated
alkaline phosphatase solution (Gibco-BRL) for 10 min. The
filters were then washed twice in buffer 1 at 20°C for 10
min and twice in 0.1M Tris-HCl (pH9.5), 0.1M NaCl, 50mM
MgCl2 (buffer 3) at 20°C for 10 min. Bound alkaline
phosphatase was visualised by incubation in the dark, at
20°C in a solution of 0.33mg/ml nitro-blue tetrazolium
(NBT) and 0.166mg/ml 5-bromo, 4-chloro, 3-indolyl
phoshate (BCIP) in buffer 3. After 1-2 h, deposition of
the blue-purple coloured reaction product was terminated
by immersing the filters in 20mM Tris (pH7.5), 5mM EDTA
and the filters baked under vacuum at 80°C for 1-2 min.
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2.2.7 RESTRICTION ENZYME MAPPING
Amplified DNA products, resuspended in 20ul restriction
enzyme buffer, were digested at 37°C for 16-20h. lOul
DNA solutions of both HPV 6b and 11 were restricted with
Ddel (22 units) (Sigma), HPV 16 and 18 with Hinfl (20
units)(Sigma) and HPV 33 with Dral (24 units)(Amersham).
The digested DNA was subjected to electrophoresis on a
2.5% agarose gel containing 2ug/ml ethidium bromide and
visualised under UV light.
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2.3 DESIGN AND OPTIMISATION OF POLYMERASE CHAIN REACTION
FOR HPV DNA DETECTION
A type-specific and highly sensitive, non-radioactive
assay was designed for detection of HPV DNA in tissues.
DNA sequences within the conserved HPV early gene E6 were
selected by computer search to optimise distinction
between HPV types. These were amplified using the
polymerase chain reaction (PCR), with different
primer pairs uniquely and exclusively effective for
each of HPV types 6b, 11, 16, 18 and 33. The amplified
DNA products were identified by both non-radioactive
oligonucleotide hybridisation and restriction
endonuclease mapping. This technique was
successfully applied to HPV-containing plasmid DNA,
cultured cells, DNA extracted from genital warts, and
frozen and archival paraffin-embedded sections of
cervical intraepithelial neoplasia and carcinoma. The
assay clearly distinguished HPV types with close
sequence homology and was sufficiently sensitive to
detect HPV DNA in 3-5 SiHa cells (each containing 1-2
copies of integrated HPV 16 DNA), amongst ten thousand
non-HPV containing cells.
2.3.1 SELECTION OF HPV TARGET SEQUENCES FOR AMPLIFICATION
HPV sequences suitable for amplification, to provide
diagnostic, type-specific products, must fulfil several
criteria. They must (1) remain intact following viral DNA
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integration, (2) have a high degree of conservation
between viruses of the same HPV type, such as genes
encoding transforming proteins, (3) show type-specific
sequence divergence, (4) be flanked by sequences suitable
for use as efficient PCR primers, and (5) contain a
central type-specific sequence appropriate for
oligoprobe hybridisation. The E6 and E7 genes fulfil
criteria 1 and 2, and were therefore searched for
suitable target sequences which meet criteria 3 to 5 and
are of 100-300 bp in length.
To distinguish belween the most similar viral types, the
E6 gene sequence of HPV 6b was compared with that of HPV
11 (these two viruses have an overall nucleotide homology
of 82% - the highest of any 2 genital HPV types), using
the University of Wisconsin (UW) computer program
COMPARE. Similarly, the E6 sequence of HPV 16 was
compared with those of types 18 and 33. The sequence
homologies were displayed graphically as dotplots using
the UW program DOTPLOT (figure 2.1). The DNA regions with
dissimilar sequences appeared as gaps in the diagonal
line of colinear homology in the dotplots. These were
then studied at the nucleotide level, using the UW
program GAP, which produced optimal sequence alignment
with the most similar HPV type, allowing determination of
the exact extent of base mismatching.
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Figure 2.1
Computer generated dotplots of the comparison of
homologies of the first 1000 nucleotides (which contain
the E 6 and E7 sequences) of (A) HPV 6b with HPV 11,
using a window of 20 bases in length, and a stringency
of 15, with each dot plotted representing the
occurrence of 15 or more identical bases out of 20
being compared at that position; and of (B) HPV 16 with
HPV 18, using a stringency of 13 within a window of 20
bases. The high density of dots along the diagonals
illustrates the strong colinear homologies, and the
gaps indicate the local regions of relative nucleotide
mismatching, which are appropriate for use as type-





























































































































































































































































































The target regions that were selected contained three
sequences with a high degree of base mismatching - one at
either end for PCR primer 1 (Pi) and primer 2 (P2)
sequences and one central sequence for the oligoprobe
(Pr) (table 2.1). These sequences had such low levels of
homology with other HPV types that no significant binding
would be expected to occur at annealing or hybridisation
temperatures of 40-60°C. To improve the sequence
specificity of the probes, oligonucleotides of up to 33
bases in length were selected, so permitting the use of
high stringency washing conditions. Occurrences of the
primer and probe sequences (including up to 5
mismatches), elsewhere in any of the HPV types were
excluded by computer search using the UW program FIND.
Guidelines for primer selection, suggested by Saiki
(1989), were taken into account, including GC content,
predicted secondary structure and 3' complementarity.
The GC content of the primers varied from 39% to 60% with
the exceptions of HPV 18 primer 1 (32%) and HPV 33 primer
1 (19%). The possible formation of significant secondary
structures by the single stranded DNA primers, which
might interfere with primer annealing during PCR, was
assessed using the UW programs FOLD and SQUIGGLES.
Secondary structures, known as stem loops, with 5 or
fewer internal base pairings were predicted for all of
the primers. No significant complementarity between the
3' ends of paired primers (for each HPV type) was
identified, thus limiting the risk of primer dimer
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formation.
2.3.2 TARGET DNA AMPLIFICATION
The protocol for amplification of target HPV DNA by the
polymerase chain reaction was optimised using plasmid DNA
as template, containing cloned full HPV genomes, and a
primer annealing temperature of 42°C. Amplified
sequences were visualised as single bands by agarose gel
electrophoresis, and were of the predicted lengths.
Amplified fragments of HPV 6b and HPV 11 were 237 base
pairs (bp) in length, while those of HPV 16, 18 and 33
were 316, 144 and 172 bp respectively (figure 2.2).
Successful amplification of HPV DNA by this technique was
achieved using a variety of templates, including DNA
extracted from a fresh vulval wart, and from frozen and
paraffin wax sections of the same lesion (figure 2.2).
The primer annealing temperature (Ta) was raised to 55°C
for assays of tissues, although a Ta of up to 60°C has
been successfully employed. This increases the
specificity of binding of primers to target HPV DNA and
reduces the risk of primers binding to near-complementary




Agarose gel electrophoresis of amplified HPV DNA:
(A) using type-specific pairs of primers with cloned
DNA for types (a) HPV 6b (fragment length 237 bp), (b)
HPV 11 (237 bp), (c) HPV 16 (316 bp), (d) HPV 18 (144
bp) and (e) HPV 33 (172 bp); and (B) using HPV 11
primers with samples of a vulval wart, harbouring HPV 11,
in the form of extracted DNA (D), frozen sections (F), or
paraffin embedded sections (P); a "template-free"
negative control track (-), and 1 kb ladder marker tracks
(M) are included.
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2.3.3 IDENTIFICATION OF AMPLIFIED DNA
Two methods were employed to confirm that the amplified
DNA, as visualised by gel electrophoresis, contained the
appropriate HPV target sequence. Dot blots of amplified
DNA were hybridised with oligoprobes, each specific for a
single HPV type. The biotinylated oligoprobes were
visualised by formation of a complex with streptavidin
and biotinylated alkaline phosphatase followed by
deposition of a coloured reaction product using NBT and
BCIP (figure 2.3). Alternatively, the amplified DNA was
analysed by restriction endonuclease mapping, using
enzymes which cut a maximum of twice within the target
sequences and generated diagnostic fragments from each of
the 5 HPV types. The sizes of the cleaved DNA fragments
were determined by gel electrophoresis (figure 2.4) and
were found to be of predicted lengths. Thus, amplified
products of HPV 6b, digested with Ddel, produced two
fragments of 133 and 104 bp/ HPV 11 also cleaved by
Ddel, produced two bands of 194 and 43 bp. Hinfl
digestion of amplified DNA of HPV 16 gave 200, 76 and 40
bp bands, and of HPV 18 gave 81 and 63 bp bands. Dral
restriction of HPV 33 amplified DNA gave fragments of 79,
75 and 18 bp.
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6 11 16 18 Neg Pos
Figure 2.3
Dot blot showing HPV type-specificity of oligoprobe
hybridisation to amplified DNA. DNA was immobilised onto
the nitrocellulose filter undiluted and in ten- and one
hundred-fold dilutions, using PCR generated amplified DNA
from HPV types 6b, 11, 16 and 18, and plasmid DNA of
pBR322 (Neg) and of pHPVll (Pos), acting as negative and
positive controls respectively. The filter was hybridised
with the biotinylated oligoprobe for HPV 11, which was
detected by a streptavidin and alkaline phosphatase
reaction. The probe identifies only amplified DNA of the
same HPV type.
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M 6b 11 16 18 33
Figure 2.4
Amplified DNA from each of the HPV types was
identified by restriction endonuclease mapping, with
the sizes of digested DNA fragments determined
by agarose gel electrophoresis. A unique pattern of
DNA fragments was observed for each HPV type/enzyme
combination: (a) HPV 6b/Dde I gave 133 and 104 bp
fragments; (b) HPV 11/Dde I gave 194 and 43 bp fragments;
(c) HPV 16/Hin fl gave 200, 76 and 40 bp fragments; (d)
HPV 18/Hin fl gave 81 and 63 bp fragments; and (e) HPV
33/Dra I gave 79 and 75bp fragments, the remaining 18 bp
fragment is not visible in this gel. In some reactions
small quantities of undigested amplified DNA products are
visible. A lkb ladder marker track (M) is shown.
123
2.3.4 HPV TYPE SPECIFICITY OF AMPLIFICATION AND
HYBRIDISATION
To establish type specificity of primer-directed
amplification each set of primers was tested with
template plasmid DNA of the 5 HPV types 6b, 11, 16, 18
and 33. Amplified DNA fragments, detected by gel
electrophoresis, were generated only when the primer
pairs were used with template DNA of the same viral type;
no amplification occurred when primers of one type were
applied to template DNA of another (figure 2.5) . To
establish type specificity of oligoprobe hybridisation,
amplified target DNA sequences from all 5 HPV types were
dot blotted onto nitrocellulose filters and tested for
cross-hybridisation using the 5 HPV type-specific
oligoprobes. Each oligoprobe generated a positive
hybridisation signal only with amplified target DNA of
the same HPV type (figure 2.3).
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Figure 2.5
The specificity of each pair of primers to direct
amplification by PCR of a single HPV type was tested
using cloned HPV genomes as templates. Agarose gel
electrophoresis shows the products of PCRs using HPV 33
primers with template plasmid DNA of HPV types 6b, 11,
16, 18 and 33. A lkb ladder marker track (M) is
included. Positive amplification is achieved only with
HPV 33 template.
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2.3.5 SENSITIVITY OF THE POLYMERASE CHAIN REACTION
The ability of the assay to detect HPV DNA in low
abundance was determined using as template, cultured
cervical carcinoma-derived cell lines with known HPV DNA
content. Test cell samples consisted of serial dilutions
of HeLa cells (containing 30-40 copies of HPV 18 per
cell) and SiHa cells (containing 1-2 copies of HPV 16
per cell), mixed with 104 control Raji lymphoblastoid
cells (without any HPV). Using appropriate
oligonucleotide primers for 35 cycles of the PCR,
amplified target DNA sequences were consistently detected
from reactions containing five Hela cells (data not
shown), or five SiHa cells (figure 2.6). Quadruplicate
reactions, nominally containing 4, 3, 2 or 1 SiHa cell
were also analysed. Two out of four reactions containing
three or four cells were positive, and none of the
reactions containing one or two cells (figure 2.6).
Since the actual number of cells in these very dilute
suspensions is determined by the Poisson distribution,
these results demonstrate a true threshold sensitivity of
between 3 and 5 SiHa cells (3-10 integrated HPV DNA
copies).
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Figure 2.6
Sensitivity of the assay is shown by agarose gel
electrophoresis of ethanol precipitated DNA from 80ul
reaction solutions after 35 cycles of PCR, demonstrating
amplification of viral DNA from SiHa cells (known to
contain 1-2 HPV genomes) directed by primers to HPV 16.
(A) The SiHa cells were serially diluted amongst a
background of 104 Raji cells: (M) lkb ladder marker
track; (a) positive control pHPV 16 plasmid DNA; (b)
negative control "template-free" reaction; (c) no SiHa
cells; (d) 1000 SiHa cells; (e) 100 SiHa cells; (f) 10
SiHa cells (g) 5 SiHa cells. Positive amplification is
seen in all reactions containing SiHa cells.
(B) Quadruplicate samples were analysed, each containing
3 or 4 or 5 SiHa cells on a background of 10,000 208F
cells. The gel shows a positive pHPVl6 plasmid control
(+), a negative template free control (-), 208F cells
without SiHa cells, two samples containing 3 SiHa cells,
both of which are positive, 4 samples containing 4 SiHa
cells, the first and fourth of which are positive, the
second and third negative, and 2 samples of 5 SiHa cells




An assay using PCR for detection of HPV DNA has been
designed with novel features of optimised specificity and
sensitivity, and this has been successfully applied to
clinical specimens containing few cells. Absolute HPV
type specificity was achieved by using two
independent stages of oligonucleotide annealing.
First, DNA from each HPV type was amplified using
separate pairs of PCR primers with unique sequences.
The large sizes of primer oligonucleotide, 20-33 bp,
allow annealing temperatures of 50-60°C to be used during
PCR, producing high stringency, and a reduced
probability of illegitimate primer annealing to near-
homologous genomic sequences. The paucity of ghost bands
indicates a highly efficient amplification of legitimate
target sequences. Second, identification of amplified
DNA by hybridisation with type-specific oligoprobes
confers a further degree of specificity. These
oligoprobes were biotinylated during chemical synthesis,
a further novel feature of this assay, thus the hazards
associated with the use of radioactivity are avoided,
and this efficient method of labelling provides a
supply of oligoprobes which are ready to use. Other
PCR-based HPV DNA detection assays have been described,
using common primers that bind to the DNA of more than
one HPV type (Shibata et a1, 1988a; Snijders et al,
1990), or one stage procedures without identification
of amplified DNA (Young et al, 1989) . These are prone
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to the theoretical risk - avoided in the present method -
of incorrect identification of HPV type. The different
sizes of amplified target DNA allow the combination of
more than one pair of PCR primers in a single reaction
(multiplex PCR) . Thus, it has been possible to
simultaneously analyse cervical neoplastic lesions for
HPV types 6b and 16 and also for HPV types 11 and 18.
The design logic of this method would also be generally
applicable to HPV infections at other sites where
detection of specific types is important, such as skin,
where HPV types 5 and 8 have been associated with
malignant lesions in renal allograft recients and
epidermodysplasia verruciformis patients (Arends et al,
1990) .
The high sensitivity of HPV DNA detection was
demonstrated by the detection, within a background of
10000 control non-HPV containing cells, of between 3-5
SiHa cells known to contain 1-2 copies of HPV 16. This
was achieved using 30-35 cycles of PCR, which
produces the maximum quantity of amplified target DNA
limited by the "PCR plateau" effect (Saiki, 1989).
Highly sensitive PCR amplification has the advantage of
applicability to small tissue samples, such as
colposcopic target biopsies of the relatively small,
circumscribed cervical acetowhite lesions typical of CIN.
There is difficulty in identifying HPV by other methods
in specimens with few cells, from which insufficient DNA
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may be extracted. Presumably, this has contributed to the
controversy over HPV involvement in these lesions. PCR is
known to be more sensitive than Southern blotting and
filter hybridisation in the detection of HPV in cervical
scrapes (Melchers et al, 1989/ Schiffman et al, 1991) .
PCR amplification of short sequences within the E6 gene
requires neither intact HPV genomes nor active viral DNA
replication to the high copy numbers per cell necessary
for detection by less sensitive techniques such as in
situ hybridization (Morris et al, 1990; Arends, 1991) .
Only simple preparative procedures such as xylene extra¬
ction of paraffin, proteinase K digestion, and boiling
are required for analysis of these tissues, reducing
the probability of loss of infrequent HPV DNA copies
during processing. The high sensitivity requires meticu¬
lous precautions to minimise the risks of contamination,
such as those used in this work, as well as the inclusion
in every experimental run of a negative control reaction,
to detect contamination should it occur, and this was
exposed to the same environment during all stages of
preparation, but without the addition of a template.
The detection of such tiny amounts of viral DNA raises
questions as to the biological significance of its
presence within lesions. It is now clear that other
events are almost certainly required for HPV to
contribute to malignant change within target epithelium
(reviewed by Arends et al, 1990). Only a small number
of copies of HPV DNA may be required for oncogenic
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activity, perhaps even a minimum of one, if integrated
correctly for continued expression and accompanied by
other appropriate genomic changes. In support of this,
it has been shown that continued expression of the E6 and
E7 genes of HPV 18 within HeLa cells is associated
with maintenance of the malignant phenotype, and
fusion of these with normal cells suppresses both
HPV 18 expression and malignancy in vivo. There
is simultaneous return of both malignancy and HPV 18
early gene expression in revertants which have lost
chromosome 11 (zur Hausen, 1986) . HeLa cells are known
to possess 30-40 copies of HPV 18, whereas another
cervical carcinoma derived cell line, SiHa, contains
only 1-2 copies of HPV 16 DNA, the E6 and E7 genes of
which are also expressed (Pater and Pater, 1988b).
This supports the hypothesis that a single HPV genome,
of a high risk type, may be sufficient to contribute to
the neoplastic phenotype, and an optimally specific and
sensitive assay, such as this, is essential for its
detection.
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2.4 HPV DETECTION IN CONTROL TISSUE, CIN AND CARCINOMA
2.4.1 CLINICAL MATERIAL
Fresh control cervix was taken at autopsy from young
women following accidental death, and frozen sections
prepared. Frozen sections of CIN lesions were obtained
from punch biopsies of abnormal aceto-white cervical
lesions detected colposcopically. Samples of carcinoma
were derived from paraffin blocks. Adjacent sections
were taken for HPV detection, and histological assessment
using sections stained with Haematoxylin and Eosin.
Sections of carcinomas were also stained with Alcian
Blue/Periodic Acid Schiff for mucin. The presence of
normal exocervical and endocervical epithelium and
glands, and the absence of abnormality, were identified
in all samples of control tissue. The grade of CIN and
cancer cell type were assessed independently by two
pathologists, using standard criteria set out in section
2.1. The small number of cases in which there was
discrepancy in CIN grade (equally distributed amongst CIN
1, CIN 2 and CIN 3), or cancer cell type, were resolved
by consensus.
The PCR assay was applied to twenty cases each of CIN 1
(mean age 30.8 yr, SD 8.58, range 19-49), CIN 2 (mean
age 28.65 yr, SD 7.43, range 19-45), and CIN 3 (mean age
31.4 yr, SD 8.43, range 22-50), as well as to twenty
four controls (mean age 35 yr, SD 11.29, range 17-56). No
significant differences in ages between any of the four
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groups were found by the ANOVA or student's t tests.
A total of 47 resected cancers were analysed: 26 cases of
squamous cell carcinoma (mean age 36.6 yr, SD 11.59 yr,
range 20-58 yr) , 17 cases of adenocarcinoma (mean 39.7
yr, SD 7.48 yr, range 28-79 yr), and 4 cases of
adenosquamous carcinoma (mean 33.2 yr, SD 5.85 yr, range
26-40 yr). No significant differences in the ages of
these three groups of cases and the control group were
found by the ANOVA or student's t tests.
2.4.2 RESULTS
No HPV DNA was detected in any of the twenty four
controls. To confirm that the control autopsy frozen
tissue samples and negative biopsy samples retained DNA
suitable for amplification by PCR, and to exclude Taq
polymerase inhibitors in these samples, they were
subjected to amplification of a reference gene, the c-Ha-
rasl gene, using specific primers (Bos et al, 1987) . All
samples tested produced amplified DNA fragments of the
appropriate size for the ras specific primers.
HPV DNA (low and high risk types) was detected in 25% of
CIN 1 cases, significantly different from 60% prevalence
in both CIN 2 and CIN 3 cases, and also from controls.
The prevalence of individual HPV types in these lesions
revealed similar frequencies of HPV 16 (45% and 55%) in





Agarose gel electrophoresis of amplified DNA from seven
cases of CIN using frozen sections as template (a-g).
Five are strongly positive and one (d) is weakly positive
for HPV 16. These were all confirmed as type HPV 16 by
oligoprobe hybridisation. One case (f) is negative.
Very few "ghost bands" are generated. A "template-free"
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Figure 2.8
(A) Bar chart of prevalence of specific HPV types (11, 16
and 18) in twenty four controls (Con) and 20 cases each
of CIN 1, CIN 2 and CIN 3. (B) Bar chart of prevalence of
low risk (HPV 11) and combined high risk HPV types (16
and 18) in 24 controls (Con), 20 each of CIN 1, CIN 2,




HPV PREVALENCE IN CONTROL TISSUE. CIN AND CARCINOMA
HPV Con. CIN 1 CIN 2 CIN 3 SQ.CA. AD.CA. A-S.CA.
Neg 24(100%) 15(75%) 8 (40%) 8(40%) 5(19%) 5(29%) 0
6 0 0 0 0 0 0 0
11 0 1( 5%) 0 0 0 0 0
16 0 3(15%) 9(45%) 11(55%) 15(58%) 5(29%) 3(75%)
18 0 1( 5%) 3(15%) 1(5%) 6(23%) 5(29%) 1(25%)
16+18 0 0 0 0 0 2(12%) 0
33 0 0 0 0 0 0 0
Total 24 20 20 20 26 17 4
Note: Percentage proportions of totals are given in brackets.
TABLE 2.3
STATISTICAL COMPARISONS OF HPV PREVALENCE DATA
SAMPLE 1 SAMPLE 2 X2 Test
p Value
25% CIN 1 0% Con. <0.00001
60% CIN 2 0% Con. <0.00001
60% CIN 3 0% Con. <0.00001
60% CIN 2/3 25% CIN 1 0.025
81% SQ.CA. 71% AD.CA. NS
81% SQ.CA. 0% Con. <0.00001
71% AD.CA. 0% Con. <0.00001
81% SQ.CA. 25% CIN 1 0.0002
71% AD.CA. 25% CIN 1 0.005
81% SQ.CA. 60% CIN 2/3 NS
71% AD.CA. 60% CIN 2/3 NS
38% HPV 16/all CIN 8% HPV 18/all CIN 0.00001
50% HPV 16/CIN 2/3 10% HPV 18/CIN 2/3 0.0001
51% HPV 16/all CA. 30% HPV 18/all CA. <0. 05
58% HPV 16/SQ.CA. 23% HPV 18/SQ.CA. <0. 05
58% HPV 16/SQ.CA. 41% HPV 16/AD.CA. NS
23% HPV 18/SQ.CA. 41% HPV 18/AD.CA. NS
Note: Con. = control; SQ.CA. = sqamous carcinoma; AD.CA. = adenocarcinoma;
A-S.CA. = adenosquamous carcinoma; Neg = Negative; 16+18 = mixed
HPV 16 and HPV 18 DNA content; NS = not significant; all CA. = 26
squamous carcinomas + 17 adenocarcinomas.
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High risk HPV DNA was found in 81% of squamous carcinomas
(58% HPV 16, and 23% HPV 18), and in 71% of
adenocarcinomas (29% HPV 16, 29% HPV 18, and 12% both
types) (table 2.2, figures 2.8 - 2.10). There was no
significant difference in HPV prevalence between squamous
carcinomas and adenocarcinomas, whereas both differed
significantly from controls and CIN 1 cases, but not CIN
2/3 (table 2.3). Closely similar prevalences were
observed if analysis of adenocarcinomas was restricted to
those cases without adjacent, potentially contaminating,
CIN (table 2.4) . In tumours of mixed differentiation,
all 4 adenosquamous carcinomas contained HPV DNA (HPV 16
in 3, HPV 18 in 1).
Twenty two of the 26 squamous carcinomas were stained by
the Alcian Blue/Periodic Acid Schiff method, of which 17
were mucin negative and 5 showed focal mucin positivity.
These 5 consisted of 2 HPV negative, 1 HPV 16 positive,
and 2 HPV 18 positive cases, indicating no obvious
relationship of HPV and focal mucin positivity of
squamous cancers, although only small numbers of such
tumours were available. All of the negative cases were
successfully amplified using primers for the reference




(A) Agarose gel electrophoresis of amplified DNA from PCR
of 8 squamous carcinomas using primers for HPV 16. Of
these cases, 5 are positive (a, b, d, e, h) and 3 are
negative (c, f, g) . (B) Amplified DNA from 9
adenocarcinomas (a-i) and 1 adenosquamous carcinoma (j)
using primers for HPV 18. Four of the adenocarcinomas
are positive (a, f, h, i), and the adenosquamous
carcinoma (j) is also positive. One kb ladder marker
tracks (M), plasmid DNA positive controls (+) and




Dot blot hybridisation of PCR amplified DNA from 10
cancer cases. (A) The oligoprobe for HPV 16 shows
positive hybridisation with three cases of adenocarcinoma
(a, b, c), one adenosquamous carcinoma (d), and one
squamous carcinoma (e). (B) The oligoprobe for HPV 18
shows positive hybridisation with four adenocarcinomas
(a, b, d, e) and one adenosquamous carcinoma (c) .
Positive controls (+) consisting of amplified DNA from an
HPV 16 plasmid, and negative controls (-) consisting of




Agarose gel electrophoresis of amplified ras DNA from 10
cancer cases that were negative for HPV DNA by PCR. A
set of primers for ras were used (Bos et al, 1987) that
generate a 60 base pair amplified product. These were
applied to four cases of adenocarcinoma (a, e, f and
j), and five of squamous carcinoma (b, c, d, g and h),
and all show positive ras amplification. A 1 kb marker
track (M), template free negative control (-) and a ras
plasmid positive control (+) are included.
140
TABLE 2.4
HPV IN ADENOCARCINOMAS WITH AND WITHOUT ADJACENT CIN
HPV + HPV -









Note: Blocks of adjacent cervical tissue were available for
histological assessment of CIN in 16 out of 17
adenocarcinomas. AD.CA. = adenocarcinoma; ADJ. =
adjacent. Percentage proportions are given in brackets.
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In the 60 CIN cases HPV 16 was found at a significantly
higher frequency of 38%, almost five-fold greater than
that of HPV 18 (8%). HPV 16 also significantly exceeds
type 18 in all cancers by a factor of 1.7 (51% to 30%),
and in squamous cancers by a factor of 2.5 (58% to 23%) .
HPV 16 and 18 are equivalent in prevalence (41%) in
glandular cancers, indicating a difference in relative
frequency according to cancer cell type (figure 2.12,
tables 2.2 - 2.6).
Possible differences in the rates of progression of CIN
to cancer were compared for the two high risk HPV types,
by calculating their CANCER/CIN prevalence ratios. The
denominators of the ratios were HPV prevalences in
premalignancies, expressed as the frequency of HPV in
all CIN lesions, or just in CIN 2 and CIN 3, the
immediate precursors, combined because of their identical
60% overall HPV prevalence. Grouping together CIN lesions
of different grade is justified as these histological
diagnoses are based on arbitrary thresholds (1/3 and 2/3
divisions of the epithelium) in a morphological
continuum. The 60 CIN cases had an overall prevalence of
38% for HPV 16, significantly greater than 8% for HPV 18,
whereas HPV 16 was present in 50% of the 40 CIN 2/3
cases and HPV 18 was identified in 10%, a significantly
lower proportion (table 2.3). The numerators of the
ratios were expressed as prevalences in all cancers (51%
for HPV 16, significantly higher than 30% for HPV 18),
squamous carcinomas (58% for HPV 16, significantly
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greater than 23% for HPV 18), or adenocarcinomas (41% for
both) . The CANCER/CIN prevalence ratios were
approximately two- to five-fold greater for HPV 18 than












ES3 HPV 16 CZH HPV 18
Figure 2.12
Bar chart of the prevalence of HPV 16 and HPV 18 in




□ CIN E22 CARCINOMA
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HPV PREVALENCE IN CERVICAL NEOPLASIA
HPV Prevalence
HPV 16 HPV 18
Figure 2.13
(A) Bar chart of the prevalence of HPV 16 and HPV 18 in
60 cases of CIN (20 each of CIN 1, CIN 2 and CIN 3) and
in 43 squamous and glandular cancers (26 and 17
respectively). (B) Graph of the prevalence of HPV 16 and
HPV 18 in 24 normal controls, 20 cases of CIN 1, 40 cases
of combined CIN 2/3, and 43 cases of cancer (26 squamous
and 17 glandular carcinomas). There is a marked
difference in the slopes of the curves between CIN 2/3
and cancer when comparing HPV 16 and HPV 18.
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TABLE 2.5
PREVALENCE RATI08 OF CANCERS AND THEIR PRECURSORS
PREVALENCE RATIO HPV 16 HPV 18 18/16
RATIO
ALL CA./ALL CIN 1.3 3 . 8 2.9
ALL CA./CIN 2/3 1.0 3 . 0 3.0
SQ.CA./ALL CIN 1.5 2.9 1.9
SQ.CA./CIN 2/3 1.2 2.3 1.9
AD. CA./ALL CIN 1.1 5.1 4.6
AD. CA./CIN 2/3 0.8 4 .1 5.1
Note: CA. = cancer; CIN = cervical intraepithelial neoplasia;
SQ.CA. = squamous carcinoma; AD. CA. = adenocarcinoma.
TABLE 2.6
HIGH RISK HPV TYPES IN SQUAMOUS AND GLANDULAR CANCERS










ISH 54% 0% 2% 40%
Wilczynsky
et al (1988)
SB 50% 7% 13% 50%
Arends PCR 58% 23% 41% 41%
Note: SQ.CA. = squamous carcinoma; AD.CA.= adenocarcinoma;
ISH = in situ hybridisation; SB = Southern blotting;
PCR = polymerase chain reaction.
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2.5 DISCUSSION
The data on HPV prevalence in normal cervices, CIN and
cervical cancers, obtained with this assay are
qualitatively similar to many previous studies in showing
high prevalence of HPV in cancer and CIN 3, but low
prevalence in CIN 1 and normal cervix. However, they
differ quantitatively from other reported work in several
respects: a higher prevalence of high risk HPV types in
CIN 2, a slightly lower prevalence in CIN 3 and cancer,
different ratios of HPV 16 to HPV 18 in squamous and
glandular cancers, and a complete absence of HPV in
normal cervices.
2.5.1 HPV IN CONTROLS
The negative results for the twenty four control samples
contrast with most previous reports. The trivial
explanation that autopsy material is unsuitable for PCR
was excluded by amplification of a reference gene.
Control prevalences, derived by PCR-based assays, have
varied between 0% and 84% (table 2.7). Using non-PCR
methods, 10%-12% of normal controls have been observed to
be HPV DNA positive (Toon et al, 1986; deVilliers et al,
1987) .
Presence of HPV DNA within cervices of the normal
population is classified as latent HPV infection, thought
to occur focally within the cervix, but producing no
clinical or histological effects (Schneider, 1990). These
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features are likely to lead to underestimation of its
prevalence if measured using small samples of localised
regions of the cervix, such as the blocks tested in this
study, rather than widespread scrape sampling. Thus, the
method of sample collection of tissue may have tended
towards underestimation.
The highest control prevalence detected by PCR was 84%
(Tidy et al, 1989a and 1989b), but this was subsequently
retracted, citing sample contamination as the source of
error (Tidy and Farrell, 1989) . Contamination may also
explain some of the other high prevalences reported in
the earliest PCR work, as the risks may not have been
widely appreciated. Stringent precautions were taken in
this study to avoid contamination, and the finding of 0%
HPV positivity in the control group is in keeping with
claims of their effectiveness.
Other reports of high HPV prevalence in control cervices
may reflect particular features of the patients chosen as
controls. Thus, Morris et al (1989) found 53% positives
in 107 cases from a high risk population taken from a
sexually transmitted disease (STD) clinic, of which two
thirds had abnormal cervical cytology. The assay tested
for types 6, 11, 16, 18 and 33. Young et al (1989) found
70% HPV positive in only 10 cases from gynaecology or
family planning clinics. These patients had at least two
consecutive negative smears, but a history of cervical
disease was not specifically excluded. The PCR assay
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detected only types 16 and 11. The subjects chosen as
controls in these 2 series may not be representative of
the normal population, since all had reason to attend STD
or gynaecological clinics. In contrast, the control
subjects analysed in the present study were not taken
from such clinics, but almost all were recruited on the
apparently random basis of being victims of road traffic
accidents or other causes of accidental death.
Low prevalence rates for HPV genomes present in control
cervices have also been reported. Melchers et al (1989),
using a PCR method to detect the same 5 HPV types as this
thesis, found 5% HPV positives in 100 cases from
gynaecology clinics, with 3 consecutive negative smears
and no history of cervical disease. The primers for HPV 6
and 33 were sited in LI however, which increases the
risk that integrated HPV DNA was not detected. The assay
presented here amplified E6 sequences for all HPV types
to avoid this risk. Van den Brule et al (1989) found 6%
HPV prevalence applying a PCR assay to 220 regularly
screened women in Holland. Manos et al (1990)
investigated the prevalence of HPV 16 in normal
populations using two PCR-based assays. One employed
consensus primers situated in Ll followed by an HPV 16
type-specific probe, and the other was type-specific
amplifying a segment of the HPV 16 URR (data sets I and
II in table 2.7). Both assays detected identical levels
of HPV 16 prevalence in three American populations: 0% in
women attending planned parenthood clinics, and 11% and
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geographically separate studies of female
students undergoing gynaecological
in health clinics.
In the control population analysed in this thesis no HPV
positive samples were found using a PCR-based assay
optimised for specificity and sensitivity, although only
small numbers were analysed (24). This is in keeping with
the 0% prevalence data from the study by Manos described
above, derived from a planned parenthood clinic, and adds
weight to the importance of the source of subjects.
Those controls found to be negative for HPV types 6b, 11,
16, 18 and 33 in this assay, may nevertheless contain
HPVs of other types which are less well defined in terms
of their oncogenic potential. Interestingly, another
study of 88 control women found 11% HPV positive by
Southern blotting, and 31% by PCR using consensus
primers, but most of the HPV infections found only by PCR
were not due to the "common genital" types (6, 11, 16,
18, 31, 33, and 45) (Schiffman et al, 1991). Manos et al
(1990) also found evidence of 20% - 30% control
positivity for HPV of types other than HPV 16, using an
LI consensus primer assay (data set I in table 2.7),
compared with 0% - 22% for HPV 16 only (data set II), in
the 3 control series described above. Thus, much of the
conflicting PCR data may be explained by the method of
tissue sampling, stringency of anti-contamination





and differences in design of PCR-based assays
(consensus or type-specific) which influence the range of
HPV types detected. There is preliminary evidence to
suggest that different HPV types may be found in normal
compared to neoplastic cervical epithelium. In keeping
with this, the data from several groups, together with
the findings presented in this thesis, are suggestive
of low prevalence rates for high risk HPV types in normal
cervices. This would tend to strengthen the association



































































































































































































































































2.5.2 HPV IN CIN
The 60% prevalence of HPV 16/18 in both CIN 2 and CIN 3
is significantly higher than the 25% for all HPV types in
CIN 1 and 0% in controls. There is also a complete
absence of HPV 6b or 11 in the high grade CIN lesions.
This relatively high prevalence of HPV 16 and 18 in CIN
2 (60%) is greater than reported previously for CIN 2
biopsies analysed by dot blots (Pater et al, 1986). Few
PCR-based studies have included separate categories of
CIN 1, CIN 2 and CIN 3, although van den Brule et al
(1989) tested cervical scrapes showing mild dysplasia and
found 31% HPV positive in a screened population and 58%
positive in a population attending a gynaecology clinic.
The data for CIN 3 biopsies in this study are similar to
the finding of 67% HPV positivity detected using PCR in
a series of scrapes showing severe dysplasia (van den
Brule et al, 1989). Higher prevalence rates were found in
a smaller PCR study that showed 100% HPV positivity in 4
cervical scrape specimens of carcinoma in situ, and 75%
HPV positivity in 8 cases of severe dysplasia (Melchers
et al, 1 9 8 9 ) . Using a consensus primer PCR assay,
Schiffman et al (1991) found all of 12 dysplastic scrapes
contained HPV DNA, but the grades of CIN were not given.
The derivation of cells within samples influences
interpretation of the data. Almost all previous PCR
studies have used cervical scrapes or lavage specimens,
which contain largely superficial cervical cells and
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fewer basal and suprabasal cells. These methods also
sample a large area of exocervical epithelium, and may
include separate regions of viral replication not
necessarily relevant to CIN lesions in other regions.
Such widespread sampling would tend to overestimate HPV
positivity in CIN. This study used tissues sampled by
punch biopsy, focussed on the regions affected by aceto-
white change suspicious of CIN. This confers the
advantage of localising the viral agent to the abnormal
cells of interest.
At the 1990 Papillomavirus Workshop, many PCR-based HPV
detection studies were reviewed giving an overall
prevalence of 60%-90% for all HPVs in high grade CIN
lesions, with HPV 16 as the most frequent type.
Undetermined HPV types (using consensus primers) were
present in 10%-15% (Stanley, 1990) . The report in this
thesis of HPV 16 and 18 positivity in 60% of CIN 3
lesions using an absolutely type-specific assay is
consistent with these data.
The findings presented here emphasise the biological
similarity of CIN 2 and CIN 3 lesions in terms of the
prevalence of high risk HPV types, and their divergence
from CIN 1. This supports a contribution of high risk
HPV types to neoplastic change in cervical epithelium,
particularly the transition to lesions of higher grade
than CIN 1.
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2.5.3 HPV IN CERVICAL CARCINOMAS
The finding of HPV 16 and 18 in 81% squamous carcinomas
and 71% adenocarcinomas is similar to prevalences of 70%-
100% reported by others using PCR methods (table 2.7)
(Xiao et al, 1988; van den Brule et al, 1989; Resnick et
al, 1990; Stanley, 1990). The results demonstrate
increasing prevalence of high risk HPV types through the
spectrum of cervical neoplasia towards malignancy (figure
2.8) .
HPV 16 was significantly more prevalent in all cervical
cancers (51%) than HPV 18 (30%). If this was due to
differences in overall prevalence of these HPV types in
the community, and HPVs had no influence upon cancer cell
differentiation, similar prevalences of HPV 16 and 18
would be expected in both squamous and glandular cancers.
However, HPV 16 was found in 58% of squamous carcinomas,
significantly greater than the 23% containing HPV 18, but
HPV 16 and HPV 18 were present in equal proportions
(41%) of glandular cancers, a much less common tumour
type (figure 2.12, tables 2.2 and 2.3) . Significant
differences were not seen comparing the prevalences of
HPV 16 in squamous versus glandular cancers, or comparing
HPV 18 positivity in the two histological types of
cancer. The overall pattern of HPV prevalence suggests a
trend towards HPV 18 overcoming a lower overall
prevalence than HPV 16 when found in adenocarcinomas.
This pattern shows some similarities to previously
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reported data gathered by in. situ hybridisation and
Southern blotting, but the more sensitive PCR assay used
here detected a higher prevalence of HPV 18 in squamous
cancers, and a greater HPV 16 positivity in glandular
cancers (table 2.6) (Tase et al, 1988/ Wilczynsky et al,
1988) .
Two groups have detected little or no HPV in cervical
adenocarcinomas. Young et al (1990) examined 21 cases of
adenocarcinoma using in. situ hybridisation and found no
evidence of HPV types 16 or 18. Griffin et al (1991)
tested 16 cases of adenocarcinoma using PCR and found low
prevalences of HPV type 16 (25%) and type 18 (4%). In the
light of the data presented here, it is much more likely
that the low prevalences detected by Young and Griffin
can be accounted for by methodological considerations.
First, i n situ hybridisation is known to be
significantly less sensitive than PCR for detection of
HPV (Levi et al, 1989), and Young et al gave no
indication of the sensitivity of the method they used.
Second, Griffin et al used a large section (50 urn thick)
of paraffin wax embedded tissue as the template for HPV
detection by PCR assay. Others have found that when
using paraffin wax embedded tissue as a template for PCR,
the product yield decreased with increasing amounts of
paraffin-embedded tissue (Lo et al, 1 9 8 9 ) . PCR
inhibitors would be expected, given the amount of this
type of tissue analysed by Griffin et al, and
furthermore, negative cases were not checked for PCR
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inhibitors by amplifying a reference gene such as ras DNA
amplification as used in this study. Third, the
possibility that samples of adenocarcinomas may be
contaminated with HPV DNA from adjacent CIN was excluded
in this study, as cases were assessed histologically for
adjacent CIN, and no relationship between this and HPV
positivity was found: 73% of cases with no adjacent CIN,
and 71% of all adenocarcinomas, contained HPV DNA.
Two explanations can be offerred for the differences in
prevalence of HPV 16 and 18 in cervical cancers (figure
2.14). The 2 HPV types may preferentially infect
different cervical cell types. Since initial infection is
thought to involve basal cells of the cervical
epithelium, this implies that certain cells are already
committed to either glandular or squamous
differentiation. There is no direct evidence to support
this, and the behaviour of cervical stem cells in forming
either glandular or squamous epithelium is not fully
understood. Alternatively, HPV 18 infection of
uncommitted stem cells in the basal layer may tend to
induce glandular differentiation of subsequently formed
cancers or their precursors, whereas HPV 16 infection may
tend to induce squamous differentiation. Further
experimental work is required to establish the validity
of either proposition.
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UN MMI ED SQUAMOUS
HPV 16 STEM CELL DIFFERENTIATION
Figure 2.14
Two possible models of the relationships of high risk
HPVs and cancer cell differentiation. In the first,
separate HPV types preferentially infect stem cells
already committed to a particular pathway of
differentiation. In the second, HPVs infect an
uncommitted stem cell and different HPV types influence
the pattern of differentiation along alternative
pathways.
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Reconstructions using cervical epithelial cells
transfected with HPV genomes and cultured on rafts in
vitro invariably display squamous differentiation
(McDougall, 1990; Meyer and Laimins, 1992). This probably
reflects the influence of the raft culture conditions on
the target cells used. Perhaps transfection of a
different cell type may be more informative, for example
embryonal stem cells which can remain undifferentiated or
can differentiate according to culture conditions.
Cervical squamous carcinomas occur more frequently and
have a better overall prognosis than adenocarcinomas
(Buckley et a1, 1988; Buckley and Fox, 1989). The
association of squamous cancers with significantly more
HPV 16 than HPV 18, compared with equivalence of HPV
prevalence in adenocarcinomas, suggests that HPV 16
confers a better prognosis in terms of histological type
of cancer, regardless of the mechanism of interaction of
HPV with the programme of cell differentiation. HPV
genes may influence cell differentiation, or genes
controlling cell differentiation may regulate expression
of HPV genes to different extents (as occurs in
replicative infections and in vitro raft cultures), or a
combination of the two.
HPV types may differentially affect progression of
precursor lesions to cancers. It is widely accepted that
squamous carcinoma can develop from CIN, and similarly
adenocarcinoma in situ (AIS) may progress to
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adenocarcinoma (Ferenczy and Winkler, 1987/ Richart,
1987). However, much less is known about the possibility
of CIN transforming to adenocarcinoma. CIN can be found
adjacent to glandular cancers in a proportion of cases,
31% in this study (table 2.4), supporting the existence
of this sequence of progression (Okagaki et al, 1989). In
contrast, AIS is uncommon, was not identified in the
material analysed here, and the possibility of its
transformation to squamous carcinoma, although remote,
cannot be excluded. In another study, HPV 18 was found in
two thirds of 88% AIS cases positive for HPV mRNA, and
one third contained HPV 16 (Farnsworth et al, 1989),
supporting a role for HPV in the AlS-adenocarcinoma
sequence.
CANCER/CIN prevalence ratios may shed light on different
rates of progression along the precursor-malignancy
sequence associated with HPV 16 and HPV 18. These may be
calculated in different ways according to the type of
precursor and cancer to be compared (table 2.5). The
overall pattern of HPV prevalence in all cancers and all
CINs gives a ratio of 1.3 for HPV 16 (51%/38%) and 3.8
for HPV 18 (30%/8%) . This three-fold difference in ratio
is maintained when comparing HPV prevalences in all
cancers and in CIN 2/3 lesions, the more immediate
precursors. This difference is demonstrated graphically
by the steeper slope between CIN 2/3 and cancer for HPV
18 compared with that for HPV 16 (figure 2.13). The
prevalence ratios move closer together, giving a two-fold
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difference between HPV 16 and HPV 18, when comparing
prevalences in squamous carcinomas either with all CINs,
1.5 for HPV 16 (58%/38%) and 2.9 for HPV 18 (23%/8%), or
with CIN 2/3 lesions, 1.2 and 2.3 for HPV 16 and 18
respectively (table 2.5). These figures are broadly
similar to those of Kurman et al (1988), who compared HPV
prevalences in squamous cancers and those in all CINs:
1.1 for HPV 16 (41%/37%) and 7.3 for HPV 18 (22%/3%).
Kurman used Southern blotting and reported lower
prevalences, particularly for HPV 18 in CINs, than those
described here. There are five-fold differences between
HPV 16 and 18 in the prevalence ratios for
adenocarcinomas and either all CINs, or CIN 2/3 lesions.
This last set of ratios should be interpreted with
caution as AIS may be a more important precursor of
adenocarcinoma than CIN, although there is a lack of
information on this question which may be related to the
relative infrequency of AIS lesions. Overall, there is a
consistent pattern of two- to five-fold difference
between HPV 16 and HPV 18 in the range of prevalence
ratios. The relatively lower frequency of HPV 18 in CIN
compared with invasive cancer may represent a more rapid
transit time through the precursor stage associated with
HPV 18. This suggests that HPV 18 is a more aggressive
type than HPV 16, in playing a role in rapidly
progressive cervical neoplasia. This proposition is
examined further in later sections of this thesis.
The prevalence data may provide an indication of the
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position in the CIN-cancer sequence at which high risk
HPVs make a key contribution and allow refinement of the
model of multistage carcinogenesis set out in chapter 1
(figure 2.15) . HPV types 16 and 18 have a low level of
association (0% — 20%) with histologically normal
epithelium (latent infection) and CIN 1. A sharp increase
in prevalence to 60% is observed for CIN 2 and CIN 3, and
a further, smaller increment to 70%-80% for invasive
cancers. The greatest increase in prevalence (3-fold) to
CIN 2/3 is suggestive of the point of maximal
contribution to neoplastic change. Experimental
reconstructions of human genital keratinocytes
transfected with HPV 16 or 18 DNA grown on raft cultures
also show morphological appearances approximately
equivalent to CIN 2/3 (McCance et al, 1988/ Rader et al,
1990/ McDougall, 1990), supporting this assignment of the
point of HPV effect. This raises the question of why high
risk HPVs may sometimes be associated with no
histological changes, sometimes CIN 1, and at other times
CIN 2/3? One possible explanation is the level of
expression of the viral oncogenes E6 and E7. Low dose
infection with small copy numbers of HPV genomes, or host
cell suppression of viral transciption, may lead to
latent infection or only minor morphological changes such
as CIN 1. Greater copy numbers of HPV DNA in basal cells,
or escape from host cell control of viral transcription,
may produce higher levels of E6 and E7 proteins. These
may reach a sufficient level to interact with cellular
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oncosuppressor proteins p53 and Rb, inactivating or
subverting them, to affect cell functions and result in
CIN 2/3 lesions. Further deregulation of expression of
E6 and E7 following viral integration, perhaps acting in
cooperation with other host cell genetic changes, may
produce malignant transformation to invasive carcinoma.
This model allows for both direct transition from normal
to CIN 2/3, or sequential progression through latent HPV
infection, or CIN 1 to CIN 2/3, according to the levels
of E6 and E7 proteins. Although high risk HPVs are
envisaged as playing a central role, other host cell
genetic changes influencing development of CIN are not
excluded, either separate from viral effects as in HPV
negative CIN lesions, or in conjunction with HPVs. Growth
advantage induced at the CIN 2/3 stage may increase the
probability of further progression to cancer, and
differences at this stage between HPV 16 and HPV 18 may
explain the more rapid transition to malignancy
associated with HPV 18. Such differences between the two
virus types may be due to functional aspects of the E6
and E7 proteins, or perhaps differences in their relative
levels of expression.
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CIN - CANCER SEQUENCE








prevalence 0% - 20% 60% 70% - 80%
Figure 2.15
Model of events in the CIN-CANCER sequence, which
incorporates the prevalence data. HPV infection of stem
cells in the cervical epithelium may lead to either
latent infection or CIN 1 (0% — 20% prevalence of HPV 16
and 18). CIN 1 may progress to CIN 2/3, or
alternatively, HPV infection may directly induce CIN 2/3
lesions (60% of which contain high risk HPV DNA).
Integration of the viral genome and other events
(oncogene activation and inactivation of oncosuppressor
genes) are likely to be involved in the transition to
invasive cancer (70%-80% of which contain high risk HPVs)
and subsequent development of metastatic cancer. The
precise point at which integration occurs is not certain,
but this may be either before or at the time of
transition to malignancy. The biggest jump in prevalence
from 20% to 60% occurs at the transition from latency/CIN
1 to CIN 2/3 and this indicates the key point of action
of high risk HPVs.
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2.6 CONCLUSIONS
1) Using a PCR-based assay with many new features, the
prevalence of high risk HPV types in normal cervical
epithelium was found to be zero.
2) The HPV prevalence data emphasise the biological
similarity of CIN 2 and CIN 3 lesions, and their
divergence from CIN 1. This suggests that high risk HPVs
may make a key contribution early in the neoplastic
process by generating these high grade premalignant
lesions.
3) HPV 16 is associated with more cancers showing
squamous differentiation, and HPV 18 with the clinically
more sinister glandular differentiation. Similarly, HPV
18 appears to be associated with a more rapid neoplastic
progression as it has higher CANCER/CIN prevalence ratios
than HPV 16. For these reasons, HPV 18 appears to be a
more aggressive type than HPV 16.
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3.1.1 APOPTOSIS IN NEOPLASIA
During tumour growth, cells may be lost by a variety of
means. These include cell death by apoptosis or necrosis,
cell migration or exfoliation, and differentiation of
tumour cells to non-pro1iferative terminally
differentiated cells. Of the modes of cell loss, death
appears to be the most numerically significant and can
occur by either necrosis or apoptosis (Wyllie, 1985) .
Necrosis does occur at elevated levels in very aggressive
tumours, buL this is thought to be related to rapid
expansion of tumour size producing zones of hypoxia and a
lack of blood-bo rne nutrients (Rotin et al, 1986),
variation in the production of angiogenic factors by the
tumour cells (Denekamp and Hobson, 1982/ Folkman, 1986)
and production of tumour necrosis factors (TNF) by the
host (Old, 1985; Klostergaard, 1 98 6) . Tumour necrosis
has been related to the state of oxygenation of blood in
the tumour environment (Schatten et al, 1962/ Lala, 1972)
and necrosis has been observed at a strikingly constant
distance from blood vessels for any tumour (Thomlinson
and Gray, 1955/ Tannock, 1968/ Jones and Camplejohn,
1983; Tozer et al, 1990) .
High tumour cell loss, however, can occur in tumours
with almost no necrosis (Lala, 1972) . There is evidence
that apoptosis accounts for regression not only of non¬
neoplastic tissues (Wyllie et al, 1973a and 1973b; Kerr
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and Searle, 1973) and preneoplastic focal proliferations
of hepatocytes (Bursch et al, 1984), but also of hormone-
dependent carcinomas (Gullino, 1980), tumour cell death
induced by anticancer agents (Barry et al, 1990/ Dive and
Wyllie, 1992), and experimental pancreatic and breast
carcinomas after treatment with peptide hormone analogues
(Szende et al, 1989). Apoptotic bodies have been observed
in many human cancers, including cervical carcinoma
(Searle et al, 1973), and these are rapidly phagocytosed
by adjacent tumour cells and degraded by their lysosomal
enzymes (Kerr and Searle, 1 972a and 1 972b) . The
paradoxically slow growth of basal cell carcinomas which
have a high mitotic index, but little or no necrosis
(Kerr and Searle, 1972a) is also attributable to
apoptosis.
Apoptosis has been suggested to be the only cellular
process capable of adequately accounting for the majority
of tumour cell loss, although there is little direct
quantitative evidence of this (Kerr et al, 1972/ Kerr and
Searle, 1972a/ Wyllie et al, 1981/ Wyllie, 1985/ Sarraf
and Bowen, 1986/ Bowen and Bowen, 1990). It is not known
whether tumour cell apoptosis occurs mostly in response
to endogenous activation of internal genetic programmes,
or whether there is a sizable contribution by exogenous
stimuli, including immune cell attack, therapeutic
agents, hyperthermia, toxins and relative hypoxia around
necrotic zones (Wyllie,1985/ Dyson et al, 1987/ Barry et
al, 1990).
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Little is known of the roles of oncogenes and viral genes
in the regulation of tumour cell apoptosis, and these are
reviewed here. Possible mechanisms of transformation by
myc and ras were described in chapter 1, and those of
human papillomaviruses are discussed in this section.
3.1.2 ONCOGENES AND TUMOUR CELL APOPTOSIS
Recently, Wyllie et al (1987 and 1989) initiated study
of whether the rates of apoptosis in tumours are
influenced by oncogene expression, by counting the
frequency with which apoptosis is found in experimentally
transplantable tumours. Oncogene expressing rodent
fibroblast lines transfected with c-myc, or mutationally-
activated c-Ha-rasl (from the T24 bladder cancer cell
line, with a point mutation at codon 12), or the c-Ha-
rasl proto-oncogene, formed malignant tumours in immune
suppressed mice (Spandidos, 1985/ Wyllie et al, 1987 and
1989) . The immortalised 208F parent cell line gave rise
to small, non-progressive nodules. About half of the mice
injected with c-myc transfeetants developed tumours at
the injection site, which grew slowly, were weakly
tumorigenic and non-metastatic at 14 days. Within these
tumours, apoptosis was conspicuous, occurring at
similarly high levels to mitosis. In contrast, over 90%
of mice injected with cells expressing activated T24-ras
developed aggressive, large, metastasising tumours in
which apoptosis was seldom seen although mitosis occurred
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at high frequency. Cells expressing the c-Ha-ras1 proto-
oncogene were intermediate in properties.
The net tumour growth was consistent with the balance of
cell gain and loss, manifested by the differing
frequencies of mitosis and apoptosis. The T 2 4 -ra s
expressing cells differed from the others, both in
combining low apoptosis with high mitosis, and in
producing more aggressive tumours. Thus, with regard to
these single examples of oncogene transfectants, there
are indications that ras and myc oncogenes appear to
differentially regulate the relative rates of cell gain
and loss within primary tumours. My c appears to
stimulate tumour cell apoptosis, whereas ras appears to
suppress it.
Others have reported similar properties of ras genes.
Withdrawal of interleukin-3 induced cell death of mouse
PB-3c mast cells, and this was reversed on induction of
Ha-ras oncogene expression (Andrejauskas and Moroni,
1989). Ki-ras expression decreased in association with
the onset of apoptosis in rat chloroleukaemic cells
(Servomaa and Rytomaa , 1987) . Other genes have also been
implicated in the control of tumour cell apoptosis.
0verexpression of the be 1-2 oncoprotein reduced
apoptotic cell death of a pro-B lymphocyte cell line
(Hockenberry et al, 1990), and extended the survival of
certain haematopoeitic cell lines after growth factor
withdrawal (Vaux et al, 1988/ Nunez et al, 1990) .
171
3.1.3 VIRAL GENES AND TUMOUR CELL APOPTOSIS
Much is known of the effects of viral genes on tumour
cell proliferation. In contrast, few studies have been
performed correlating DNA viral gene activity with
effects on tumour cell apoptosis. One such investigation
involved the Epstein-Barr virus (EBV), a human
herpesvirus. EBV is associated both with infection and
transformation of B cells. Persistent infection implies a
mechanism of viral persistence in B cells in vivo which
usually have only a limited lifespan. EBV has also been
implicated as a key aetiological agent in the African
form of Burkitt's lymphoma (BL) (a B cell malignancy),
and nasopharyngeal carcinoma (epithelial cancer) in China
(Lenoir and Bornkamm, 1987/ Rickinson, 1990). EBV latent
proteins have been shown to suppress apoptosis in
Burkitt's lymphoma clones (Gregory et al, 1991). Thus,
inhibition of tumour cell apoptosis, by certain viral
genes, may be an important contributor to oncogenic
growth.
The possibility also exists that HPV influences apoptosis
of its target cell, either during infection altering the
lifespan of the infected cell, or following
transformation affecting the rate of population expansion
of neoplastic cells. This hypothesis is explored in this
thesis. The molecular mechanisms of HPV-induced cell
transformation may also be relevant to viral control of
tumour cell gain and loss, and these will be reviewed.
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3.1.4 HUMAN PAPILLOMAVIRUS TRANSFORMATION
Studies of transformation by bovine papillomavirus (BPV1)
and other animal papillomaviruses (Howley et al, 1986),
established the carcinogenic properties of this group of
DNA viruses and set out the systems for analysis of
transforming potential of human PVs once these became
available as cloned genomes. Early experiments
demonstrated that human papillomaviruses 5, 16 and
18 were capable of transforming to tumorigenicity, the
established rodent cells C127 or NIH3T3 (Watts et al,
1984/ Yasumoto et al, 1986/ Bedell et al, 1987).
Subsequently, high risk genital HPV types 16, 18, 31 and
33, but not low risk HPV types 6b and 11, were shown to
cooperate with mutationally activated human c-Ha-rasl
to transform primary rodent kidney epithelial cells to
malignancy (Pater et al, 1988a/ Storey et al, 1988/ Crook
et al, 1 98 8 ) . Primary rodent cell transformation in
cooperation with high risk HPV types is also observed
with v-fos (from the FBJ murine sarcoma provirus), but
not v-fms, v-mos, c-src or the human p53 minigene (Crook
et al, 1988).
The natural target cell of HPV in vivo is, of course,
not the rodent fibroblast or kidney epithelial cell,
but the keratinocyte. HPV alone does not transform
primary human keratinocytes or other cell types to
tumorigenicity. However, experimental introduction of DNA
of HPV types 16, 18, 31 or 33, but not types 6b or 11,
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into human foreskin or cervical keratinocytes induces
several key attributes of the neoplastic phenotype.
These include immortalization (rescue from senescence),
aneuploidy and a reduced growth factor requirement
(growth in low serum) (Durst et al, 1987b; Pirisi et
al, 1987 and 1988; Woodworth et al, 1988 and 1989) . HPV
18 DNA is 5 times more efficient than HPV 16 DNA at
immortalizing human keratinocytes, regardless of the
method of transfection, indicating the more aggressive
properties of HPV 18 (Barbosa and Schlegel, 1989) .
HPV 16 or 18 transfected keratinocytes retain the ability
to stratify, but fail to differentiate normally when
cultured on "dermal equivalent" collagen rafts in
vitro, and show histological abnormalities similar to
genital intraepithelial neoplasia in. vivo (McCance et al,
1988; Rader et al, 1990) . These stratified raft cultures
show downregulation of differentiation-specific keratins
(such as K6a and K14), and increased resistance to
differentiation signals, such as calcium and TPA (Kaur
and McDougall, 1989) . Complete loss of differentiation
was observed in late passage HPV 18 immortalized cells
(Hudson et al, 1990), and one HPV 18 immortalized line
has been derived which is tumorigenic at high (>60) but
not low (<20) passage number (McDougall, 1990) .
The addition of mutationally activated v-Ha-ras or v-Ki-
ras to HPV 16-immortalized human keratinocytes results in
full malignant transformation, with production of
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squamous cell carcinomas on injection into
immunologically incompetent mice (DiPaolo et al, 1989/
Durst et al, 1989).
The E6-E7 subgenomic fragment has been shown to encode
the transforming functions of HPV 16 and 18 in
established rodent cell lines ( Matlashewski et al, 1987;
Bedell et al, 1987/ Storey et al, 1988/ Vousden et al,
1988 and 1989), and also the immortalizing functions in
primary human genital keratinocytes (Kaur et al, 1989;
Munger et al, 1 9 8 9a) . Studies on transforming
activities of single genes, subcloned from high risk
HPV types, showed that the activity of E6 was lower
than that of E7 (Kanda et al, 1988/ Vousden and Jat,
1989/ Storey et al, 1988/ Crook et al, 1988). E7 genes
from low risk HPV types 6b and 11 show markedly reduced
transforming activity by comparison (Storey et al, 1990) .
E7 but not E6 can immortalize human genital keratinocytes
- although the efficiency is enhanced by E6 (Hudson et
al, 1990). The E7 and E6 genes apparently influence
different aspects of the transformation phenotype in
other experimental models (Yutsudo et al, 1988) . Both
E6 and E7 sequences were required for HPV 16 induced
extension of life span of human fibroblasts (Watanabe et
al, 1 98 9) . The E6-E7 region may not be the sole
transforming domain, as transfection experiments with
rodent NIH3T3 cells have demonstrated a lower level of
transforming activity in the E2-E4-E5 region of both HPV
16 and 18 (Vousden et al, 1988; Bedell et al, 1989). This
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activity may reside in the E5 gene, which is known to
have a transforming function in BPV1, and has been shown
to activate, by tyrosine phosphorylation, the membrane
receptors for epidermal and platelet-derived growth
factors (Martin et al, 1985; Petti et al, 1991) . BPV 1 E5
also binds to the 16Kd component of vacuolar H+-ATPases
critical for the function of cellular compartment
processing of membrane-associated molecules such as
growth factor receptors (Goldstein et al, 1991) .
Differences in oncogenic potential of high and low risk
HPV types have been investigated by comparison of the
nucleotide sequences of HPV 16 and 18 with those of HPV
6b and 11. This has revealed that within the E6 sequences
of the two high risk viruses there are potential internal
RNA splice sites, both donor and acceptor. When used
by the host cell RNA splicing machinery in the
processing of E6 containing transcripts, smaller E6
proteins (E6*, E6** and E6***) are produced with
different carboxy termini (Schneider-Gadicke and
Schwar z, 1986; Schneider-Gadicke et al, 1988;
Cornelissen et al, 1990) . E6 splicing may influence the
rate of translation initiation from the E7 start codon
(Sedman, personal communication). HPV 6b and 11 can also
generate E7 mRNA by a different mechanism from HPV 16 and
18, by using a promotor within the E6 sequence, which is
not present in HPV 16 and 18 E6 sequence (Smotkin et al,
1989). It remains to be evaluated whether these sequence
differences in the E6 genes contribute a higher
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oncogenic potential upon HPV 16 and 18, confer some
other function upon them, or are merely harmless relics
of viral evolution.
Experimental reconstructions therefore, strongly suggest
that E6 and E7 are the viral transforming genes. Three
strands of further evidence support the view that E6 and
E7 sequences are the HPV genes which confer some
of the oncogenic properties upon human tumour cells.
(1) E6 and E7 sequences are conserved on integration.
There is a consistent pattern of viral DNA integration
in cervical carcinomas and cell lines, which
conserves intact URR-E6-E7 DNA sequences and allows
continued expression of the E6 and E7 genes (see chapter
1) •
(2) E6 and E7 proteins are expressed in neoplastic cells.
Both human cervical carcinomas and carcinoma derived
cell lines express mRNA and proteins of E6 (11-18
kDa protein) and E7 (12-15 kDa protein) (Smotkin
and Wettstein, 1987/ Baker et al, 1987/ Seedorf et al,
1 987 / Androphy et al, 1 987/ Shirasawa et al, 1987 ) .
Human cervical cells, both immortalized by high
risk HPV DNA (16, 18, 31 or 33), and malignantly
transformed in 2 stages by HPV 16 and activated ras,
express E6 and E7 proteins (Woodworth et al, 1989/
DiPaolo et al, 1989) .
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(3) E6 and E7 bind DNA and interact with tumour
suppressor proteins. Both HPV E6 and E7 amino acid
sequences contain a conserved pattern of repeating
cysteine doublets (Cys-X-X-Cys), similar to those found
in steroid receptor zinc finger proteins, which mediate
coordination of zinc, and DNA binding (Baker, 1987/ Cole
and Danos, 1987/ Barbosa et al, 1989/ Grossman et al,
1989/ Grossman and Laimins, 1989/ Vousden et al, 1989).
Cysteine mutations in the HPV 16 E7 Cys-X-X-Cys motifs
also decrease E7 transformation and transactivation
efficiency (Storey et al, 1990).
The HPV 16 E7 amino acid sequence contains a motif shared
with the SV40 large T antigen, the conserved domains
1 and 2 of adenovirus Ela protein, and the v- and c-
myc oncoproteins. This motif has been shown to encode
the transforming function of SV40 large T antigen and
the specific binding of the 105 kDa protein encoded by
the retinoblastoma tumour suppressor gene (pl05Rb). In
addition, the homologous regions of SV40 large T, Ela
and c-myc proteins are required for cotransformation of
primary cells with ras oncogenes (Phelps et al, 1988/
Figge and Smith, 1988/ Figge et al, 1988/ Dyson et al,
1989). This motif, which has been referred to as the
cell division or CD motif, is present in the E7 protein
sequences of genital HPVs associated with malignant
tumours (types 16, 18, 31 and 33), but not those
associated with benign tumours (types 6b and 11), in
which the first amino acid at the N terminus of the CD
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motif does not match (Figge and Smith, 1988/ Arends et
al, 1990b) . HPV 16 and 18 E7 proteins bind with high
affinity to pl05Rb (HPV 18 has a greater affinity than
HPV 16), whereas HPV 6b and 11 E7 proteins bind with
significantly lower affinities (Phelps et al, 1988) . The
HPV 16 amino acid sites critical for binding map to the N
terminus of the CD motif (Munger et al, 1989b and 1991;
Barbosa et al, 1990) .
The C terminus of the CD motif serves as a substrate for
casein kinase (CK) II, which phosphorylates 2 serine
residues at this site, replacement of which by non-
phosphorylatable amino acids reduces but does not abolish
transforming activity, and does not affect pl05Rb binding
(Barbosa et al, 1990) . Phosphorylation rates are faster
for HPV 18 E7 than for HPV 16 E7, which in turn is faster
than that for HPV 6b E7. Rb binding and phosphorylation
are independent activities which are required for
efficient transformation. E7 can also transactivate the
adenovirus E2 promotor, and this function maps to an
overlapping domain (Chesters et al, 1990/ Watanabe et al,
1990/ Storey et al, 1990). Neither E7 phosphorylation nor
E7 transactivation are required for E7 transformation,
but transformation is associated with Rb binding (Edmonds
and Vousden, 1989/ Storey et al, 1990).
The ability to bind the Rb oncosuppressor protein has
been demonstrated for two other DNA tumour virus
oncoproteins: SV40 large T antigen (SVLT) and adenovirus
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Ela protein (AdEla) (Whyte et al, 1988; DeCaprio et al,
1988). HPV E7, SVLT, and AdEla all share the ability to
immortalize cells, induce cellular DNA synthesis and
transcriptionally transactivate various viral or cellular
promoters. Mutational analysis of these proteins has
shown that the CD motif acts as a specific region within
E7, SVLT, and Ela, which is necessary for Rb binding
(Dyson et al, 1989). Mutant forms of E7 protein which are
unable to bind Rb also cannot transform or immortalize
cells in culture (Barbosa et al, 1990) .
Viral transforming proteins synthesised by the same three
viruses also bind a second cellular tumour suppressor
protein, namely p53. p53 was first identified by its
binding to the SV40 large T antigen (Lane and Crawford,
1979). The adenovirus protein Elb can complex with p53
(Sarnow et al, 1982), and an in vitro association between
HPV E6 and p53 has been described (Werness et al, 1990) .
This association is type-specific, in that HPV 16 and 18
E6 proteins bind the p53 tumour suppressor protein,
whereas the E6 proteins of HPV 6b and 11 do not (Werness
et al, 1 9 9 0) . This interaction produces increased
degradation of p53 by a ubiquitin-dependent protease
system (Scheffner et al, 1991) .
3.1.5 TUMOUR SUPPRESSOR PROTEIN FUNCTIONS
Possible roles for the two tumour suppressor genes Rb and
p53 include regulation of the cell cycle, perhaps
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negatively controlling entry or progress through it. The
pl05Rb product is a nuclear phosphoprotein with DNA
binding activity (Lee et al, 1987) . The phosphorylation
state of Rb changes with the phases of the cell cycle,
and the master cell cycle kinase p34cdc2 can
phosphorylate Rb (Lewin, 1990). The Rb protein is not
phosphory1 ated in GO or G1 phase cells but becomes
phosphorylated as the cells enter S phase (Buchkovich et
al, 1 9 8 9) . It has been suggested that the
unphosphory1 ated form of Rb is the active form, in
preventing progression through the cell cycle, and this
is supported by the observation that SV40 large T antigen
only binds the unphosphorylated form of Rb (Ludlow et al,
1989). Senescent and quiescent fibroblasts are known to
contain unphosphorylated Rb, which is phosphorylated in
quiescent cells after serum stimulation, but is
apparently irreversibly dephosphorylated in senescent
cells (Stein et al, 1990) .
The growth inhibitory effects of TGF beta on epithelial
cells may be the result of suppression of Rb
phosphorylation (Laiho et al, 1990), and the down-
regulation of c-myc expression in keratinocytes by TGF
beta is also mediated through Rb (Pietenpol et al, 1990).
Rb binds to at least seven nuclear proteins, including
the cellular transcription factor E2F (or DTRF) and c-
myc, through a common "pocket" that mediates binding to
the viral oncoproteins SVLT, AdElA, and HPV 16 or 18 E7
(Wagner and Green, 1991). Rb has also been implicated in
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negatively regulating expression of c-fos, another
nuclear protein important in the control of tumour cell
growth (Robbins et al, 1990).
Rb was originally identified as the genetic locus
undergoing homozygous deletion in heritable
retinoblastomas (Knudson, 1971), and it is now regarded
as a prototype tumour suppressor gene. This is clearly
demonstrated by experiments in which wild-type Rb gene
sequences have been transfected into tumorigenic
retinoblastoma cells lacking functional Rb, and producing
reversion of the tumorigenic phenotype (Huang et al,
1988) .
p53 appears to have both positive and negative activities
in regulating cell cycle activity. Wild-type p53 can
suppress cellular transformation by a variety of
oncogenes (Finlay et al, 1989), and transfection of wild-
type p53 into colorectal carcinoma cells also blocks
their cell division (Baker et al, 1990). Wild type p53
has been implicated in promoting cell differentiation
(Stanbridge, 1990), mediating growth arrest by growth
inhibitory cytokines (Deiss and Kimchi, 1991), and
inducing apoptosis in leukaemic cells (Yonish-Rouach et
al, 1991) . Many tumour cells appear to have lost wild-
type p53 function, in keeping with the role of wild-type
p53 in negative growth control, but many other tumour
cell types express mutant p53 proteins which can exert
dominant transforming activity.
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It has been suggested that p53 can adopt at least two
differing conformational states which may be identified
using different antibodies (Gannon et al, 1990) . One
conformation appears to be associated with wild-type p53
protein, the other conformation with dominantly
transforming mutant p53 protein, and also transiently by
the wild-type protein during its function as a positive
regulator of cell growth (Milner et al, 1990). It may be
that the dominantly transforming p53 mutants have been
frozen in the second conformation resulting in the loss
of the negative control function and continuous
expression of the positive control function. The
inactivation of wild-type p53 by E6-induced degradation
might have the same consequences as the deletion of the
p53 locus frequently observed in many tumours. It also
explains why the E6/p53 complex, which was originally
described and studied in vitro. has been so difficult to
demonstrate in vivo. The importance of both the E6-p53
and E 7 -Rb interactions is further suggested by the
correlation between ability to bind these cellular tumour
suppressor proteins and the oncogenic potential of the
HPV type: high affinity binding is associated with high
risk HPV types (Munger et al, 1989b; Werness et al,
1990) .
In summary, high risk HPV types can immortalize human
genital keratinocytes, and induce similar morphological
changes to intraepithelial neoplasia when these cells are
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grown as raft cultures. E 6 and E7 are the viral
transforming genes, and their products interact directly
with cellular oncosuppressor proteins p53 and Rb.
Mutationally activated ras can transform such cells to
malignancy. It is not known how these genes influence
tumour cell growth, in particular the balance of cell
gain and cell loss. One approach to these problems would
be to study cervical cancers from patients. However,
authentic human tumours are often heterogeneous in
genotype and phenotype, and this may complicate analysis
of the growth kinetics. In this thesis, monoclonal cell
lines were constructed to provide homogeneous populations
of cells, eliminating this possible source of
variability, and allowing correlation of changes in
growth parameters with specific genetic manipulations.
The genes investigated were mvc, ras and HPV sequences.
Rodent fibroblasts were selected for ease of culture,
genetic manipulation and study of cell turnover both in
vitro and in vivo.
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3.2 METHODS
3.2.1 MOLECULAR BIOLOGY TECHNIQUES
3.2.1.1 PLASMID DIGESTION BY RESTRICTION ENDONUCLEASES
Plasmid DNA was digested by the relevant restriction
enzyme and the appropriate ionic strength buffer in
sterile Eppendorf tubes. 10 x stock buffer solutions
were used and diluted 1:10 with DDW in the final
reaction. Sufficient enzyme was used to ensure complete
digestion, usually 10 units of enzyme per lug of plasmid
DNA for 2 hours at the appropriate temperature. The
amount of enzyme was kept below 10% of the final volume
however, as glycerol present in the enzyme storage buffer
may interfere with enzymatic activity.
3.2.1.2 GEL ELECTROPHORESIS
Gel electrophoresis was performed to confirm that DNA
digestion had occurred, to further characterise plasmids
or to isolate specific DNA fragments. Loading buffer
(0.25% Bromophenol Blue, 1% Ficoll, 50% Glycerol, 0.1%
SDS, 25mM EDTA at pH 8.0) was added to DNA samples
(diluted 6-fold) , before these were loaded into sample
wells of 0.7% or 1.0% agarose gels, composed of
electrophoresis grade or low melting temperature agarose,
in xl TBE buffer. One ul of 1 Kilobase Ladder Marker
(Gibco BRL) was usually included on the gel as a size
marker. Following electrophoresis at the appropriate
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potential difference/current and time (4-18 hours) to
separate DNA fragments of various sizes, ethidium bromide
at 0.5ug/ml was used to stain the DNA with visualisation
under UV light.
3.2.1.3 ISOLATION OF DNA FRAGMENTS
DNA fragments within low melting temperature agarose gels
were visualized under UV light, the correct band
identified, excised and transferred to an Eppendorf tube.
Three volumes of TE (lOmM Tris (pH 8.0) and ImM EDTA)
were added and the tube incubated at 65°C for 15 minutes
to melt the agarose. To this was added an equal volume
of phenol, pre-warmed to 65°C, equilibrated with TE and
supplemented with 0.1% hydroxyquinolone and 0.2% beta-
mercaptoethanol. The sample was vortexed vigorously and
centrifuged at 13,000rpm for 5 minutes. The upper
aqueous phase was transferred to a fresh tube and to this
was added a half volume of phenol (equilibrated as above)
and a half volume of 24:1 (v/v) mixture of chloroform and
isoamyl alcohol. The sample was again vortexed,
centrifuged at 13,000rpm for 5 minutes and the upper
aqueous phase transferred to a new tube. An equal volume
of chloroform: isoamyl alcohol was added, the tube
vortexed, centrifuged at 13,000rpm for 5 minutes and the
upper aqueous phase transferred once more. The DNA was
precipitated from the resulting aqueous solution with a
half volume of 7.5M ammonium acetate and 2 volumes of
absolute ethanol. This was mixed and maintained at -20°C
186
for 60 minutes before being centrifuged at 13,000rpm for
20 minutes at 4°C. The resulting pellet was dried in a
vacuum dessicator and resuspended in TE.
3.2.1.4 LIGATION OF DNA FRAGMENTS
Plasmids containing the insert and vector DNA fragments
to be ligated were digested with appropriate restriction
enzymes to generate the desired fragments of DNA with
overhanging cohesive termini. These fragments were
isolated from low melting temperature agarose gels, and
small samples were electrophoresed on an agarose gel with
a known amount of Hind III digested lambda DNA to provide
a measure of their concentration, in order to produce a
J:I ratio of >1 and <3 for the ligation reaction. The
ratio of concatemeric ligation products depends on the
parameters J & I, where J is a measure of the length of
the DNA molecule and I is a measure of all complementary
termini in the solution. An equal or slightly greater
concentration of insert to vector DNA is also required to
favour intermo1ecu1ar as opposed to intramolecular
ligation.
0 . 2ug of vector DNA in l-3ul was placed in a sterile
microfuge tube, 0.2ug of insert DNA in l-3(il was added,
and DDW to 8ul. The solution was warmed to 45°C for 5
minutes to melt any cohesive termini that had re-annealed
and then chilled to 0°C. 10 units T4 DNA ligase enzyme
in lul, lul xlO T4 DNA ligase buffer (final xl
187
composition: 20mM Tris-HCl at pH 7.6, lOmM MgCl, lOmM
dithioerythritol, 6mM ATP) were added and the reaction
incubated at 14°C for 18 hours. Two control reactions
were set up with the vector DNA alone, and the insert DNA
alone. lOul of the ligation reactions were used to
transform competent bacteria.
3.2.1.5 PREPARATION OF COMPETENT BACTERIAL CELLS
E.coli (strain HB101) competent cells for introduction of
exogenous DNA were prepared by collection during the mid-
logarithmic phase of growth. A colony of E.coli bacteria
freshly grown on a nutrient agar plate was used to
inoculate 10ml of LB medium (Luria-Bertani medium: lOg
Bacto-Tryptone, 5g Bacto-yeast, lOg Sodium Chloride,
per litre of DDW, autoclaved before use), and incubated
at 37°C for 18 hours with rotational mixing at 225rpm.
500ml of LB medium was inoculated with this 10ml
bacterial culture and similarly incubated for 2-3 hours
until the cell density approached 1 x 108 cells/ml
(optical density at 550nm of 0.2-0.4). The cells were
centrifuged at 4,000g for 5 minutes and the resulting
pellet was resuspended in freshly prepared TSB
(Transformation Buffer: 10% Polyethylene Glycol 3000, 5%
DMSO, lOmM MgCl2, lOmM MgS04) . The cells were placed on
ice for 1 hour and dispensed into sterile, pre-cooled
Eppendorf tubes in 200ul aliquots.
Known amounts of DNA were used to ascertain the
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transformation of the competent cells. lOng, lng, and
O.lng of pUC19 were used as controls, the number of
resultant colonies counted and the efficiency was
calculated. Successful transformations occurred with
formation of 10 x 105 or more control colonies per ug of
DNA.
lOul of the ligation reaction containing DNA was added to
an aliquot of 200ul of competent bacterial cells. This
suspension was held on ice for 30 minutes, heat-shocked
at 42°C for 2 minutes, and chilled on ice for 2 minutes.
0.9ml of TSB supplemented with 20ul of 1M glucose was
added to the suspension and this was incubated at 37°C
with rotational mixing at 225rpm for 1 hour. The cells
were concentrated by a 30 second pulse of centrifugation
at 13000rpm and the supernatant was decanted. The cells
were resuspended using a pipette in a volume of 200ul
TSB, which was plated out onto a LB agar plate with
appropriate antibiotics (50ug/ml ampicillin and/or
400ug/ml hygromycin B) using a glass rod. This was
incubated at 37°C for 20 hours and antibiotic resistant
colonies were isolated and inoculated onto a master LB
agar plate with antibiotics (50ug/ml ampicillin and/or
400ug/ml hygromycin B).
3.2.1.6 SMALL SCALE PREPARATION OF PLASMID DNA
A single bacterial colony (from the master plate) was
transferred into 1ml of LB medium containing appropriate
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antibiotics (50ug/ml of ampicillin and/or 400ug/ml
hygromycin B) and incubated for 18 hours at 37°C with
rotational mixing at 225rpm. This was centrifuged at
13,000rpm for 30 seconds at 4°C and the supernatant
aspirated. The bacterial pellet was resuspended, by
vigorous vortexing, in lOOul of ice-cold solution MI
(50mM glucose, 25mM Tris.Cl at pH 8.0, lOmM EDTA),
containing 5mg/ml of lysozyme (Sigma), to digest
bacterial cell wall. 200ul of freshly prepared solution
Mil (0.2M NaOH, 1% SDS) was added, and the suspension
mixed by inversion several times before cooling on ice.
150ul of solution Mill (3M Potassium acetate/2M Acetic
acid (11.5ml Glacial acetic acid in 100ml solution) was
added, to precipitate chromosomal DNA and bacterial
protein, and this solution was vortexed and stored on ice
for 5 minutes. The solution was then centrifuged at
13,000rpm for 5 minutes at 4°C, and the supernatant,
containing plasmid DNA, was transferred to a fresh tube.
An equal volume of phenol:chloroform isoamyl alcohol was
added, (25;24:1) the solution was vortexed and
centrifuged at 13,000rpm for 2 minutes at 4°C. The upper
aqueous phase was transferred to a fresh tube and the
DNA was precipitated with 2 volumes of absolute ethanol
at room temperature and centrifuged at 13,000rpm for 5
minutes at 4°C. The supernatant was gently aspirated and
the pellet dried before being redissolved in 50ul of TE
(pH 8.0) containing DNAase-free pancreatic RNAase at
20ug/ml and stored at -20°C. This DNA was analysed by
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restriction enzyme digestion and gel electrophoresis.
Clones showing the correct restriction maps were
identified and their bacteria (from the master plate)
were grown up on a large scale as outlined below, for use
in further experiments.
3.2.1.7 LARGE SCALE PREPARATION OF PLASMID DNA
This protocol is a larger scale version of the method
previously described. A single bacterial colony was
inoculated into 10ml of LB medium containing appropriate
antibiotics (50ug/ml of ampicillin and/or 400ug/ml
hygromycin B) and incubated for 18 hours at 37°C with
rotational mixing at 225rpm. This was transferred to
500ml of LB medium containing appropriate antibiotics and
incubated for 18 hours at 37°C with rotational mixing at
225rpm. After centrifugation at 5,000rpm for 10 minutes
at 4°C, the bacterial pellet was resuspended in ice-cold
100ml NTE (lOOmM NaCl, lOmM Tris (pH 8.0), 1 mM EDTA
solution), and immediately centrifuged at 5,000rpm at 4°C
for 10 minutes. The bacterial pellet was resuspended in
10ml of solution MI containing 5mg/ml of lysozyme
(Sigma), and held on ice for 5 minutes. 20 ml of solution
Mil was added and the suspension was mixed by gently
swirling several times before standing on ice for 5
minutes. 15ml of ice-cold solution Mill was added, the
mixture was inverted three times, and maintained for 30
minutes on ice. It was centrifuged at 8,000rpm for 20
minutes at 4°C, the high molecular weight DNA and
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bacterial debris forming a pellet. The supernatant was
transferred to a new tube and the DNA precipitated by
adding 1 volume of ice-cold isopropanol, and maintaining
on ice for 30 minutes, before centrifugation at 12,000g
for 30 minutes at 4°C. The resulting DNA pellet was
washed with 70% ethanol, dried in a vacuum dessicator,
and resuspended in a total volume of 4ml of TE (pH 8.0).
A caesium chloride-ethidium bromide gradient was prepared
by the addition of 4.0g of caesium chloride and
approximately 400ul of lOmg/ml ethidium bromide while
adjusting the refractive index to 1.392. This was
transferred to a Beckman polyallomer tube, sealed, and
spun in an ultracentrifuge at 38,000rpm for 60 hours at
20°C. This produced separation of plasmid DNA into two
bands, the upper band of nicked circular and linear
plasmid DNA (also containing any residual bacterial DNA)
and the lower band of closed, circular plasmid DNA. The
lower band was extracted and transferred to a fresh tube.
An equal volume of butanol (saturated with TE) was added
and after centrifugation at 13,000rpm for 5 minutes, the
upper phase of butanol containing ethidium bromide was
drawn off and a fresh volume added. This was repeated
until no ethidium bromide dye was observed in either
layer (approximately three to five times). The aqueous
phase containing DNA was removed and the DNA precipitated
with an equal volume of isopropanol and maintained on ice
for 1 hour. The resulting suspension was centrifuged at
13,000rpm for 5 minutes at 4°C and the pellet dried in a
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vacuum dessicator before being resuspended in 500ul of
TE.
The concentration of DNA in solution was estimated by
measuring the optical density (OD) of a 1:100 dilution of
the DNA at 2 6 0nm in a spectrophotometer (OD of
l=50ug/ml), and purity determined by measuring the OD at
280nm and calculating the 260/280nm ratio (1.8-2.0 is the
target range). The plasmid structure was confirmed by
restriction enzyme digestion and gel electrophoresis.
3.2.1.8 INTRODUCTION OF EXOGENOUS DNA INTO RODENT CELLS
BY ELECTROPORATION
Cultures of the parent fibroblast cell line (208F), or
other target cells (Ml, Tl), were harvested and 0.8ml
volumes containing 5.106 cells/ml PBS were prepared in
electroporation cuvettes (Biorad) and maintained on ice.
20ug of circular plasmid DNA was added to the cell
suspension, mixed by inversion, and this was kept on ice
for 10 minutes prior to e 1 ectroporation. For each
combination of plasmid/cell several electroporation
conditions were used, with a fixed capacitance (25uFD)
and variable voltage settings (0.4KV, 0.8KV, 1.6KV,
2.4KV), which produced an electrical discharge with 0.5-
0.8msec time constants (Biorad Gene Pulser).
The plasmid/cell suspension was held on ice for 10
minutes after electroporation, before addition to 4ml
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DMEM/10% HINCS and seeded into small flasks (25cm2) .
These were cultured without selection for 24 hours,
followed by selection with geneticin (G418) at 300ug/ml
or hygromycin B at 150ug/ml for 20-30 days. Single
colonies were isolated and transferred to separate
culture flasks to establish monoclonal cell lines.
3.2.1.9 DETECTION OF TRANSFECTED DNA IN CELL LINES BY
SOUTHERN BLOTTING
A) EXTRACTION OF DNA FROM CULTURED CELLS
The technique used was a modification of that described
in Maniatis et al (1982) . Cells grown in a 150 cm2
culture flask were harvested and counted as above, and
resuspended in 0.1ml PBS. 10ml of lysis buffer (10 mM
Tris (hydroxymethyl) aminomethane.HC1 (Tris.HCl) pH 7.4,
lOmM EDTA, 150mM NaCl) was added. After mixing, sodium
dodecyl sulphate (SDS) was added at 0.2% of the final
volume, to induce lysis of the cells. RNAse A (heat-
treated at 10°C for 10 minutes to destroy DNAse activity)
was added at a final concentration of 50 ug/ml, and
incubated at 37°C for 30 minutes. Proteinase K was added
at a final concentration of 100 ug/ml and incubated at
48°C for 16 hours.
The sample was extracted in one volume of
phenol/chloroform-isoamyl alcohol (24:1) and again by 1
volume chloroform-isoamyl alcohol (24:1) . The DNA was
precipitated for 16 hours at -20°C after the addition of
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one volume of 5M ammonium acetate and 2.5 volumes of
absolute ethanol.
The sample was centrifuged at 3000 rpm for 30 minutes at
4°C. The DNA pellet was resuspended in 2 ml of 70%
ethanol and centrifuged at 3000 rpm for a further 30
minutes at 4°C. The DNA pellet was dried under vacuum,
resuspended in 0.5 ml TE (lOmM Tris.HCl pH8, ImM EDTA)
and stored at 4°C.
The concentration and purity of the sample were estimated
using an ultra-violet spectrophotometer (Phillips PU8620
series) to measure its optical density (OD). 10 ul of
the sample DNA was dissolved in 990 ul TE, and the
absorbance of ultra-violet of wavelengths of 260 nm and
280 nm was measured. An OD,,„ of 1.0 was taken toZ 6 0
represent 50ug/ml of DNA in the sample, and an OD26Q:
OD280 ratio of 1.6 - 2.4 was accepted as adequately high
purity for further analysis (Maniatis et al, 1982). The
DNA was dissolved in TE at 4°C by gentle mixing, and held
at this temperature for a minimum of one week prior to
use.
B) DIGESTION OF CELLULAR DNA BY RESTRICTION ENDONUCLEASE
To 10 ug DNA was added restriction endonuclease (at four
times the recommended concentration for cleavage of this
amount of DNA, in order to ensure complete digestion)
with an appropriate volume of lOx concentrated reaction
buffer and deionised distilled water (DDW), to a final
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volume of 30 - 40 ul. This was incubated at the
appropriate temperature for the restriction endonuclease
for 16 hours. An additional lOu of the same restriction
endonuclease was added and incubated for a further 3
hours. The reaction was stopped by adding 3 ul of
sterile loading buffer (lOOmM EDTA, 30% sucrose (w/v),
0.25% bromophenol blue [w/v]).
C) SEPARATION OF DNA FRAGMENTS BY GEL ELECTROPHORESIS
The digested DNA samples were loaded onto a 0.7% agarose
gel in TBE (0.089M Tris.HCl pH8, 0.089M boric acid, ImM
EDTA) and electrophoresed in TBE for approximately 16
hours at 2.6 V/cm, until the bromophenol blue marker had
travelled 90% of the length of the gel. The gel was
stained in 0.05% ethidium bromide in DDW for 10 minutes,
destained in DDW for 15 minutes and photographed under
ultra-violet light, to determine the presence of DNA in
each track.
D) SOUTHERN BLOTTING
The gel was placed in 500 ml of denaturing solution (0.5M
NaCl, 1.5M NaOH) for 15 minutes to denature the double-
stranded DNA to single-stranded fragments. The DNA
fragments within the gel were blotted onto a nylon filter
(Genescreen Plus/ DuPont) by capillary blotting
(Southern, 1975). The gel was placed on top of a wick of
filter paper (2 sheets Whatman No.6, 3mm paper)
supported on a glass plate, with the ends of the wick
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submerged in 500 ml of 0.5M NaOH/ 1.5M NaCl solution. A
nylon filter, cut to the same size as the gel, was placed
carefully on top of the gel, excluding air bubbles.
Above this was placed four sheets of filter paper
(Whatman No.6) cut to the size of the gel, a 30 cm pile
of paper towels, and a 1 kg weight. Capillary blotting
occured over 24-48 hours, changing the saturated paper
towels as necessary.
The filter was retrieved and neutralised in buffer (0.5M
Tris.HCl pH7.4, 3M NaCl) for 30 - 60 minutes. It was
dried at room temperature to anchor the DNA fragments,
and stored in a sealed polythene bag at room temperature.
E) PREPARATION AND LABELLING OF HYBRIDISATION PROBES
Filters were probed for the presence of transfected DNA.
Hybridisation probes included mvc and ras oncogene DNA
derived from the transfected plasmids, by cleavage with
appropriate restriction endonucleases. The cleaved
DNA fragments from these restriction reactions were
electrophoresed in low melting temperature agarose, and
the DNA fragments to be used as hybridisation probes were
cut out of the gel. These probes were extracted once in
pheno1/ch1oroform - isoamyl alcohol (25:24:1) and
precipitated for 60 minutes at -20°C after addition of
0.1 volumes of 3M sodium acetate (pH 5.2) and two volumes
of absolute ethanol.
The probes were radioactively labelled by the random
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primer oligolabelling method (Klenow fragments, random
hexamer primers and reaction buffer from Pharmacia) using
a procedure based on that of Feinberg and Vogelstein
(1983 and 1984). To a volume containing 100 ug of probe
DNA was added DDW, 10 ul of nucleotide and buffer
solution (dATP, dGTP and dTTP), 2ul bovine serum albumin
(BSA; DNAse and RNAse free), 2ul purified cloned Klenow
fragment of DNA polymerase 1 (£L_ Co1i), and 5ul 32p-
labelled d-CTP (50 uCi; Amersham Intnl.). This was
incubated at 20°C for 16 hours. 2 ul of "stop" buffer
(d-CTP, EDTA, SDS, NaCl, and buffer) and 30 ul of DDW
were added. The sample was passed down a Sephadex column
(Nick Column/ DuPont) to remove unincorporated
nucleotides, and the specific activity of a 5 ul sample
in 4 ml of scintillant was measured using a
scintillation counter (LKB Rackbeta). The probes were
used immediately.
F) PREHYBRIDISATION, HYBRIDISATION AND WASHING
i). Prehybridisation: 30 ml of prehybridisation solution
was prepared, containing 6 x SSC (sodium citrate pH 7,
sodium chloride), 1% SDS (w/v; pH7.2), 10% dextran
sulphate and 3 mg sonicated salmon sperm DNA (heated to
100°C for 10 minutes and snap-cooled on ice to denature
the DNA) in DDW , and incubated at 65°C for 30 minutes to
remove air bubbles. This solution was added to a
polythene bag (Hybaid system) containing the nylon filter
to be probed, the bag was sealed, and incubated at 65°C
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for 4-6 hours.
ii). Hybridisation: 10 - 20 ml of the prehybridisation
solution was removed from the bag and to this was added
the radiolabelled probe plus sonicated salmon sperm DNA
(heat denatured at 100°C for 10 minutes and snap-cooled
on ice) at a final concentration of 25mg/ml. The
hybridisation solution plus probe was inserted into the
bag, sealed and inverted several times to ensure uniform
bathing of the filter. This was incubated at 65°C for 16
hours.
iii). Washing: The polythene bag containing the nylon
filter was drained of hybridisation solution and the
filter was washed three times, once in 2 x SSC, and twice
in 2 x SSC / 1% SDS using the Hybaid apparatus (Hybaid).
The filter was removed from the bag and washed in 0.1 x
SSC for 30 minutes. The filter was sealed in a polythene
bag without allowing it to dry to allow re-probing if
necessary.
G) AUTORADIOGRAPHY
The sealed bag containing the nylon filter was placed
next to an Fuji RX X-ray photographic film in an X-ray
cassette (Kodak), and left at -70°C. The film was
developed in D19 developer (Kodak) for 5 minutes, washed
briefly in water (10 - 15 seconds), fixed in FX40
fixative (Kodak) for 8 minutes at 20°C, washed in tap
water for 30 minutes and dried.
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3.2.1.10 DETECTION OF TRANSFECTED DNA IN CELLS BY
POLYMERASE CHAIN REACTION
Protocols used for the preparation of cells and
amplification of defined target DNA sequences were
identical to those described in section 2.2. The HPV
type-specific primers, previously described and validated
(section 2.3), were used for HPV DNA amplification.
Primers specific for c-Ha-ras, c-myc and human beta
actin were designed and applied to the oncogene
transfected cell lines (section 3.5).
3.2.1.11 PREPARATION OF RNA FROM CELL CULTURES
5 x 107 cells were cultured in a 75cm2 flask, the medium
was removed and the cells rinsed twice in ice-cold PBS.
4ml ice-cold ULC (6M Urea, 3M Lithium Chloride) was added
to the flask, which was maintained at 4°C for 1 hour, to
lyse the cells and solubilise RNA. This solution was
removed to a fresh sterile tube and the flask rinsed out
with a further 4ml ULC, which was also added to the
sterile tube. This solution was strictly kept at 4°C,
sonicated on ice with 4 bursts of 15 seconds (MSE cell
disruptor, set at 10mA), and maintained at 4°C for 18
hours. This solution was transferred to a sterile Corex
tube and centrifuged at 10,000rpm for 30 minutes at 4°C.
The supernatant was discarded and pellet resuspended in
0.5ml lOmM Tris (pH 7.4), lOmM EDTA, 0.1% SDS at room
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temperature. In sterile Eppendorf tubes this solution
was extracted once in an equal volume
phenol:chloroform:isoamyl alcohol (25:24:1) and again in
an equal volume of chloroform:isoamyl alcohol alone. A
tenth volume of 5M Ammonium Acetate and one volume of
absolute ethanol were added and the solution stored at
-20°C. The concentration of RNA was measured using a
1:100 dilution TE to determine the optical density at
260nm (0Dl=40ug/ml for s/s RNA; OD 260/280 ratio of 2.0 =
ideal purity) . For recovery of RNA, the appropriate
volume was removed from -20°C, a further 1 volume of
absolute ethanol was added and the solution maintained at
-70°C for 18 hours. This was centrifuged at 13,000rpm
for 20 minutes at 4°C, the pellet was dried and
resuspended in the appropriate volume of TE.
3.2.1.12 ANALYSIS OF CELLULAR RNA
A) FORMALDEHYDE-AGAROSE GEL ELECTROPHORESIS OF RNA
A 1% agarose solution in MSE was prepared containing
formaldehyde (1 volume 12.3M formaldehyde to 4.6 volumes
agarose solution, added after cooling below 60°C). 10 x
MSE running buffer (0.2M morpho linopropanesulfonic acid
[pH 7.0], 50mM sodium acetate, lOmM EDTA [ph 8.0]) for
RNA gel electrophoresis was prepared. RNA samples of
lOug in 4.5ul were prepared in sterile tubes with 2ul of
10 x MSE, 3.5ul 12.3M formaldehyde and lOul formamide,
and incubated at 55°C for 15 minutes to denature any RNA
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secondary structure. To this was added 2ul sterile RNA
loading buffer (50% glycerol, ImM EDTA, 0.4% bromophenol
blue, 0.4% xylene cyanol) and these samples were loaded
into the gel for electrophoresis as above.
B) DOT BLOT HYBRIDISATION OF RNA
lOug samples of cellular RNA were denatured as above in
15 x SSC and transferred to nitrocellulase filters using
Hybridot apparatus following the manufacturer's
instructions, and the filters baked at 80°C in a vacuum
for 1 hour. These were pre-hybridised, hybridised and
washed using the same conditions as for Southern blot
hybridisation.
C) REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION
ANALYSIS OF RNA
To detect the expression of specific genes, RNA prepared
from cells was amplified using a two stage procedure.
First, RNA was copied to cDNA by reverse transcription.
Second, cDNA was amplified using the polymerase chain
reaction (PCR). Strict PCR precautions against
contamination by extraneous sequences (see chapter 2)
were observed throughout including use of autoclaved
tubes, gloves, preparation in a laminar air flow Class II
biological safety cabinet, and maintenance of all
solutions on ice during preparation stages.
The reverse transcriptase (rT) reaction consisted of the
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following reagents in a final volume of 20 ul: IX PCR
buffer (50 mM KC1, 10 mM Tris HC1 [pH 8.3 at room
temperature], 1.5 mM MgCl2, 0.01% gelatin), 1 mM each
dNTP, 1 unit/ul of RNasin, 100 pmol downstream PCR primer
(primer 2), 10 ug of RNA (in lOul TE), and 200 units of
Moloney Murine Leukaemia Virus (MoMuLV) reverse
transcriptase enzyme (Gibco-BRL). The RNA was heated to
90° for 5 minutes and snap-frozen on ice, prior to
addition to the rT reaction solution, to denature RNA
secondary structure. The rT reaction solution was
incubated for 10 minutes at 20°C, followed by 45 minutes
at 42°C, and finally 10 minutes at 95°C with snap cooling
on ice. The final 95°C heat treatment denatured the RNA-
cDNA hybrids and inactivated the reverse transcriptase.
The second stage of PCR amplification consisted of adding
to the heat treated rT reaction solution, 80 ul of 1 X
PCR buffer, 100 pmol of upstream PCR primer (primer 1),
2.5 U of Taq Polymerase (Cetus-Perkin-Elmer), and 200uM
of each dNTP. This was mixed, and a layer of 100 (il of
mineral oil was added to the top of the PCR solution, to
prevent evaporation of liquid. Thermal cycling on an
automated heating block (Hybaid), consisted of 30 cycles
of denaturation at 94°C for 1 minute, primer annealing at
45°C for 2 minutes, and DNA synthesis at 72°C for 3
minutes. The initial cycle had a 94°C denaturation step
of 1.5 minutes duration, and the final cycle had a 72°C
DNA synthesis step lasting for 10 minutes. 30 ul of the
reaction product was electrophoresed on a 2% agarose gel
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(3:1 Nusieve GTG:Seakem agarose) containing 2 ug/ml
ethidium bromide, and this was visualised under UV light.
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3.2.2 CELL BIOLOGY TECHNIQUES
3.2.2.1 FIBROBLAST CELL CULTURE
Sterile reagents, equipment and technique were employed.
The fibroblast cell lines were maintained as monolayer
cultures attached to plastic tissue culture compatible
flasks (Costar) . Culture medium used was the Glasgow
modification of minimum Eagle's medium (GMEM: Northumbria
Biologicals), supplemented with L-glutamine (228mg),
sodium bicarbonate (0.01M) and 10% heat-inactivated
neonatal calves' serum (HINCS: GIBCO) at 37°C in a
humidified 5% C02 atmosphere.
To harvest a culture monolayer, the cells were washed
briefly (5-30 seconds) in 0.02% ethylene diamine tetra¬
acetate (EDTA) in phosphate buffered saline (PBS). The
EDTA was replaced by a solution of 0.1% trypsin in PBS
and incubated at 37°C until the monolayer had
disaggregated into a single cell suspension. This was
transferred to a conical-bottomed universal container,
and an equal volume of GMEM/10%HINCS added to neutralise
the trypsin. The cells were centrifuged at 1000 rpm for
10 minutes at 20°C, and resuspended in PBS. A sample of
cells was counted prior to further use.
Primary cultures of rat fibroblasts were also prepared
for comparison with immortalised 208F cells and
experimentally transformed cells. The lungs were removed
from a freshly-killed 6 week old female Sprague-Dawley
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rat and dissected into 0.25 - 1 mm fragments. These
fragments were digested in a sterile solution of 0.25%
trypsin, 2.5 ug/ml amphotericin and 100 ug/ml kanamycin
in phosphate buffered saline (PBS) at 37°C for 60
minutes, mixing frequently. The sample was centrifuged
at 1000 rpm for 10 minutes at 20°C. The supernatant
(including any large fragments not in the pellet) was
discarded. The pellet, containing single cells and small
fragments, was resuspended in 20 ml GMEM/10% HINCS and
filtered through nylon wool to remove any large clusters
of cells. The remaining cells, in single cell
suspension, were prepared for flow cytometry.
3.2.2.2 PREPARATION OF CELLS FOR T RAN SFECTION BY
ELECTROPORATION
Parent cells for transfection, mostly 208F Fischer rat
fibroblasts, but also Ml and T1 fibroblasts in some
experiments, were harvested while growing in log phase
(50-80% confluence). They were washed twice in ice cold
sterile PBS, counted and resuspended at a concentration
of 5.106 in 0.8ml PBS, prior to addition of 20ug of
plasmid DNA and electroporation (see section 3.2.1.8) .
3.2.2.3 FREEZING AND THAWING OF CELLS
Following transfection and cloning, cell lines were
stored in the vapour above liquid nitrogen (N2) at
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-196°C, in 10% dimethyl sulphoxide (DMSO) and 50% HINCS.
Cells were thawed rapidly at 37°C (2-3 minutes) and
immediately mixed with 20ml of GMEM to dilute the toxic
effects of DMSO at room temperature or above. The cells
were centrifuged at lOOOrpm for 10 minutes at 20°C,
washed in PBS, resuspended in 20ml of GMEM/ 10%HINCS
and seeded into a culture flask. Cells were initially
grown in a humidified 5% C02 incubator at 37°C, but
after passage, the pH of the medium was adjusted to 7.4
with 5% C02 and the cells were grown in sealed flasks at
37°C.
An aliquot of frozen cells from each cell line was
subsequently frozen in liquid N2 to maintain a frozen
stock of cells. Cells were harvested, washed in PBS and
counted, centrifuged at lOOOrpm for 10 minutes at 20°C,
and resuspended in a volume of cryoprotectant (10% DMSO,
50% HINCS) at a final concentration of 2 - 5 x 106 cells
per ml. The cell suspensions were frozen slowly (approx.
1°C per minute) by placing them at -70°C for 16 hours.
The cells were transferred to liquid N2 for long-term
storage.
3.2.2.4 QUANTITATION OF CELL CONCENTRATION
The cell concentration was determined using the Neubauer
improved haemocytometer. Two separate samples were taken
from a single cell suspension, four independent counts
were made of the cell number, and the mean calculated.
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3.2.2.5 ASSESSMENT OF MORPHOLOGY OF APOPTOSIS
A) ELECTRON MICROSCOPY
Two specimens were collected: (1) cellular bodies
released into the medium above a growing culture of
cells, and (2) monolayer cells attached to the
substratum. These were prepared for electron microscopy
by standard methods. The cellular bodies were washed in
PBS, and centrifuged at 1000 rpm for 10 minutes at 20°C.
The pellet was resuspended and fixed in 3% glutaraldehyde
in sodium cacodylate for four hours, rinsed in sodium
cacodylate buffer and fixed in 1% sodium tetroxide. The
sample was dehydrated through increasing grades to 100%
ethanol. The sample was impregnated through grades of
araldite, to 100% araldite; after 1 hour, the araldite
was polymerised at 56°C. Representative sections were
cut, 50 - 60 nm thick, and stained with uranyl acetate
and lead citrate. The specimen grids were viewed and
representative fields photographed.
B) FLUORESCENCE MICROSCOPY
Samples of the cellular bodies released into the medium
above cells attached to the flask substratum were stained
with equal volumes of lOug/ml acridine orange in PBS and
viewed under UV light.
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3.2.2.6 ASSAY OF ENDOGENOUS ENDONUCLEASE ACTIVITY
Monolayers of near-confluent cells growing in 175cm2
flasks were harvested, washed in PBS and the total
numbers counted. The cells were centrifuged at 1000 rpm
for 10 minutes at 20°C, and resuspended in 3 ml of buffer
A (150mM NaCl, 1.5mM CaCl2, lOmM Tris.HCl pH7.4, 3% [v/v]
glycerol, autoclaved prior to use) at 4°C; all succeeding
reagents and apparatus were pre-cooled to 4°C. 3ml of
freshly-prepared buffer B (90% [v/v] buffer A, and 10%
[v/v] Nonidet P40) was added to induce lysis of the
cells. After 15 minutes the cell lysate was layered on
top of 3ml of buffer C (25% [v/v] glycerol, lOmM Tris.HCl
pH7.4, 1.5mM CaCl2, autoclaved prior to use) in a Corex
test tube, and centrifuged at 600 rpm for 10 minutes at
4°C. The supernatant was discarded and the white pellet
containing the nuclei retained. 200 ul of buffer A was
added, the pellet resuspended, and the volume accurately
determined. A further volume of buffer A was added and
agitated gently. Samples of the processed nuclei were
used in an overnight incubation to test for calcium- and
magnesium-sensitive endogenous endonuclease activity
capable of digesting the nuclear chromatin in the
presence or absence of divalent cations. To demonstrate
that chromatin cleavage was enzymic, zinc ions were added
at 2mM to inhibit the reaction.
Three 100 ul samples were taken from each preparation of
nuclei. These were incubated at 37°C for 16 hours after
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adding CaCl, to give a final concentration of 1.5mM Ca2+
to the first, MgCl2 plus CaCl2 to give a final
concentration of 1.5 mM of each of Mg2+ and Ca2+ to the
second, and lOOmM EDTA and lOOmM EGTA (chelators of
divalent cations) to the third, as a control.
After the overnight incubation at 37°C, 30 ul of 0.2M
EDTA was added to each of the three test cell samples and
they were incubated at 4°C for 30 minutes. All samples
were centrifuged at 1300 rpm for 5 minutes at 20°C. DNA
was precipitated by the addition of 30 ul 5M NaCl, and
600 ul absolute ethanol at -20°C for 16 hours.
The samples were centrifuged at 1300 rpm for 15 minutes
at 4°C and the supernatants discarded. DNA fragments in
the pellets were resuspended in 100 ul TE, and 5 ul 10%
[v/v] SDS was added. The sample was extracted through an
equal volume of pheno1/ch1oroform/isoamy1 alcohol
(25:24:1). 25 ul of each sample was removed and to this
was added 5 ul DNA loading buffer (lOOmM EDTA, 30% [w/v]
sucrose, 0.25% [w/v] bromophenol blue) and the sample
e1ectrophoresed on a 1% agarose gel in TBE, also
containing 0.05% ethidium bromide. The gel was
photographed under ultra-violet light. This assay
ascertained the presence or absence of a "chromatin
ladder" of DNA fragments signifying endonuclease activity
typical of apoptosis. The DNA content of bands in the gel
tracks was assessed by laser densitometry (LKB Ultrascan
XL Enhanced Laser Densitometer).
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3.2.2.7 RATE OF CELL POPULATION EXPANSION
Nine tissue culture compatible Petri dishes (Falcon;
Becton Dickinson) were seeded with 3.5 x 105 cells in 5
ml GMEM/10% HINCS for each cell line. The dishes were
incubated at 37°C in a humidified 5% co2 atmosphere. At
24, 48, and 72 hours the cells were counted as described
above, using three of the dishes at each time point and
calculating the mean value.
The rates of expansion of the different cell lines were
compared by calculating the proportional increase in
terms of the ratio of cells at 48 and 24 hours (N48/N24:
where N is the number of cells at each time point). This
choice of time points was designed to allow for three
potential problems. (1) Differences in seeding efficiency
between the cell lines were minimised. (2) The cells were
allowed to enter the phase of maximal growth (unlimited
by growth factors in serum or nutrients in the medium).
(3) The cells had not reached confluence by the end of
the test period. The figure of 3.5 x 105 cells to be
seeded initially was arbitrarily chosen to give a large
enough sample of cells for accuracy of counting, and also
so that the cells were not significantly confluent after
72 hours growth in vitro. However, some variation in the
expansion rate between 48 and 72 hours could be caused by
localised areas of cells in culture becoming confluent
and undergoing contact inhibition of growth (for some
cell lines), or by depletion of growth factors or
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essential nutrients from the medium. Thus, the 24 to 48
hour period excluded any such bias.
There were two reasons for using, as a measure population
expansion, the proportional increase (N48/N24) rather
than the linear increase (N48 - N24), as measured by the
gradient of the expansion curves. First, although the
rate of population expansion did not conform exactly to
a simple mathematical equation, the shape of the
population expansion curve approximated more closely to
an exponential pattern of growth rather than a linear
pattern (see figure 3.16). Second, the gradient was more
likely to be significantly affected by small differences
in cell number at 24 hours, as may have been caused by
different seeding efficiencies of the cell lines, or
minor errors in the numbers of cells seeded.
3.2.2.8 CELL PROLIFERATION INDEX
An EPICS (Electronically Programmable Individual Cell
Sorter) flow cytometer (Coulter Electronics; EPICS CS
system) was used for cell cycle analysis by determination
of the proportion of cells in each phase of the cell
cycle according to DNA content. The method used cells
growing in maximal growth phase in culture. All samples
for flow cytometric study were prepared by the method of
Vindelov et al (1983a); nuclear preparations were
obtained and stained with propidium iodide (Fluka) , a
fluorescent dye which binds DNA with a stoichiometric
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relationship, and the fluorescence was measured on the
flow cytometer.
The cells to be analysed were passaged into 75 cm2
culture flasks in a ratio of approximately 1:4 from
confluence 48 hours before the analysis was carried out.
This ensured that the cells were growing in maximal
growth phase at 50 - 70 % confluence, ensuring the cell
population contained actively proliferating cells, as
confluent monolayers demonstrate decreased growth rates
(Martz and Steinberg, 1973). The medium was removed from
each flask (retained at 4°C for subsequent analysis of
the cellular bodies), and replaced with 20ml GMEM/10%
HINCS, so that cells were not growth limited by
utilisation of the essential nutrients. Flasks were
incubated at 37°C for 4 hours.
The cells were harvested, washed in PBS and counted, and
centrifuged at 1000 rpm for 10 minutes at 4°C. 106 cells
were resuspended in 100 ul citrate buffer (250mM sucrose,
40mM trisodium citrate.2H20 pH7.6, 5% [v/v] DMSO). To
each cell sample was added 20 ul of chicken red blood
cells (approximately 106 cells) in DMSO, to act as an
internal standard for each trial (Vindelov et al, 1983b).
450 ul of solution A (3mg trypsin in 100ml stock solution
[3.4mM trisodium citrate.2H20, 0.1% [v/v] Nonidet P40,
1.5mM spermine tetrachloride. 0.5mM Tris.HCl pH7.6]) was
added, and the sample incubated at 20°C for 10 minutes.
325 ul of solution B (50mg trypsin inhibitor, lOmg
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RNAse A [heat treated at 100°C for 10 minutes to
eliminate DNAse activity] in 100ml of stock solution) was
added, and the sample incubated for 10 minutes at 20°C.
250 ul of solution C (41.6mg propidium iodide and lOOmg
spermine tetrachloride in 100ml stock solution) at 4°C
was added, and the sample incubated on ice for 10
minutes. The cells were fully resuspended by reflux
using a fine needle to disaggregate clumps of cells and
produce a single cell suspension. The processed cell
samples were analysed within 30 - 60 minutes of
preparation, although they were known to be stable for
up to three hours (Vindelov et al, 1983a).
The flow cytometer passes a stream of single cell nuclei
through a laser beam (known to excite the fluorescence of
the DNA-bound propidium iodide) and records the amount of
fluorescence produced by each nucleus. Data is stored on
computer disc, and can be viewed as a two parameter
histogram of red fluorescence (DNA content) versus total
number of cells, as shown in figure 3.19. The results
were subsequently analysed using two different computer
software programs, PARA 1 and SFITS (Coulter Electron¬
ics) . These programs use different mathematical models
to estimate the proportion of cells in each phase of the
cell cycle.
The cell cycle profile was used to compare the cell cycle
parameters for different cell lines, to give a measure
of the proliferative capacity of the cells following 48
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hours growth. The proportion of cells in S plus G2/M
phases of the cell cycle was defined as the proliferative
index in vitro.
Cell cycle profiles were assumed to be similar for the
various cell lines, in terms of the lengths of the three
separately determined phases or phase combinations
(G0/G1, S and G2/M), and that the distribution of the
cells within S phase is similar. The validity of these
assumptions is supported by the derivation of all
transfectants from the same parent cell line (208F), and
the lack of apparent differences in the cell cycle
profiles observed. Cell samples were tested in maximal
growth phase (40 - 70% confluence), when growth was not
limited by a lack of nutrients or growth factors. This
provided a measure of proliferation during maximal growth
phase of the cell population.
The computer analysis of the cell cycle relied on
analysis of the total DNA content of the cells and used
mathematical models to determine the proportions of cells
in each phase of the cell cycle (Baisch et al, 1 982) .
This method of analysis of the proportion of cycling
cells may have been inaccurate if the cells became
blocked in S phase, if the cells became synchronised in
their passage through the cell cycle, or if a
subpopulation of any cell line had evolved a different
DNA ploidy compared with the majority of the cells. The
initial use of two different computer programs (PARA 1
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and SFITS, using different mathematical models) on eleven
of the cell lines produced similar data. The homogeneous
samples of asynchronously growing cells allowed
minimisation of these differences. No separate aneuploid
peaks or unusual peaks in the S phase area of the DNA
histogram were observed.
One factor which may theoretically alter the cell cycle
profile of some of the cell lines is the proportion of
normal cells released into the growth medium. Cells tend
to round up during mitosis, and some may lose contact
with the culture flask substratum. For some of the T24-
ras transfected cell lines, 10% - 50% of the released
cellular bodies had the morphology of normal cells, and
it is possible that erroneously low proliferative indices
were measured using monolayer cells for the assay, due to
the loss of some cells in the G2/M phases of the cell
cycle. However, the total number of viable cells
released into the medium was usually fairly small (about
3% - 8% of the total number of attached cells) for
those cell lines with high proportions of viable released
cellular bodies, indicating that this potential source of
error was numerically small.
3.2.2.9 RATE OF CELL DEATH BY APOPTOSIS
The medium which was removed from the monolayer cells
growing for flow cytometric analysis was centrifuged at
1000 rpm for 10 minutes at 20°C, and the cellular bodies
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resuspended in 0.5 ml PBS. This sample was counted for
the total number of cellular bodies using an improved
Neubauer haemocytometer. 0.2 ml of this sample was mixed
with 0.2 ml of acridine orange (0.5 mg/ml) (a DNA and RNA
binding dye) on a glass slide, and viewed under ultra¬
violet light. 100 - 200 cellular bodies were counted,
quantifying the proportion of apoptotic bodies and non-
apoptotic cells, differentiated by the characteristic
morphological differences between apoptotic and normal
cells.
The apoptotic index was calculated as a measure of
production of apoptotic bodies in 48 hours, taking into
account the number of surviving cells, according to the
following equation:
Apoptotic Index = %A x B x 100
(AI) (%NA x B) + C
B = Total number of cellular bodies released into
the medium above a growing culture of cells in
48 hours.
%A = Proportion of B which consists of apoptotic
cells.
%NA = Proportion of B which consists of non-apoptotic
cells .
C = Total number of surviving monolayer cells after 48
hours.
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This experimental technique was developed for this study
from previously used methods (A.Wyllie, personal
communication). A number of points arise regarding its
design.
(i) The method used to measure the rate of apoptosis
utilised the observation that one of the earliest events
in apoptosis is the loss of cell-cell contact producing
detachment of apoptotic cells from their viable
neighbours (Kerr et al, 1972/ Wyllie et al, 1981; Wyllie,
1985), and also from the culture substratum. The vast
majority of these cells subsequently float freely in the
growth medium, with only occasional phagocytosis of
apoptotic cells by adjacent viable cells. Those cell
lines with high apoptotic rates (c-myc transfectants)
showed 70% - 90% of the released cellular bodies were
apoptotic in nature. For some of the cell lines with low
apoptotic rates ( T 2 4 -ra s transfectants and MT7) the
proportion of apoptotic cells in the medium was
frequently as low as 10 - 20% (although the total number
of released cells and bodies was always considerably
smaller than the number of monolayer cells). This
effect was taken into account in the design of the
equation for calculation of the apoptotic index.
(ii) Depletion of serum growth factors was known to
increase the rate of apoptosis in some cell lines, (eg Ml
A.Wyllie, personal communication). This potential source
of error was avoided by collecting released cell bodies
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over the relatively short period of 48 hours, before
cell growth had significantly depleted growth factors.
Low densities of cells, never reaching more than 70% also
limited growth factor depletion.
(iii) Culture medium was removed from the assay flask of
cells four hours before the monolayer cells were
harvested, and this medium was used to analyse the
released cellular bodies. The same samples of monolayer
cells were used to measure cell proliferation.
(iv) The method of quantification of the total number of
released cellular bodies by phase-contrast microscopy was
designed to take into account the small size of some of
the released apoptotic bodies. A cut-off size threshold
was used for each count, based on the criteria that
cellular bodies were membrane-bound (rejecting large
debris), contain nuclear material (rejecting non-cellular
matter), and bodies below a certain size (25% of the
diameter of viable cells) were not counted. Considerable
care was taken to use the same size cut-off point between
different cell lines, since some lines (those with higher
apoptotic indices) tended to have more small cellular
debris within the medium. On several occasions, and on
the first count in any experiment, counting of the same
cell population was repeated to determine
reproducibility; this was found in almost all cases to
be greater than 95%.
(v) The quantitation of apoptotic versus non-apoptotic
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(viable) cellular bodies was determined by fluorescence
microscopy after staining with acridine orange, based on
the characteristic morphological appearances of apoptotic
bodies. In a small proportion of cases it was not
possible to classify some cellular bodies due to
ambiguous morphological appearances, poor staining or
overlapping of cells; these bodies were categorised as
neither apoptotic nor viable cells, and this category
never exceeded 5% of the total number of cells counted.
(vi) The apoptotic index was calculated based on the
number of monolayer cells after 52 hours growth in a
flask. A possible future refinement of the technique
which may improve the accuracy of the apoptotic index
would be to determine the exact number of cells seeded
into the flask, allowing for possible differences of
seeding efficiencies and expansion rates of the cell
lines, in order that similar numbers of cells would be
present in each flask after 52 hours growth.
3.2.2.10 ANALYSIS OF TUMOUR GROWTH PARAMETERS IN VIVO
All transfected fibroblast cell lines were analysed for
in vivo tumour growth, including the parent immortalised
rat fibroblast cell line (208F), ten oncogene
transfectants and four HPV/oncogene transfectants. 107
cells from each cell line were obtained from 150cm2
culture flasks grown to near 100% confluence. The cells
were harvested with 0.02% EDTA and 0.1% trypsin, washed
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and resuspended in PBS at a concentration of 108 cells
per ml. The assay used between six and twelve female mice
(CBA), previously rendered immune suppressed by
thymectomy, total body x-irradiation of 750 rads and
treatment with cytosine arabinoside (supplied by Dr L
Foster, prepared using the method described by Wyllie et
al, 1987) . 107 cells, suspended in 0.1 ml of PBS, from
each of the cell lines were injected subcutaneously into
the left groin of each mouse. Most animals were killed
after 12 days, and autopsies were performed.
The size of the primary tumour was measured in three
dimensions, and multiplied to calculate a tumour "box"
volume. Local tumour spread and distant metastasis were
also assessed. A small number of animals were killed
earlier (9-11 days) if signs of terminal illness were
evident (this only affected T1 and MT7). In order to
compare the relative rates of tumour growth in vivo, the
tumour "box" volume attained at 12 days was taken as an
approximate measure. As some experiments were terminated
before 12 days, the tumour volumes were adjusted to take
this into account, by standardizing to 12 days. This
adjustment assumed linear growth over the final 1-3 days
of the 12 day period, almost certainly underestimating
the final tumour size generated by T1 and MT7 cells,
which produced some of the largest tumours. Errors
introduced by this simple calculation were more likely to
reduce, rather than increase, the chances of finding
statistically significant differences when compared with
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the smaller tumours produced by the parent and c-myc
transfected cell lines.
Blocks of tumour were taken and analysed histologically
for mitosis and cell death. The number of mitotic and
apoptotic figures per ten high power (x400) fields were
determined. The criteria set out by Baak (1990) were used
for identification of mitotic figures: absence of nuclear
membrane, absence of clear zone in nuclear centre,
presence of hairy rather than triangular or jagged
chromosomal projections, relative basophilia of
surrounding cytoplasm instead of eosinophi1ia, and
omission of doubtful structures. Counting mitotic figures
is a well established histological method (Silverberg,
1976/ Scully, 1976/ Norris, 1976) that can generate
reliable comparative data (Ellis and Whitehead, 1981),
particularly under these ideal experimental conditions
where there was no fixation delay (Donhuijsen et al,
1990) .
Apoptotic figures were identified using criteria set out
by Kerr et al (1 972) and Wyllie et al ( 1 9 8 0) :
condensation of nuclear chromatin into densely staining
crescentic caps at the periphery of the nucleus, or more
commonly chromatin condensation into variably sized
spheres which are often multiple, eosinophilia of
surrounding cytoplasm, clusters of eosinophilic bodies of
variable sizes containing variable numbers of condensed
chromatin spheres, often within an apparent space in the
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tissue rather than closely abutting onto adjacent cells,
and omission of doubtful structures. Tumour necrosis was
identified as confluent zones of eosinophilic material
often containing cell ghosts, and was assessed semi-
quantitatively using an arbitrary scale of 0-4.
Mitotic and apoptotic counts made from tissue sections
vary with three parameters. (1) The frequency of
occurrence of the event (mitosis or apoptosis). (2) The
duration of histological observability of the event. (3)
The proportion of the population capable of undergoing
each event. In this fibroblast series, mostly homogenous
monoclonal cell lines were used for comparison, and these
were derived from the same parent fibroblast line. Both
of these elements in the design of the system should
minimise possible sources of error due to variations in
the second and third parameters described above. Finally,
the calculation of the ratios of mitosis:apoptosis (M/A),
or vice versa (A/M), was designed to cancel out effects
due to differences in high power field samples, including
cell size and density. Thus, the M/A or A/M ratios were
designed to be single indices that reflected cell
turnover in terms of the relative frequencies of mitosis
and apoptosis, allowing more accurate comparison of lines
with different cell sizes.
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3.3 PLASMID STRUCTURE AND CONSTRUCTION
3.3.1 EXISTING PLASMIDS
3.3.2 CONSTRUCTION OF NEW PLASMIDS
The fibroblast cell lines under study were derived from
the 208F rat fibroblast cell line (Quade, 1979) by
transfection with expression plasmids containing c-myc
(pMCGMl or pHRMCGMl), mutated c-Haras1 (pH05Tl or
pHRH05Tl, both containing the T24-ras oncogene), and HPV
6b, 11, 16 and 18 (partial viral genomes containing the
URR, the two transforming genes E6 and E7, and most of
the other early genes El, E2, E4, and E5, but only part
or none of the two late genes L2 and LI), subcloned into
the pJ40 expression vector.
3.3.1 EXISTING PLASMIDS
The structures of pH05Tl, pMCGMl and the pJ40.HPV
plasmids are shown in figures 3.1-3.3.
pH05Tl was constructed by Spandidos and Wilkie (1984) .
The T24 human c-Ha-ras-1 gene (T24-ras contains a point
mutation at codon 12 - encoding valine instead of
glycine) in a 6.6kb DNA fragment (Santos et al, 1982;
Reddy et al, 1982; Capon et al, 1983) . This fragment was
inserted into the Homer 5 expression vector at the Bam HI
cleavage site, forming a 15.3kb plasmid. The Homer 5
plasmid contains a powerful constitutive
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promoter/enhancer element derived from the genome of
Simian Virus 40 (SV40), plus the aminoglycoside
phosphohydro1 ase (aph or neo) gene which confers
resistance to geneticin (G418) (Colbere-Garapin et al,
1981). G418 is a powerful aminoglycoside antibiotic which
is lethally toxic to mammalian cells in culture at doses
of 100 to 400ug/ml.
pMCGMl was constructed (Spandidos and Wilkie, 1984) by
inserting a 2.9kb DNA fragment containing the aph gene
linked to the Moloney Virus long terminal repeat sequence
(MoLTR: known to contain a powerful constitutive
promoter/enhancer element) into the Eco R1 cleavage site
of plasmid pMC41Cl (Watson et al, 1983; Battey et al,
1983), which contains the human c-mvc proto-oncogene, to
form a 15.6 kb plasmid.
pJ40.HPV plasmids were constructed by Storey et al (1988)
by insertion into the multiple cloning site of the parent
vector pJ40mega, of fragments of HPV genomes, containing
all the early genes and most of the upstream regulatory















Plasmid maps of pHMR.272, containing the hygromycin
resistance (Hmr) gene, and pH05Tl containing the T24-ras
gene with 4 exons, and the geneticin resistance gene
(aph). These were both cleaved at the unique HindiII







Plasmid maps of pHMR272, containing the hygromycin
resistance gene (Hmr), and pMCGMl containing the c-myc
oncogene with 3 exons, and the geneticin resistance gene
(aph). These were cleaved at their unique HindiII sites

























Plasmid maps showing construction of expression vectors
containing HPV genomes. These were subcloned into the
parent vector pJ40mega, at its multi cloning site (MCS),
which is followed by a splice donor (SD) and splice
acceptor (SA) site with a final SV40 T poly A site for
termination of transcription. Upstream of the MCS there
is a viral enhancer within the long terminal repeat (LTR)
of the Moloney-Murine Leukaemia Virus (Mo-MULV). Four
HPV types were used, 6b, 11, 18 and 16. Those regions of
viral genomes used are indicated by shading of the
relevant open reading frames, which correspond to the
genes set out at the top of the diagram. All
constructions contained most of the upstream regulatory
region and the transforming genes E6 and E7 within a
continuous DNA sequence.
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3.3.2 CONSTRUCTION OF NEW PLASMIDS
Expression vectors for myc and ras oncogenes that
contained a drug selection gene different from aph were
synthesised for two purposes. First, independent clones
of single oncogene transfectants derived by different
transfection and selection protocols could be compared,
so that similar phenotypic effects could be ascribed to
the introduced gene rather than the experimental
procedure. Second, serial transfection of myc and ras
oncogenes into cells required separate selection methods.
Thus, a DNA insert containing the hygromycin resistance
gene (HmR) was introduced into the existing T 2 4 -ra s
expression plasmid pH05Tl to produce pHRH05Tl, and also
into the c-my c expression plasmid pMCGMl to give
pHRMCGMl.
3.3.2.1 pHRH05Tl PLASMID
The pHRH05Tl plasmid (19.4 kb) was constructed by
insertion of the Hind III linearised plasmid pHMR272
(Bernard et al, 1985) into the Hind III cleavage site in
pH05Tl (figure 3.1). pH05Tl contains the mutated T24-ras
oncogene linked to the SV40 promotor/enhancer element and
the aph drug resistance gene, as well as the ampicillin
resistance gene for bacterial selection (Spandidos and
Wilkie, 1984). pHMR272 contains the Hmr gene (Raster et
al, 1977; Bernard et al, 1985) which confers resistance
to hygromycin B, an aminoglycoside antibiotic which is
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lethally toxic to mammalian and bacterial cells at
appropriate doses. Thus, bacteria successfully
transformed by recombinant plasmids were selected using
agar with L-broth media containing both ampicillin and
hygromycin B. Correct construction and orientation of the
insert was confirmed by restriction mapping with EcoRI,
BamHI, and HindiII which digested the plasmid into DNA
fragments of the predicted lengths (figures 3.1 and 3.4).
3.3.2.2 pHRMCGMl PLASMID
pHRMCGMl plasmid (19.7 kb) was constructed by insertion
of the Hind III linearised plasmid pHMR272 into the
Hind III cleavage site in plasmid pMCGMl, linking the
hygromycin B resistance gene to the c-myc expressing
sequences. Successfully transformed bacteria were
selected using agar with L-broth media containing both
ampicillin and hygromycin B. Correct construction and
orientation of the insert was confirmed by restriction
mapping with EcoRI. BamHI, and HindiII which digested the
plasmid into DNA fragments of the predicted lengths
(figures 3.2 and 3.5) .




Agarose gel electrophoresis showing restriction
endonuclease mapping of the two newly constructed
plasmids pHRH05Tl (two clones tested in tracks a and b, h
and i) and pHRMCGMl (two clones tested in tracks f and g,
m and n). Enzymic digestions are also shown for the
parent plasmids pH05Tl (tracks c and j), pHMR272 (tracks
d and k) and pMCGMl (tracks e and 1). The first 7 tracks
(a-g) show restriction with Hindlll. The second 7 tracks
(h-n) show restriction with Bglll. The central tracks (M)
are marker tracks consisting of lambda DNA digested by
Hindi11, giving bands of 23, 9.4, 6.6, 4.3, 2.3 and 2.0
kb. (A). HindiII cleaves pHRH05Tl into two fragments of
15.3 and 4.1 kilobases (a and b), pH05Tl into a single
fragment of 15.3 kb (c), pHMR272 into a single fragment
of 4.1 kb (d), pMCGMl into a single fragment of 15.6 (e),
and pHRMCGMl into two fragments of 15.6 and 4.1 kb (f and
g). BglII cleaves pHRH05Tl into three fragments of
approximately 8, 7 and 4 kb (h and i), pH05Tl into two
fragments of approximately 8 and 7 kb (j), pHMR272 into a
single fragment of 4.1 kb (k), pMCGMl into a single
fragment of 15.6 kb (1), and pHRMCGMl into two fragments
of approximately 13 and 6.7 kb (m and n). These patterns
of restriction enzyme digestion were used to confirm
successful ligation and to determine orientation of the




Agarose gel electrophoresis showing restriction
endonuclease mapping of the two newly constructed
plasmids pHRH05Tl (two clones tested in tracks a and b, h
and i) and pHRMCGMl (two clones tested in tracks f and g,
m and n). Enzymic digestions are also shown for the
parent plasmids pH05Tl (tracks c and j), pHMR272 (tracks
d and k) and pMCGMl (tracks e and 1). The first 7 tracks
(a-g) show restriction with EcoRI. The second 7 tracks
(h-n) show restriction with BamHI. EcoRI cleaves pHRH05Tl
into six DNA fragments of approximately 7.4, 7.3, 2.2,
I.7, 0.5, and 0.3 kb (a and b), pH05Tl into three
fragments of 7.3, 5.8 and 2.2 kb (c), pHMR272 into 3
fragments of 3.3, 0.5 and 0.3 kb (d), pMCGMl into two
fragments of 12.7 and 2.9 kb (e), and pHRMCGMl into five
fragments of approximately 10, 6, 2.9, 0.5 and 0.3 kb (f
and g). BamHI cleaves pHRH05Tl into three fragments of
II.2, 6.6, and 1.6 kb (h and i), pH05Tl into two
fragments of 8.7 and 6.6 kb (j), pHMR272 into one
fragment of 3.9 kb and a small fragment lost from the gel
(k), pMCGMl into one fragment of 15.6 (1), and pHRMCGMl
into two fragment of approximately 18 and 1.5 kb (m and
n). There is evidence of mild activity of BamHI at its
known secondary recognition site (associated with high
enzyme concentration) in tracks j, k, 1, m and n. These
patterns of restriction enzyme digestion were used to
confirm successful ligation and to determine orientation
of the insert as shown in the plasmid maps.
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TABLE 3.1 SUMMARY OF PLA8MID BEOUENCE8
DESIGNATION ONCOGENE ENHANCER DRUG
RESISTANCE
pH05Tl T24-ras SV40 G418
pHRH05Tl T24-ras SV40 G418, HmB
pMCGMl c-myc Mo-LTR G418
pHRMCGMl c-myc Mo-LTR G418, HmB
Note: Transfected oncogenes included the T24-ras
oncogene, a genomic human sequnce of c-Ha-ras.
mutationally activated at codon 12 (glycine to valine),
and the c-mvc. a genomic human proto-oncogene. The
enhancers were derived from the viral genomes of Simian
Virus 40 (SV40) and Moloney Murine Leukaemia virus long
terminal repeat (Mo-LTR), and both were known to possess
powerful promoter/enhancer activity. The drug selection
genes conferred resistance to geneticin (G418) and
Hygromycin B (HmB).
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3.4 CELL LINE CONSTRUCTION AND CHARACTERISATION
3.4.1 TRANSFECTION WITH ONCOGENE AND HPV DNA
The transforming potentials of high and low risk HPVs -
alone or in combination with activated c-Ha-rasl - were
compared in cultured fibroblasts.
208F fibroblasts were electroporated with pJ40 expression
plasmid vectors containing the cloned HPV DNA of types
6b, 11, 16 and 18. HPV genes were linked to strong
heterologous promotor and enhancer sequences (Mo-MuLV
LTR) in the pJ40 plasmid. The plasmid pH05Tl contained
T24-ras linked to the SV40 enhancer region and an aph
gene. The plasmid pSV2NE0, containing only the
aminoglycoside phosphohydro1 ase gene (aph) , was
cotransfected in a 1:10 ratio with HPV expression
plasmids to confer resistance to geneticin (G418), for
selection of positive transfectants. Combinations of HPV
and ras expression plasmids in a 1:1 ratio were used.
Numbers of surviving colonies after G418 selection were
counted in three transfection experiments, and these
colonies also demonstrated morphological changes (figure
3.6). Single colonies were subsequently isolated and
established as clonal cell lines for further studies of
tumour growth.
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Figure 3.6
Bar chart of the number of morphologically transformed
foci of cells following transfection of 208F cells with
expression vectors (pJ40mega) for HPV genomes 6b, 11, 16
and 18, either alone or in combination with ra s
(pH05T1). Transfection of the ras expression vector
alone is also shown for comparison.
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Large numbers of foci were observed for HPV types 16 and
18, both alone and with T 2 4 -ra s, and these showed
morphological transformation from the parental flat,
topo-inhibited monolayer cells to spindle-shaped,
retractile cells which pile up (figure 3.7). No foci were
seen with HPV 11 alone and only two non-transformed
colonies with HPV 6b alone. The combinations of HPV types
with T2 4-ras produced similar or lesser numbers of foci
than T24-ras alone (figure 3.6) .
Fourteen cell lines were selected for study, all
derivatives of 208F containing HPV, c-myc or T24-ras,
alone or in certain combinations with each other (table
3.2) . As a control, primary fibroblasts were prepared
from freshly dissected rat lungs, and grown in. vitro.
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Figure 3.7
Morphological appearances of HPV transfected cell lines
using phase contrast photo-microscopy. The four cell
lines all appear morphologically transformed, H16R and
H18R more so than H16 and H18, with spindle shaped,


































































































































































































The parent cell line was 2 0 8F, an established rat
fibroblast line with a hyperdiploidkaryotype. This cell
line was derived from the Fischer rat fibroblast line
F2408 as a variant which was resistant to thioguanine
after mutagenesis with ethyl-methane-sulphonate (Quade et
al, 1979).
RFMCGM1 (called Ml hereafter) and RFH05T1 (called Tl)
were originally derived from 208F by Spandidos and Wilkie
(1984) . Ml contains the c-myc expression plasmid pMCGMl,
and Tl contains the T24-ras expression plasmid pH05Tl,
both as a result of transfection with calcium phosphate
and selection by geneticin. Multiple colonies of G418
resistant cells were cultured as mixed populations from
which the cell lines were derived.
M7 and M8 were independently derived from 208F by
transfection with the c-myc expression plasmid pHRMCGMl
using electroporation. Transfectants were selected with
hygromycin B (to which the plasmid confers resistance) .
Unlike Ml, they were clonally selected. T2. and T3 were
similarly clonally selected independent 208F
transfectants, obtained by electroporation with the T24-
ras expression plasmid pHRH05Tl, and selection by
hygromycin B.
Four mixed T 2 4 -r a s and c-myc transfectants were
constructed. MT 4 was derived from Ml cells by
electroporation with the T2 4-ras expression plasmid
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pHRH05T1. MT7 cell line was derived from Tl cells by
e1ectroporation with the c-my c expression plasmid
pHRMCGMl. MT9 and MT10 were both derived from 208F by
simultaneous electroporation with the c-myc and T24-ras
expression plasmids (pHRHMCGMl and pHRH05Tl). In these
experiments transfectants were selected with hygromycin B
and single colonies isolated as clones.
Four cell lines containing high risk HPV genomes,
either alone or in combination with activated ras, were
derived from 208F. HI6 was constructed by cotransfection
with the HPV 16 expression plasmid pJ40.16 and the drug
resistance selection plasmid pSV2NE0, in a 10:1 molar
ratio. Similarly, HI8 was derived by cotransfection with
the HPV 18 expression plasmid pJ40.18 and the drug
resistance selection plasmid pSV2NEO, in a 10:1 molar
ratio. HI6R was constructed by cotransfection with the
HPV 16 expression plasmid pJ40.16 and the T 2 4 -ra s
expression plasmid pH05Tl (which also contains the aph
gene conferring geneticin resistance), in a 1:1 molar
ratio. H18 R cell line was similarly derived by
cotransfection with the HPV 18 expression plasmid pJ40.18
and the T24-ras expression plasmid pH05Tl, in a 1:1 molar
ratio. Transfectants were selected with geneticin and
single colonies isolated as clones.
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3.4.2 IDENTIFICATION OF TRANSFECTED DNA
Transfectants were assayed for exogenous DNA either by
Southern blotting or PCR. In the 10 oncogene
transfectants, c-myc and T24-ras sequences were detected
using Southern blots prepared from cell line DNA
digested by Hindlll, and probed with Hindlll-restricted
plasmids pHRH05Tl (Tl, T2, T3, MT4, MT7, MT9 and MT10),
or pHRMCGMl (Ml, M7 and M8). The 10 oncogene-transfected
cell lines exhibited bands of the appropriate sizes
expected of the introduced oncogene fragments and these
were not seen in 208F (figure 3.8). Bands of other sizes
and faint bands present in 208F may have represented
plasmid DNA sequences disrupted during integration, or
endogenous ras or myc DNA sequences. In the four HPV
transfectants, transfected DNA was detected by PCR assay,
either using the specific primers for HPV 16 or 18
described in chapter 2, or using human specific Ha-ras




Southern blots of oncogene transfectants. (A) The three
ras transfectants Tl, T2 and T3 are compared with the
parent cell line 208F and a plasmid DNA control
(pHRH05Tl). The blot was probed using labelled pHRH05Tl
plasmid DNA. The parent cell line is negative but the
three transfeet ants contain the ras sequence. The
strongest hybridisation signal is seen in Tl, followed by
T2 and lastly T3 with the weakest signal. (B) The three
c-myc transfectants Ml, M7 and M8 are compared with the
parent 208F. There are two bands present in the
transfectants which are absent in the parent (arrows)
which demonstrate transfection of the c-myc oncogene.
Labelled plasmid pHRMCGMl was used as the probe. (C) The
four co-tranfectants MT4, MT7, MT9 and MT10 were probed
with the ras probe using labelled pHRH05Tl. This shows




Agarose gel electrophoresis showing detection of
transfected DNA using PCR. (A) HPV 16 primers were used
to generate an amplified product of 316 base pairs in the
cell lines H16R and H16. A 1 kb ladder marker track (M),
positive control (+) of cloned HPV16 DNA and a negative
template free control (-) are included. (B) HPV 18
primers were used to generate an amplified product of 144
base pairs in the two cell lines H18 and H18R. Similar
positive and negative controls are included. (C) The
set of ras primers developed by Bos et al (1987) were
used to generate amplified products of 60 base pairs from
the human c-Ha-rasl gene in the cell lines H16R and H18R,
which were not present in the parent 208F. A positive




A new assay based on reverse transcription and polymerase
chain reaction (rT-PCR) was developed for the detection
of c-myc and c-Ha-ras1 mRNA, using a similar approach to
that described in chapter 2 for primer selection. Species
specific primers were chosen in exons 2 and 3 of human c-
myc (Watson et al, 1983/ Battey et al, 1983), and exons 3
and 4 of human c-Ha-ras (Santos et al, 1982/ Reddy et al,
1982/ Capon et al, 1983) . As an internal reference,
primers in exons 3 and 4 of beta actin were also used
(Nudel et al, 1983/ Ng el al, 1985). These "exon-
connecting" primers allowed clear distinction between
products amplified from cDNA (introns spliced out
confirming transcription) and genomic DNA (introns
retained) . The c-myc primers amplify a sequence of 1610
bp in genomic DNA and 234 bp in cDNA reverse transcribed
from RNA. The primers for c-Ha-ras1 amplify a product of
800 bp from genomic DNA and 103 bp from cDNA. Homology to
rat sequences was less than 80% for both oncogenes
(tables 3.3 and 3.4).
The rT-PCR assay was applied to RNA extracted from single
oncogene transfectants after exclusion of significant RNA
degradation by formaldehyde-agarose gel electrophoresis.
208F was negative for both myc and ras expression. Bands
of the appropriate sizes for myc transcripts were
generated from M7 and M8 RNA samples, and similarly for
ras mRNA from Tl, T2 and T3, and for control actin
244
transcripts from the 4 newly constructed single oncogene

























































































































































































































Agarose gel electrophoresis of products generated by the
reverse transcription - polmerase chain reaction assay
used to detect specific RNA species within cells. (A) ras
specific RNA is detected in the three ras transfectants
Tl, T2 and T3. This amplified product measures 103 bp in
length (arrow) . A negative template free control (-) , a
positive control (+) using as template the genomic ras
gene in plasmid pH05Tl (which generates a DNA amplified
product of 800 bp) , and a 1 kb ladder of marker track are
included. (B) mvc primers were used to generate reverse
transcribed and PCR amplified products for M7 and M8, of
length 234 bp (arrow). The positive control (+) used as
template the genomic c-myc sequence in plasmid pMCGMl
(which generates a DNA fragment of 1610 bp). A 1 kb
ladder marker track is included. (C) Detection of
expression of the actin gene was used as a control.
Primers specific for actin RNA sequences were used to
generate reverse transcribed and PCR amplified products
of length 126 bp (arrow) for the cell lines M8, T3, M7
and T2. A positive control ( + ) was included which used as
template the actin cDNA cloned in a plasmid. A
template-free negative control (-) and a 1 kb marker
track are also included.
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Validation of this new assay and independent confirmation
of c-myc expression in the 2 newly constructed myc
transfectants was obtained using dot blot hybridisation
of extracted RNA. M7 and M8 gave strongly positive
hybridisation signals with a myc labelled probe (8.4 kb
DNA fragment from EcoRI - Hindi 11 digested pMC41Cl
plasmid, containing the 3 myc exons), whereas the parent
(208F) was gave a weaker signal, as expected of an
actively proliferating cell line not transfected with
myc. Approximately equal loading of cellular RNA was
confirmed by hybridisation with a ribosomal sequence
probe (10 kb DNA fragment from Hindlll digested pXLRlOlNH
plasmid [Dr N Hunter, personal communication] , containing
Xenopus ribosomal sequences) (figure 3.11).
249
M7 M8 208F M7 M8 208F
PROBE c-myc ribosomal
Figure 3.11
Dot blot hybridisation of RNA extracted from the M7 and
M8 cell lines which contain the c-myc oncogene and also
the parent 208F line. On the left the blot was probed
with labelled c-myc DNA, and the hybridisation signals
are stronger for M7 and M8 compared with 208F. On the
right, a duplicate blot was hybridised with a labelled
ribosomal DNA probe and this showed approximately
equivalent loading of RNA from the three cell lines.
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3.5 GROWTH PARAMETERS OF ONCOGENE TRANSFECTANTS
3.5.1 GROWTH IN CULTURE
3.5.1.1 MORPHOLOGICAL TRANSFORMATION PHENOTYPES
The morphological appearances of oncogene and HPV
transfectants were recorded by phase contrast
photomicroscopy (figures 3.12 and 3.7). Three criteria
were used to assess morphological transformation:
intercellular relationships including focus formation and
overlapping cytoplasmic processes, cell shape, and
refractile appearance. These features, although open to
bias from subjective observation, may be important
features of tumour cells, in that they may represent
alterations in cytoskeletal architecture, contact-
inhibition of growth and changes of surface attachments
or interactions of tumour cells.
i. Parental Established Rat Fibroblast (208F).
The parental 208F cell line demonstrated topo-inhibition
of growth in culture by forming a flat confluent
monolayer with no gaps between adjacent cells. The cells
did not grow in foci or overlap each other, and had a
non-refractile polygonal appearance, typical of non-
transformed cells.
Controls for subsequent experiments included
untransfected 208F cells, cells electroporated with no
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DNA, or transfected with the drug selection vector only
(pSV2NE0), all of which showed no evidence of
morphological transformation.
ii. C-myc transfectants (Ml, M7, M8).
The three c-myc transfected cell lines demonstrated
similar morphological features in vitro. The flat
spindle-shaped cells were only mildly retractile, and
were able to form near-confluent monolayers. At both high
and low cell densities there was very tight side-to-side
clustering of cells, producing a fascicular appearance.
At low cell densities a limited degree of overlap of
cellular cytoplasmic processes was also seen at the
expanding edges of cell colonies, but foci of greater
than 2-3 cells high were not observed.
iii. T24-ras transfectants (Tl, T2, T3).
The three T24-ras transfected cell lines showed similar
characteristic morphological features when growing in
culture at low cell densities: tubular, spindle-shaped
cells, showing marked retractility, and piling up in
foci, with adjacent cells overlapping, often 2-4 cells
high. At high cell densities, Tl and T2 tended to
overlap to a greater degree, and did not form a confluent
carpet of cells, whereas T3 formed a dense near-confluent
carpet of moderately retractile cells with considerable
cellular overlap within it.
iv. Serial myc-ras transfectant (MT4, MT7).
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The MT4 cell line exhibited a similar appearance to its
immediate parent, the c-myc expressing line Ml, with
mildly refractile cells growing in fascicular patterns to
form a monolayer. The tendency for cells to overlap in
foci at lower cell densities was not seen at higher cell
densities.
The MT7 cells showed similar morphological appearance to
its immediate parent, the T24-ras expressing line Tl, at
low densities, they grew in foci of overlapping cells,
at high densities they formed a dense carpet with gaps
between adjacent cells. The cells were spindle-shaped
and highly refractile.
v. myc-ras cotransfectants (MT9, MT10).
MT9 and MT10 both formed confluent monolayers with no
gaps between adjacent cells, but with a limited degree of
piling up of cells at low cell densities; these cell
lines tended to grow not in foci, but in a more diffuse
manner. The cells were moderately refractile.
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Figure 3.12
Appearances of morphologically transformed cells recorded
by phase contrast photomicroscopy. (A) Three c-myc
transfectants, Ml, M7 and M8 show a mild degree of
transformation with mild retractility but a more striking
fascicle formation whereby cells line up in their
longitudinal axes. The 3 ras transfectants Tl, T2 and T3
show moderate to high degrees of morphological
transformation, with retractility, spindle cell formation
and overlapping of cytoplasmic processes. Tl and T2 show




(B) The parent cell line, 208F, at medium and high power
magnification is compared with the 4 double oncogene
transfectants MT4, MT7, MT9 and MT10. Varying degrees of
morphological transformation are seen. MT7 shows the
greatest degree of transformation with MT9, MT10 and MT4
all showing similarly moderate degrees of morphological
transformation.
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vi. HPV 16 and 18 transfectants (H16 and H18).
Both high risk HPV transfectants formed confluent
monolayers with no gaps between adjacent cells, and a
limited degree of piling up of cells at low densities.
Moderate refractility of the cells was observed, but
fascicular formation was not seen.
vii. HPV 16 + ras / HPV 18 + ras transfectants (H16R and
H18R).
The combined high risk HPV plus ras transfectants
displayed a highly transformed morphology at both low and
high cell densities, forming foci of overlapping cells.
Individual cells were spindle-shaped and highly
refractile. It was not possible to morphologically
distinguish these from fibroblasts transfected with ras
alone (T1 or T2).
viii. Primary Rat Lung Cells
The flat round or polygonal cells were non-refractile and
formed a confluent monolayer, demonstrating topo-
inhibition. They showed no piling up, or overlapping of
cells and no focus formation (data not shown).
Control experiments in which 208F cells either underwent
electroporation without any DNA, or were transfected with
a "dummy" plasmid (pBR322), showed no morphological
transformation afterwards and died during aph or HmB drug
selection. Other experimental studies have also included
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controls in which 208F cells were transfected with
similar plasmid sequences without an oncogene, but
containing the same promoter/enhancer elements, drug
selection genes and bacterial sequences. These
experiments showed no morphological transformation
(Spandidos and Wilkie, 1984/ Spandidos, 1985).
3.5.1.2 INVESTIGATION OF CELL DEATH IN CULTURE
3.5.1.2.A MORPHOLOGICAL STUDY OF CELL DEATH
Ultrastructurally, cells recovered from the monolayers
of all cell lines showed similar features (data not
shown). Some lines (to be detailed later) also released
cells into the medium in substantial numbers. These
showed all the cardinal features of apoptosis (figure
3.13 parts I and II) . Cytoplasmic changes included
shrinkage in cell volume with compaction of
morphologically normal organelles, formation of dilated
endoplasmic reticulum vesicles some of which appeared to
fuse with the cell membrane, and the appearance of semi-
crystalline arrays of ribosomal particles. Nuclear
changes included condensation of chromatin, with
peripheral margination into crescentic caps or toroidal
structures, nucleolar segregation and dispersion. Many
cells showed fragmentation of the nuclear structure
into discrete spherical masses of chromatin, numbering
between three and twelve. Phagocytosis of apoptotic
bodies by monolayer cells was only occasionally observed.
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Figure 3.13
(I). Ultrastructural appearances of viable and apoptotic
transfectants. (A) Two viable fibroblasts taken from the
monolayer. The nuclei display both euchromatin and
heterochromatin with one or more nucleoli. (B) In
apoptosis, the chromatin condenses around the periphery
of the nucleus forming either toroids or crescentic caps,
and the nucleolus undergoes a characteristic pattern of
disintegration. (C) The fibrillar centre of the
nucleolus is conserved, following dissociation of the
dense fibrillar and granular components seen in the
central zone of the nucleoplasm. (D) The conserved
fibrillar centre is seen adjacent to the condensed
chromatin at the nuclear margin, separated by a thin
layer of nucleoplasm which is less electron dense. In
the cytoplasm there is vacuolation around the periphery
of the cell just below the plasma membrane. Some of
these vacuoles appear to fuse with the cell membrane. (E)
Nucleolar disintegration into the three components is
apparent. (F) In phase 2 of apoptosis, the nucleus
splits up into smaller spheres of darkly staining
condensed chromatin seen here scattered through the




(II). (A) Prior to fragmentation of the apoptotic
nucleus, the condensed chromatin often aggregates in
dense clumps at the periphery of the nucleus. (B) The
nucleus appears todevelop pseudopodium-1ike structures
filled with condensed chromatin as it splits up into
separate spheres of chromatin. (C) Multiple densely
staining spheres of chromatin are formed and ribosoms are
often seen detached from the endoplasmic reticulum,
aggregated into semi-crysta 11ine arrays. (D) The
apoptotic cell fragments into several small apoptotic
bodies which may or may not contain condensed chromatin,
and some of these are phagocytosed by adjacent cells in
the monolayer (E), or may be released into the culture
medium. (F) Phagocytosed apoptotic bodies eventually
undergo degradation, and the residual bodies may resemble
fragments of necrotic cells.
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Most apoptotic cells were released into the culture
medium and after an extended period these showed
secondary degenerative changes, such as membrane rupture
and swelling. In contrast, primary necrosis of cells was
observed very seldom.
Fluorescence microscopy of wet preparations of cells
released into the media, stained in acridine orange,
showed closely similar nuclear morphology of apoptotic
cells compared to electron microscopy. These were clearly
demonstrated as DNA stained with acridine orange emitted
yellow-green fluorescence. In particular, there was
chromatin condensation into single nuclear structures or
multiple spherical masses. In a small proportion of
apoptotic cells the arrays of ribosomal particles, were
discernable by acridine orange staining, as single-
stranded RNA emitted red fluorescence (figure 3.14). This
morphological correlation validated the technique of
identification of large numbers of apoptotic cells by
fluorescence microscopy, and their differentiation from
viable cells. Thus, whereas electron microscopy was of
use in defining qualitative aspects of apoptosis,
fluorescence microscopy permitted quantitation.
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Figure 3.14
Comparison of viable (left) and apoptotic (right) cells
released into the culture medium by a myc transfectant.
The cells were stained with acridine orange and viewed
under ultraviolet light using fluorescence microscopy.
In viable cell nuclei, internal structure can be
discerned, including denser staining of the
heterochromatin around the periphery of the nucleus and
brighter staining of the nucleolus. In the apoptotic
cells, nuclei have often fragmented into multiple small
spherical particles of condensed chromatin which stain a
brighter yellow/green fluorescence. Ribosomal arrays in
apoptotic cells may also stain as bright red dots
(acridine orange stains single stranded nucleic acids
red) .
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3.5.1.2.B ENDOGENOUS ENDONUCLEASE ACTIVITY IN APOPTOTIC
AND VIABLE CELLS
To determine whether the structural form of DNA within
the cellular bodies released into culture medium was that
of apoptosis, cell bodies were harvested from the media
overlying confluent cultures of cells. DNA was extracted
and analysed by agarose gel electrophoresis. DNA from 2
samples of released cell bodies of the c-myc oncogene
transfectant Ml is shown as an example (figure 3.15A).
The typical "chromatin ladder" of DNA bands representing
o1igonuc1eosoma1 fragments was seen, indicating
activation of the endogenous endonuclease associated with
apoptosis and further confirming that these were
apoptotic cells.
Expression of this endonuclease activity by viable
cells, taken from the monolayer, was examined for the
single myc and ras oncogene transfectants. Glycerol
purified nuclei were prepared from monolayer cells grown
at high or low serum concentrations for 4 hours prior
to analysis. These were tested in an autodigestion
assay, designed to allow digestion of chromatin within
the nuclei by the endonuclease, if present, following its
activation by manipulation of the ionic environment. The
nuclease activity of the endogenous endonuclease
associated with apoptosis is known to be sensitive to the
2 divalent cations calcium and magnesium, and these must
both be present at critical concentrations for full
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enzymic activity (nuclease activity can also be inhibited
by zinc ions).
DNA was extracted from autodigested nuclei and analysed
by agarose gel electrophoresis. Using nuclei derived from
cells grown in high serum concentrations (10% HINCS) and
autodigested in the presence of both cations this assay
showed chromatin cleavage into o1igonuc1eosoma1
fragments in Ml, M7 and M8, but not in 208F, or T1
(figure 3.15B). The oligonucleosomal sized DNA bands from
myc transfectants were sometimes seen on a background of
DNA smears. Only high molecular weight DNA, with minimal
or no low molecular weight DNA smears or
oligonucleosomal fragments, were seen in the samples of
208F and T1. This suggested that Ml, M7 and M8 viable
cells expressed endonuclease, whereas T1 and 208F viable
cells did not. There was markedly less nuclease activity
in the myc transfectant nuclei if only one cation
(calcium) was present, and in the case of M8, a cell line
with high endonuclease activity, there was complete
inhibition of nuclease activity by zinc ions.
Low endonuclease activity was present in T2 and T3 nuclei
prepared from cells grown in high serum (10% HINCS)
concentrations, but this activity was markedly increased
by growth in low serum (0.05%) for 4 hours prior to
analysis (figure 3.15C). At high serum there was mild
cleavage of chromatin into mostly large oligonucleosomal
fragments, but at low serum a greater proportion of
263
digested chromatin appeared as small oligonucleosomes, in
particular the bottom two rungs of the chromatin ladder,
representing mono- and di-nuc1eosomes, were more
prominent. This was confirmed by densitometric
measurement of DNA bands and comparison of "digestion
ratios". These ratios were calculated by taking the
amounts of DNA in higher order oligonucleosomes (the
upper half of the third rung of the chromatin ladder, and
all rungs above including the high molecular weight DNA
smear), and dividing by that in the lower order
oligonucleosomes (the first and second rungs, and the
lower half of the third). Ionic sensitivity of the
nuclease activity in T2 and T3 nuclei prepared from cells
grown at both serum concentrations was confirmed. In
contrast, Tl showed no endonuclease activity at low
serum, whereas M8 demonstrated marked nuclease activity






(A) Agarose gel electrophoresis ot z DNA samples




transfectants. This shows the chromatin
typical of apoptosis.
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IONIC SENSITIVITY OF ENDONUCLEASE
ACTIVITY IN VIABLE NUCLEI
2 0 8 F Ml M 7 M 8 T1
MC C MC C MC C Z MC C MC C M IONS
Figure 3.15
(B) Ionic sensitivity of endogenous endonuclease activity
within nuclei prepared from viable cells. This shows DNA
extracted from nuclei following auto-digestion in the
presence or absence of magnesium and calcium ions (MC for
both, C for calcium only). The parent 208F shows no
chromatin digestion, the three c-myc transfectants, Ml,
M7 and M8, show chromatin laddering which is more marked
when both cations are present. M8 chromatin digestion is
completely inhibited by the presence of zinc ions (in the
presence of magnesium and calcium ions). Samples from
the ras transfectant Tl show no endonuclease activity.
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SERUM SENSITIVITY OF ENDONUCLEASE
ACTIVITY IN VIABLE NUCLEI
1.1 1.9 - - 0.6 1.0 0.4 0.7 DIGESTION
RATIO
Figure 3.15
(C) Serum sensitivity of endogenous endonuclease
activity in viable nuclei using the auto-digestion assay.
Cells were grown for 4 hours in either low (0.05% HINCS)
or high (10% HINCS) serum prior to analysis. Digestion
ratio data (see table 3.5) are quoted under the
appropriate track for each cell line tested at either
low or high serum (for assays performed in the presence
of both calcium and magnesium ions). M8 shows digestion
of chromatin into oligonucleosomal fragments at both
serum concentrations, with a slight increase in digestion
to lower order oligonucleusomes at low serum levels
indicated by the decrease in digestion ratio. T1 shows no
significant chromatin digestion at either high or low
serum. The tracks for the remaining 2 ras transfectants
T2 and T3 show a pattern of chromatin digestion which
differs according to the serum concentration as well as
the ionic content of the assay solution. There is
considerably greater chromatin digestion in the presence
of both calcium and magnesium compared with calcium ions
alone. Digestion patterns illustate that both T2 and T3
show low levels of chromatin digestion, mostly into the
higher order oligonucleosomes, at high serum, (measured
as higher digestion ratios). In contrast, at low serum
there is greater digestion into lower order
oligonucleosomes (measured as reduced digestion ratios).
The overall pattern is one of serum sensitive expression
of endonuclease activity in T2 and T3. One kb ladder
marker tracks (M) are included in figures B and C, and
the positions of marker track bands are indicated in
figure A. These confirm chromatin cleavage into DNA
fragments that are multiples of the length of DNA wrapped















































































































































































































































3.5.1.3 CELL GROWTH KINETICS
3.5.1.3.A CELL POPULATION EXPANSION
The rates of expansion of the total number of cells in
growing populations were plotted as expansion curves
(figures 3.16). The total number of cells after 72 hours
growth and the gradients of the curves at 24 - 48 hours,
were related not only to the rate of population
expansion, but also the seeding efficiency and residual
contact inhibition of each cell line. Therefore, the
ratio of the mean cell number at 48 and 24 hours was
calculated as a single measure of the proportional
increase in cell number over one day, in order to compare
the rates of population expansion (PE) between different
cell lines whilst in maximal growth phase.
(i) ONCOGENE TRANSFECTANTS
The parent cell line 208F gave a PE value of 1.53, by
comparison T1 (3.56), T2 (3.67) and M T 7 (4.06)
demonstrated higher PE rates, whereas M8 (1.20) and MT4
(1.44) showed lower values than 208F, with M7 (1.54)
very similar to 208F. The PE values for Ml (2.89), T3
(1.77), MT9 (1.67) and MT10 (2.30) were intermediate
(figure 3.17 and table 3.6). No statistical analysis was
applied to these results as the 24 and 48 hour cell




Population expansion curves are shown, which represent
the net rates of growth in culture for oncogene
transfectants. 3.10 cells were seeded at time 0, and
total cell numbers were counted at 24, 48 and 72 hours.
(A) The three c-myc transfeetants, Ml, M7 and M8 are
compared to the parent 208F. M7 and M8 show similar or
slightly slower growth than that of the parent, whereas




(B) Comparison of the population expansion curves for
the 3 ras transfectants Tl, T2, and T3 and the parent
208F. All transfectants show faster growth curves than
the parent, with Tl having the steepest growth curve and




(C) Comparison of the population expansion curves for
the 4 co-transfeetants MT4, MT7, MT9 and MT10. MT7 and
MT10 show the steepest gradients of their growth curves
whereas MT9 is intermediate and MT4 has a slow growth




Bar chart of population expansion rates (N48/N24) for the



























































































































































































































































































(ii) HPV AND ONCOGENE TRANSFECTANTS
Similar values for population expansion were observed for
three of the HPV containing transfectants: H16 had a PE
of 2.2, H18 1.7, and H16R 1.5 (figure 3.18 and table
3.6). The only statistically significant difference found
between these three values was in comparing H16 with H16R
(p=0.032, student's t test on 8-9 experiments) (table
3.7A). In contrast, H18R had the substantially higher
value for population expansion of 3.7 (p=0.0007 for
comparison with both H16 and H18, and p < 0.00001
compared with H16R; student's t test on 8-9 experiments
for each cell line).
275
GROWTH IN CULTURE OF HPV TRANSFECTANTS
APOPTOSIS/POP EXP PROLIFERATION
H16 H16R H18 H18R
APOPTOSIS POP EXP □ PROLIFERATION
Figure 3.18
Bar chart of the growth parameters in culture of the four
HPV transfectants H16, H16R, H18 and H18R. This allows
comparison of the population expansion rates (N48/N24),
the apoptotic indices and the proliferation indices.
Three lines, H16, H16R and H18 have similar overall
profiles for these three parameters, but H18R differs
with higher population expansion and lower apoptosis.
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TABLE 3.7A
POPULATION EXPANSION: RELATIVE COMPARISON BY STUDENT'S T TEST
16 16R 18 18R
16R 0.032
18 NS NS —
18R 0.0007 < 0.00001 0.0007
TABLE 3.7B
CELL PROLIFERATION: RELATIVE COMPARISON BY STUDENT'S T TEST
16 16R 18 18R
16R NS
18 NS 0.012
18R NS NS NS
TABLE 3.7C
APOPTOSIS: RELATIVE COMPARISON BY STUDENT'S T TEST
16 16R 18 18R
16R NS
18 NS NS
18R NS NS 0. 028
NOTES: p values quoted
NS = not significant
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3.5.1.3.B CELL PROLIFERATION
Cell cycle analysis was performed by flow cytometric
measurement of the nuclear DNA content using cells
growing in the maximal growth phase for each cell line.
Two computer software programs, SFITS and PARA1, were
used to determine the proportion of cells in each phase
of the cell cycle. The proliferative index in culture
was calculated as the proportion of cells in S plus G2/M
phases of the cell cycle (growth fraction). This measures
the proportion of actively proliferating cells in each
sample.
Several control experiments were carried out to confirm
the validity of the cell preparation protocol and flow
cytometric analysis.
a. For five of the cell lines, one cell sample was
separated into two parts each of which was prepared
separately. The average co-efficient of variance (CV)
comparing the two separately prepared samples for each
cell line was 7.11. This indicated that the preparation
technique was reproducible.
b. Nine of the cell lines were grown in two separate
flasks in parallel, and these were prepared and analysed
separately. The average CV in this case was 8.35,
indicating a reproducible similarity between two samples
from the same cell line.
c. Two samples of three of the cell lines were grown and
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prepared separately, but one sample from each pair did
not have the medium replaced 4 hours before harvesting.
The CV in this case was 9.19, indicating that growth
medium replacement was not absolutely necessary to
eliminate variation in the results.
(i) ONCOGENE TRANSFECTANTS
The proliferative indices for the parent cell lines, 208F
(35.6), and the ten oncogene transfected cell lines, Ml
(40.4), M7 (29.8), M8 (39.9), T1 (40.1), T2 (38.9), T3
(36.6), MT 4 (39.4), MT 7 (33.1), MT 9 (43.7) and MT10
(40.8), were determined using SFITS computer program
analysis of cell cycle data from 5-8 experiments (figure
3.19 and table 3.6). These were statistically analysed by
the ANOVA test, which showed no significant differences
(F=1.38, vl=10, v2=75). Paired comparisons by the
student's t test confirmed the absence of statistically
significant differences, with one exception: M7 and MT9
(p=0.02) (table 3.8). Cell cycle analysis by PARA1
computer software produced similar results with no







Flow cytometric analysis of the proportion of
proliferating cells in log phase cultures.
(A) Theoretical graph of DNA content against number of
cells (a) shows two major peaks. The first peak contains
cells with the normal DNA content (G0/G1), the second
peak cells about to undergo division (G2/M), with the S
phase proportion of cells lying between the two peaks.
Actual DNA histogram from flow cytometric analysis of the
Ml cell line (b). The histogram shows the two major
peaks, and chicken red blood cells which are included as
a DNA content standard (approximately 35% of the DNA




(B) Bar chart of proliferative indices (S+G2/M) of parent
208F and 10 oncogene transfectants (mean + SEM),



















































































































































(ii) HPV AND ONCOGENE TRANSFECTANTS
There were similar proliferation index values for the
four cell lines H16 (34.7), H16R (31.9), H18 (42.9) and
H18R (34.7) (figure 3.18 and table 3.6) . The only-
significant difference was between H18 and H16R (p =
0.012, student's t-test on 8-9 experiments) (table 3.7B).
3. 5.1.3.C CELL DEATH BY APOPTOSIS
(i) ONCOGENE TRANSFECTANTS
The apoptotic indices (Al) were spread over a wide range
(table 3.6). M7 (41.52) and M8 (15.44) had very high
apoptotic indices, whereas T1 (0.77), and MT7 (0.62) had
very low values. The value for T2 (1.83) was lower than
that of the parent cell line 208F (2.62), and the
remaining cell lines had intermediate apoptotic indices:
Ml (4.57), T3 (8.44), MT 4 (4.10), MT 9 (5.95) and MT10
(2.30) (figure 3.20). The apoptotic index values were
log-transformed and both the linear and log data were
analysed using the ANOVA test, which indicated
significant variation between the cell lines in both
cases (p < 0.0001). AI values, both linear and log, for
individual pairs of cell lines were compared by the
student's t test which showed statistically significant
differences for most comparisons; in particular, M7 and
M8 were significantly higher, and T1 and T2 were
significantly lower than most of the other cell lines
(table 3.9).
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(ii) HPV AND ONCOGENE TRANSFECTANTS
The moderate levels of apoptotic index for the three
transfectants H16 (1.28), H18 (1.56) and H16R (1.22) were
similar, with no significant differences by the student's
t test. However, the very low value for H18R (0.74) was
similar to that for T1 (0.77), and was significantly
different from the value for H18 (p = 0.028, student's
t-test on 8-9 experiments) (figure 3.18, and tables 3.6
and 3.7).
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208F M1 M7 M8 T1 T2 T3 MT4 MT7 MT9 MT10
Cell Una
Figure 3.20
Bar chart of the mean apoptotic index ± SEM for the












































































































































































































































3.5.2 TUMOUR GROWTH IN IMMUNE SUPPRESSED MICE
All T24-ras containing transfectants formed tumours in
every mouse injected, whereas 2 out of 11 mice injected
with Ml, 1 out of 7 with M7, and 1 out of 7 with M8 (14%-
18%) failed to form primary tumours. The parent cells
(208F) formed indolent nodules in 10 out of 11 mice, and
these did not increase in size. Histological analysis
revealed that although some of the 208F cells mingled
with subcutaneous adipocytes, there was no evidence of
invasion of skin or muscle. There was a small amount of
208F cell turnover, in that low counts of mitotic and
apoptotic figures were seen within these nodules (see
below). Simple calculations, based on estimation of 208F
cell volume and the volume of the nodule, showed that
the numbers of 208F cells must have been of the same
order of magnitude at the end of the 12 day assay period,
as in the inoculum, confirming the non-progressive and
non-malignant nature of these nodules.
3.5.2.1 TUMOURS FORMED BY ONCOGENE TRANSFECTANTS
Sizes of the primary tumours formed by the 3 T24-ras
transfected cell lines T1 (2.2), T2 (2.24), and T3 (2.2)
were greater than the 3 cell lines transfected with the
c-myc oncogene Ml (0.37), M7 (0.51), and M8 (0.13), and
also the nodules formed by the parent cell line 208F









208F M1 M7 M8 T1 T2 T3 MT4 MT7 MT9 MT10
Cell Line
EH mitosis apoptosis S® necrosis 1H tumour size
Figure 3.21
Growth properties of tumours derived from the parent 208F
and 10 rat fibroblast cell lines transfected with c-myc
and/or T 2 4 -r a s . Mean tumour sizes (3 dimensions
multiplied together) are shown after 12 days growth in
immune suppressed mice injected with 107 cells. Oncogene
transfectants generated progressively enlarging invasive
malignant tumours, whereas 208F formed non-progressive,
indolent nodules. Mitosis and apoptosis within apparently
viable regions of tumours were scored as figures per 10
high power fields. Necrosis was assessed
semiquantitatively using an arbitrary scale. The T24-ras
containing cell lines formed the largest tumours, with
much necrosis, which displayed mostly high mitotic but
low apoptotic rates. In contrast, the c-myc transfectants
generated smaller tumours, with little necrosis, that


















































































































TUMOUR SIZE; RELATIVE COMPARISONS BY STUDENT'8 T TEST
208F 16 16R 18 18R
16 NS —
16R 0.0001 0.0037 —
18 0. 035 NS NS —
18R NS NS NS NS —
NOTES: p values quoted
NS = not significant
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For the cell lines transfected with both oncogenes,
however, MT4 (4.65) produced the largest tumours,
whereas MT7 (2.42), MT9 (1.02) and MT10 (1.42), produced
tumours of intermediate size, compared to the 3 ras
transfectants, although all were greater in size than the
3 myc transfectants and the parent cell line. The ANOVA
test demonstrated statistically significant variations
between these values (p<0.0001), and differences between
particular pairs of cell lines were revealed by the
student's t test (table 3.10A).
Higher amounts of tumour necrosis were observed in all
transfectants containing the ras oncogene (T1 31.7, T2
21.7, T3 14.2, MT4 9.2, MT7 40.0, MT9 12.5, and MT10
16.7) compared with those containing myc (Ml 1.7, M7
13.3, and M8 5.0) and the parent cell line (208F 0.0)
(figure 3.21). Statistical analysis was not applied as
these observations were based on subjective
semiquantitative assessment of regions of necrosis.
Comparison of the relative values for cell proliferation,
as measured by the mitotic count, showed that all
oncogene transfected cell lines had greater values than
the parent cell line 208F (1.03) (table 3.6 and figure
3.21) . Two of the three T2 4 -ra s transfectants had
greater mitotic counts (T1 18.2, T2 18.2) than the 3 c-
myc transfectants (Ml 3.4, M7 9.6, M8 1.95), and the
third (T3 6.35) was similar. Three of the double
oncogene transfectants containing both T24-ras and c-myc
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had intermediate values (MT 4 11.7, MT 9 12.2, MT10
16.1), and one (MT7 26.1) was comparable with the two
highest ras transfectants. ANOVA testing indicated
significant variation between these values (p<0.0001),
with significant differences between almost all
comparisons of pairs of cell lines were demonstrated by
the student's t test (table 3.11).
In contrast, a different pattern emerged when comparing
the measures of cell death by apoptosis, as determined by
the apoptotic counts. All transfected cell lines had
higher levels of apoptosis than the parent cell line 208F
(2.8). Overall, 2 out of 3 of the c-myc transfectants
had higher measures of apoptosis (Ml 7.3, M7 22.6, M8
12.9), compared with the 3 T24-ras transfectants (T1 3.9,
T2 11.6, T3 11.1). The double oncogene transfectants
containing both T24-ras and c-myc had similar values to
the ras only transfectants, with the exception of MT4
(derived from c-myc transfectant Ml) with an apoptotic
count of 40.3 (MT 7 4.1, MT9 3.6, MT10 10.9) (figure
3.21). There was significant variation between these
values by ANOVA testing (p<0.0001), with significant
differences revealed by the student's t test for most






































































































































































































































































































































































The raw data for mitotic counts and apoptotic counts were
combined to form ratios of mitosis/apoptosis and
apoptosis/mitosis (table 3.6). The ratios (M/A and A/M)
simplify the comparison of different tumour cell lines by
combining parameters for cell proliferation and cell
death by apoptosis in one index. It also adjusts for any
bias introduced according to differences in cell size:
morphological analysis of primary tumour growth shows
that cell lines containing the T24-ras oncogene formed
tumours with large cells of high cytological grade,
whereas those containing c-myc oncogene formed tumours
with smaller cells and lower cytological grade. High
power fields of different tumours were likely to contain
slightly different numbers of cells due to the difference
in cell size and cell density, and a combination of the
mitotic count divided by the apoptotic count (or vice
versa) cancels out any bias due to differences in cell
size between the different lines.
The means of the M/A ratios of the parent 208F and the
ten oncogene transfectants showed significant variation
on ANOVA testing (p<0.0001), with most of the paired
comparisons by the student's t test revealing significant
differences (table 3.13) . There was a striking
relationship between the mean M/A ratio and the mean
tumour size for the 3 c-myc transfectants when compared
with those values for the 3 T24-ras transfectants (figure
3.22) . The 3 c-myc transfectants had low values for M/A
ratio which were less than unity (Ml 0.50, M7 0.50, M8
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0.16) and also low values for tumour size (Ml 0.37, M7
0.51, M8 0.13), as did the parent 208F (M/A ratio 0.44;
tumour size 0.29), whereas the 3 T24-ras transfectants
had higher values for the M/A ratio (T1 5.3, T2 1.9, T3
0.7) and also formed larger tumours (T1 2.2, T2 2.2, T3
2.2). The mean M/A ratios correlated with the mean tumour
sizes with a value of r = 0.65 (for 208F, Ml, M7, M8, Tl,
T2 and T3) . The 4 double oncogene transfectants
containing both T24-ras and c-myc also showed both high
M/A ratios and produced large tumours, with the
exception of MT4 (derived from Ml) which had an M/A ratio
of 0.3 and a tumour size of 4.7 (M/A ratios: MT7 6.8, MT9
3.5, MT10 1.6; and tumour sizes: MT7 1.4, MT9 1.0, MT10
1.4). The A/M ratios were also calculated as they
represent the in vivo equivalent of the apoptotic index
in culture. A/M ratios for all 15 cell lines (parent
208F, 10 oncogene transfectants, and 4 HPV transfectants)
showed an inverse correlation with tumour sizes of





















































































































































































MITOSIS/APOPTOSIS AND TUMOUR SIZE
M/A Ratio
208F M1 M7 M8 T1 T2 T3 MT4 MT7 MT9 MT10
Cell Line
i Mitosis/Apoptosis Hi Tumour Size
Figure 3.22
Bar chart of the mean ratios of mitosis/apoptosis ± SEM,
compared with the mean tumour sizes ± SEM, for the parent
208F and 10 oncogene transfectants.
3.5.2.2 TUMOURS FORMED BY TRANSFECTANTS CONTAINING
PAPILLOMAVIRUS AND RAS GENES
The tumour growth parameters were compared for the 4
transfectants H16, H18, H16R and H18R (figure 3.23 and
table 3.6). All transfectants formed tumours which were
larger in size than the parent cell line 208F (0.29).
Tumours formed by H18 (1.05), were larger than those
formed by H16 (0.41), whereas H16R (0.99) were similar
in size to those formed by H18R (0.92) . Student's t
tests showed significant differences between 208F and
both H16R (p=0.0001) and H18 (P=0.035); and also between
HI6 and H16R (p=0.0037) (Table 3.10B).
All 4 transfectants formed tumours with similarly high
levels of necrosis: H16 26.7, H16R 28.3, H18 17.5 and
H18R 21.7 (figure 3.23). The values for tumour cell
proliferation, as determined by the mitotic counts, were
in a range from 12.8 to 17 for the 4 transfectants (H16
12.8, H16R 14.9, H18 16.7, H18R 17.0) (table 3.6 and
figure 3.23) . There was significant variation between
them detected by the ANOVA test (p=0.001). The student's
t test showed significant differences only between H16




208F H16 H16RAS H18 H18RAS
Cell Line
I mitosis I apoptosis Hi necrosis tumour size
Figure 3.23
Bar chart of growth properties of tumours derived from
the parent 208F and 4 HPV ± ras transfectants (H16, H16R,
H18, H18R). Tumour size, necrosis, mitosis and
apoptosis are shown. H16R generated larger tumours than
H16, but both showed high levels of necrosis. The
presence of ras along with HPV 16 suppressed the levels
of apoptosis whereas those of mitosis increased only
slightly. H18R and H18 showed similar tumour sizes and
levels of necrosis, but the presence of ras suppressed
tumour cell apoptosis, whereas the levels of mitosis were
almost identical.
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Measures of cell death by apoptosis, as determined by
apoptotic counts, varied between the 4 cell lines by
ANOVA testing (p<0.0001), with H16 having a higher value
(20.3) in comparison with the markedly smaller value for
H16R (6.2). Similarly tumours formed by H18 had higher
measures of apoptosis (11.5) than those formed by H18R
(3.1) (figure 3.23) . All paired comparisons by the
student's t test of the values for these four
transfectants were showed significant differences at
p<0.00001 (table 3.12) .
The measures of mitosis and apoptosis were combined to
form M/A and A/M ratios, which showed sigificant
variation on ANOVA testing (p<0.0001), with many
significant differences in paired comparisons by the
student's t test (tables 3.6 and 3.13) . These
differences were most marked between the transfectants
containing HPV alone, compared with those containing both
HPV and T24-ras. Tumours formed by H16 had significantly
lower M/A ratios (0.73), than those generated by H18
(1.50) (p=0.005). The trend for larger M/A ratios in
tumours formed by H16R (3.14), as compared with those of
H16 and H18 was not significant. In contrast, M/A ratios
in H18R tumours (5.77) were significantly larger than
those in H16 tumours (p=0.002) and H18 tumours
(p=0.004). M/A ratios were also compared to the sizes of
tumours generated by the HPV transfectants (figure 3.24).
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MITOSIS/APOPTOSIS AND TUMOUR SIZE
M/A Ratio
7




Bar chart of the ratios of mitotis/apoptosis ± SEM,
compared with the mean tumour sizes ± SEM, for HPV
transfectants. H18R has a markedly greater M/A ratio




3.6.1 CONSERVATION AND EXPRESSION OF TRANSFECTED GENES
The presence of transfected plasmid DNA within each of
the cell lines was confirmed by Southern blotting or
PCR. Transcription to RNA of c-mvc in M7 and M8, and
T24-ras in Tl, T2 and T3, was confirmed by a new assay
using reverse transcription followed by PCR, validated
by dot blotting for c-mvc. Oncogene expression in Ml and
Tl has been demonstrated previously (Spandidos, 1985;
Wyllie et al, 1987). The levels of expression are not
yet established, however northern blot or ELISA
analysis would allow relative quantitation. Molecular
and morphological data are mutually supportive, in that
transformation was observed immediately following
transfection.
3.6.2 CLUSTERING OF PHENOTYPIC PROPERTIES OF THE
TRANSFECTANTS
All cell lines differ from one another in some respects.
However, some are similar in certain characteristics,
and this raises questions about why such clustering of
phenotypic properties should occur. Clustering may
provide important insights into relationships between
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Transfectants were categorised into mild, moderate or
marked levels of expression of phenotypic properties
(tables 3.14 to 3.16), and these groups were considered
together (table 3.17) . Grouping of cell lines involved
some simplification of the data, in particular in the
definition of boundaries between categories. Where
possible, boundaries were positioned at naturally
occurring gaps in the numerical distribution of the
data. Despite this limitation, categorisation allowed
simpler visualisation of the clustering of phenotypic
properties amongst the 14 transfectants . Measures of
proliferation in culture revealed very similar levels
for all transfectants, and therefore these were not
inlcuded in analysis of phenotypic clustering.
Morphological categorisation (table 3.14) indicated one
group that contained the 3 mvc transfectants M8, M7 and
Ml, as well as MT4 (derived from Ml), and these often
formed tight fascicles of cells which were poorly
refractile and spindle-shaped to only a mild degree. The
second group showed moderate degrees of refractility
and spindle cell shape, and comprised H16, H18, T3, MT9,
and MT10. The third group displayed marked morphological
transformation, as judged by focus formation, spindle
cell shape and retractility, and included the ras
transfectants T1 and T2, the derivative of T1 (MT7), and
the HPV and ras cotransfectants H16R and H18R. Thus, mvc
and ras tend to polarise at opposite ends of the
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spectrum of morphological change.
The group of transfectants showing prominent fascicle
formation, that included M7 and M8, and to a lesser
extent Ml and MT4, often showed similar degrees of
expression of other phenotypic properties (tables 3.14 -
3.17). These c-myc containing lines had low levels of
net growth both in vitro (population expansion) and in
vivo (tumour size) . They showed high levels of apoptosis
in culture (apoptotic index) and in tumours, relative to
mitosis (M/A ratio). The effects of myc appeared to
dominate in the serial transfectant MT4, derived from
Ml. These data indicate that c-myc induced slow net
growth with high levels of tumour cell apoptosis.
The group of transfectants that displayed marked
refractility and focus formation, including the T24-ras
containing lines Tl, T2 and MT7, and to a lesser extent
H16R and H18R, also showed other similarities. They had
high levels of population expansion and tumour size, but
low apoptosis in culture and in tumours. T 2 4 -r a s
appeared to dominate in the MT7 serial transfectant,
derived from Tl. This pattern of clustering indicated
that T24-ras stimulated fast net growth with suppression
of tumour cell apoptosis.
The inclusion within this group of the combined HPV +
T24-ras transfectants, H18R more so than H16R, perhaps
reflects the dominance of the effects of ras over HPV
genes. H16 and H18, which contained HPV genomes alone,
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were mostly intermediate in phenotypic properties,
although H16 showed a higher value for tumour apoptosis
than H18. These findings suggested that HPV 16 may
stimulate tumour cell apoptosis to a greater extent than
HPV 18.
The serial transfectants containing both c-myc plus T24-
ras showed patterns of apoptosis and net growth, in
culture and in tumours, which broadly parallelled their
cell of origin. MT4 (derived from the c-myc transfectant
Ml) showing a high level of apoptosis, and MT7 (derived
from the T24-ras transfectant Tl) showing a low level of
apoptosis. The cotransfectants MT9 and MT10 showed
intermediate values for apoptosis and net growth.
There is sufficient phenotypic clustering of the cell
lines (table 3.17), with mvc and ras often polarised at
opposite ends of the spectra, to suggest that tumour
behaviour may depend critically on expression levels of
oncogenes. This would probably be best measured by
enzyme-linked immunosorbent assay (ELISA) of the protein
products in cells growing under different conditions: in



























3.6.3 APOPTOSIS IN VITRO AND IN VIVO
Cellular bodies released into the culture medium by
growing tumour cells were unequivocally shown to be
apoptotic, both by morphological observation and
demonstration of chromatin cleavage into
oligonucleosomes.
Tumour cell apoptosis was demonstrated to be independent
of cell proliferation both i_n vitro and i_n vivo . In
culture, 2 out of three T24-ras transfectants (T1 and
T2) had reduced apoptotic indices compared with
controls, and two out of three c-myc transfectants (M7
and M8) showed considerably increased apoptosis. The
rank order for the levels of apoptosis of these examples
of single oncogene transfectants was identical in
tumours. Scatter plot comparison of log apoptotic index
in culture with log A/M measured in tumours, shows a
strong correlation of r = 0.72 (figure 3.25). Thus,
apoptosis appears to be an intrinsic feature of cell
lines, rather than being solely determined by the
environment. This is consistent with genetic
regulation of tumour cell apoptosis, perhaps via priming
of cells for apoptosis (see chapter 4). However,
environmental factors may have additional effects on the
intrinsic rate of apoptosis, in particular by triggering
the process by either specific or non-specific stimuli.
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Figure 3.25
Scatter plot of log apoptotic index of transfectants
growing in culture versus log A/M ratio of tumours
formed in immune suppressed mice. Three sets of symbols
are used that correspond with the families of
transfectants with clustering of phenotypic properties,
discussed in section 3.2. The parent control, 208F, is
included in the myc transfectant family. There is a good
correlation between these two measures of apoptosis
(correlation coefficient r = 0.72). This suggests that
each cell line maintains an intrinsinc rate of apoptosis
either in culture or as a tumour.
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3.6.4 RELATIONSHIP OF POPULATION EXPANSION IN CULTURE
WITH CELL BIRTH AND CELL DEATH
Analysis of growth parameters in culture revealed that
proliferative indices of the 14 transfectants showed
almost no significant differences. However, variations
were observed in both the rates of cell population
expansion and the rates of apoptosis, using dynamic
measures of changes in cell or apoptotic body numbers
over time. Population expansion measures and apoptotic
indices showed a strong inverse correlation (r = - 0.84;
figure 3.26) for the ten oncogene transfectants,
excluding 208F. Similarly, the 4 cell lines containing
high risk HPVs with or without T24-ras, showed a strong
inverse correlation (r = - 0.87; figure 3.27) . There was
no other obvious means of exit from the proliferating
pool (such as necrosis or differentiation). Thus, the
rate of apoptosis appears to be the major regulator of






Graph of log apoptotic index versus population expansion
rate for the oncogene transfectants growing in culture.
The scatter plot shows a strong inverse correlation
(correlation coefficient r = - 0.84) for the 10 oncogene
transfectants . Two of the 3 single mvc transfectants,
M7 and M8, are seen at the top of the graph with high
apoptosis but low population expansion, whereas 2 of the
3 single ras transfectants, T1 and T2, and the T1
derivative, MT7, are seen at the bottom of the graph
with high population expansion and low apoptosis.
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Figure 3.27
Graph of apoptotic index versus population expansion
rate for the 4 HPV transfectants growing in culture.
The scatter plot shows a strong inverse of correlation
(correlation coefficient r = - 0.87). The 3 cell lines
Hi 6, H16R and H18 are clustered together with moderate
to high apoptosis and low population expansion, whereas
H18R shows low apoptosis and high population expansion.
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3.6.5 REGULATION OF APOPTOSIS BY ONCOGENES AND HPV
The effects of mvc and ras on apoptosis were shown
clearly in 2 out of 3 examples for each set of single
oncogene transfectants. C-myc was associated with
stimulation of apoptosis, and T24-ras with suppression
of apoptosis. The 2 exceptions were the T3 and Ml
transfectants. Preliminary immunocytochemica1
experiments to determine the levels of expression of the
p21ras protein have shown that Tl, and to a lesser
extent T2, contained high levels of ras product, whereas
T3 expressed the ras oncogene at lower levels, and these
data showed a strong inverse correlation with measures
of apoptosis in culture (N. Toft, personal
communication). Southern blotting showed a similar rank
order of cell lines in terms of approximate ras gene
copy number indicated by strength of hybridisation
signal (figure 3.8A). This suggests that the high rates
of apoptosis demonstrated by T3 may have occurred as a
result of expression of ras protein at a level too low
to effectively suppress apoptosis.
Tumours generated by the Ml transfectant showed higher
primary tumour take rates, and lower tumour apoptotic
counts in this study compared to those previously
recorded (Wyllie et al, 1987) . One explanation may be
that this cell line has undergone selection for growth
advantage over the four to five year period between its
construction by Spandidos and Wilkie (1984), and
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experimental analysis in this study. Given the
similarity of measures of cell proliferation in culture
shown by the different cell lines studied here, such
evolution of a faster growing Ml subclone may have
occurred by reduction of apoptosis.
A pattern of differential regulation of apoptosis was
also observed in the behaviour of transfectants
containing high risk HPV genomes. Those with HPV alone
had moderate to high levels of apoptosis in. vivo and in
vitro. During tumour growth HPV 16 was associated with
higher apoptosis and lower M/A ratios than HPV 18.
Cotransfectants containing both HPV and T24-ras were
associated with lower apoptosis in. vivo compared to
those containing HPV alone, presumably reflecting the
strong influence of ras in suppression of apoptosis.
This was particularly notable for HPV 18 plus ras, which
also displayed decreased apoptosis in vitro. Of the
two high risk HPV types, tumours containing HPV 18
showed less apoptosis than those containing HPV 16, with
or without activated ras . In summary, there is further
evidence that activated ras appeared to suppress
apoptosis, and both high risk HPVs appeared to stimulate
tumour cell apoptosis, HPV 16 more so than HPV 18,
though to a lesser extent than c-mvc.
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3.6.6 RELATIONSHIP OF NET TUMOUR GROWTH AND CELL
TURNOVER
There was an interesting relationship between tumour
size and cell turnover, calculated as a single index
using the mitosis/apoptosis ratio (figures 3.22 and
3.24). High M/A ratios were observed in large and
mode rate1y-sized tumours formed by the T2 4 -ra s
-containing transfectants Tl, T2, MT7, H16R and H18R,
whereas low M/A ratios were found in small tumours
generated by the 3 c-myc transfectants M8, M7 and Ml.
However, a poor correlation of r = - 0.18 for these two
parameters is shown in the scatter plot of tumour size
versus log A/M for all cell lines (figure 3.28). The
level of correlation increases to r = - 0.63 if the
outlier MT4 is excluded. Scatter plot comparison of the
population expansion data with tumour sizes for all cell
lines (figure 3.29), also shows a poor correlation of r
= 0.20 (increases to r = 0.66 if MT4 is omitted). Large
tumour size appears to relate more simply to presence of
T24-ras, as shown by the 5 cell lines (MT7, Tl, T2, T3
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Figure 3.28
Scatter plot of tumour size versus log A/M ratio for all
cell lines growing as tumours in immune-suppressed mice.
There appears to be a trend towards a loose inverse
correlation between size and cell turnover, with the
exception of MT4 which shows large size and high log A/M
ratios.
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Scatter plot of population expansion rate for
transfectants growing in culture versus tumour size in
immune suppressed mice. There is a trend towards a
loose correlation between these 2 measures of overall
growth, with the exception of MT4 which shows a very
high tumour size but only a low population expansion
rate.
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In tumours, both mitosis and necrosis showed variability
between transfectants, and hence affected net tumour
growth. The measure of cell turnover (A/M ratio)
reflects levels of apoptosis relative to those of
mitosis and cancels out any bias due to differences in
cell size and density. Thus, differing levels of
necrosis may account for the poor correlation of tumour
size with cell turnover as measured by the A/M ratio.
This indicates a more complex relationship of these
parameters affecting net growth in vivo, compared with
that in culture, due to other, possibly limiting/
factors such as angiogenesis (Denekamp and Hobson, 1982;
Tozer et al, 1990).
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3.6.7 TUMOUR NECROSIS
High levels of necrosis were seen mostly in
transfectants containing the T 2 4 -r a s oncogene that
formed moderate or large tumours (Tl, T2, MT7, H16R and
H18R). Necrosis appeared to be of minor importance in
transfectants containing the c-mvc oncogene (M8, M7, Ml
and its derivative MT4).
Scatter plot comparison of tumour necrosis with cell
turnover (log A/M) for all cell lines (figure 3.30)
shows a strong inverse correlation of r = - 0.76. This
may reflect a relationship of necrosis to mitosis that
relates to the traditional view of tumour necrosis
occurring as a result of rapid tumour growth
outstripping the provision of blood supply (Thomlinson
and Gray, 1955/ Jones and Caplejohn, 1983/ Tozer et al,
1 990) . Furthermore, the reduced capacity to undergo
apoptosis of ras transfectants may necessitate necrosis
as the only mode of cell deletion available for cells
subjected to an insufficient blood supply.
The overall tumour size, which reflects the balance of
mitosis, apoptosis and necrosis, correlates poorly with
tumour necrosis (figure 3.31) with a correlation
coefficient of r - 0.26 (increases to r = 0.65 if MT4 is
omitted). The MT4 transfectant (derived from Ml) differs
from the others in several respects, in that it showed
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Figure 3.30
Scatter plot of tumour necrosis versus log A/M ratio of
transfectants growing as tumours in immune suppressed
mice. There is a good inverse correlation between
necrotic cell death and this indirect measure of
apoptotic cell death relative to mitosis (correlation
coefficient r = - 0.76).
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The reasons for this are not apparent, and MT4 makes an
interesting subject for further investigation. One
possibility is that some combination of moderate mitosis
but low necrosis, resulted in fast net growth despite
high apoptosis.
Axes may be positioned, somewhat arbitrarily, on the
scatter plot of size versus necrosis (figure 3.31) that
divide the transfectants into 4 groups that relate
necrosis to the transfected gene and to morphology. The
3 c-myc transfectants Ml, M7 and M8, together with the
parent 208F (and to a lesser extent MT9) generated small
tumours with low necrosis. The 4 HPV containing lines
formed small tumours, but with high necrosis. Tl, T2 and
MT7, which contained T 2 4-r a s (and MT10 to a lesser
extent), produced large tumours with much necrosis. Only
MT4 and T3, which are exceptional in other regards,
formed different sized tumours with low necrosis.
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Figure 3.31
Scatter plot of tumour size versus tumour necrosis for
transfectants growing in immune suppressed mice.
Arbitrary axes have been superimposed on the scatter
plot, which divide the transfectants into 4 major
groups. Mvc transfectants and 208F form small tumours
with low necrosis. The 4 HPV transfectants form tumours
of low to moderate size with high necrosis. MT4 and to a
lesser extent T3 form large tumours with little
necrosis. The ras transfectants T1 and T2, together with
MT7 form large tumours with large amounts of necrosis.




1. Fibroblast tumour cell death in culture is by
apoptosis, characterised u1trastructura11y and by
chromatin cleavage.
2. The apoptotic rate of each tumour cell line appears
to be intrinsically determined. There is a strong
correlation between apoptosis in vitro and in vivo.
3. Apoptosis is a key determinant of net growth in
vitro. as it shows a strong inverse correlation with the
rate of population expansion. Variability in tumour
mitosis and necrosis ensure a more complex relationship
of apoptosis with tumour size.
4. C-myc stimulates tumour cell apoptosis, as do HPV
types 16 and 18, although to a lesser extent. In
contrast, activated c-Ha-rasl suppresses apoptosis,
either alone or in combination with other genes.
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4. FINAL DISCUSSION
4.1 Transition from CIN to Cervical Cancer
4.2 High Risk HPVs Influence Apoptosis
4.3 Regulation of Tumour Cell Apoptosis by Ras, Myc and
HPV E6 and E7 Genes
4.4 Two Classes of Event are Required for Apoptosis
4.5 Myc and Ras Control Cell Fate
This chapter will attempt to synthesise clinico-
pathological data about the influence of high risk HPVs
on neoplastic progression from CIN to cervical cancer
described in chapter 2, with the effects of HPVs on cell
proliferation and apoptosis set out in chapter 3. This
leads on to a discussion of the regulation of apoptosis
by ras and myc, including possible commonality of
mechanism of HPV E7 and myc, and suppression or
activation of priming and triggering for apoptosis. The
regulation of apoptosis is finally discussed within a
wider view of the control of cell fate, in terms of
transition between stable states of growth arrest, rapid
turnover, and population expansion.
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4.1 TRANSITION FROM CIN TO CERVICAL CANCER
The transition from precursor to malignancy and the
development of metastatic potential represent the two key
neoplastic changes that threaten the life of the patient.
In the cervix, the immediate precursors are high grade
CIN lesions (CIN 2/3), shown earlier in this thesis to
contain high risk HPV types 16 and 18 in 60% of cases.
Cancers contain these HPV types in 70% - 80% of cases.
These data indicate a greater tendency for HPV-associated
CIN lesions to progress to malignancy compared with non-
HPV containing precursor lesions. This suggests that HPVs
influence the transition.
An earlier discussion presented the view that a more
rapid transition from CIN to cancer appears to be
associated with HPV 18 relative to HPV 16. This was
based on the evidence of two - five fold greater
CANCER/CIN prevalence ratios for HPV 18 compared with HPV
16, depending on the groups of CIN or carcinoma lesions
compared. Many possible explanations may be suggested
for differences in relative aggression between these two
viral types (see below).
The rate of production of new CIN cells is one factor
that is likely to directly affect the probability of
further genetic change required for malignancy, such as
integration of the HPV genome, activation of cellular
oncogenes or loss of oncosuppressor genes. This thesis
has shown that the rate of generation of cells results
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from the balance of cell gain and cell loss. Different
levels of tumour cell apoptosis were observed for HPV 16
and 18.
4.2 HIGH RISK HPVs INFLUENCE APOPTOSIS
The two high risk HPV types were associated with
moderate to high levels of tumour cell apoptosis in vivo.
HPV 18 was associated with lower levels of tumour
apoptosis and A/M ratio than HPV 16. In combination with
r a s, the HPV 18 transfectant, H18R, showed faster
population expansion in culture than H16R.
Explanations for the differences between these two high
risk HPV types may be sought at the level of molecular
interactions of their protein products. The E7 protein of
HPV 18 binds Rb with a higher affinity than HPV 16 E7
(Phelps et al, 1988/ Munger et al, 1989b), and also has a
faster rate of casein kinase II phosphorylation than HPV
16 E7, both of which are more rapid than the rates for
low risk HPV E7 proteins (Barbosa et al, 1990).
The efficiency of transformation of 208F shown in this
thesis is greater for HPV 18 than for HPV 16, and this is
consistent with a five-fold more efficient rate of
immortalisation of human cervical keratinocytes by HPV 18
compared with HPV 16 (Barbosa and Schlegel, 1989) .
A further reason for some of these differences is that
compared with HPV 16, HPV 18 has a more efficient
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transcriptional regulatory region producing higher levels
of expression of the E6 and E7 genes. This was shown to
be a major determinant of their different immortalising
activities (Romanczuk et al, 1991) .
Phenotypic analysis of authentic human cervical cancers
containing these viral genomes shows greater aggression
for HPV 18 in terms of neoplastic progression from CIN to
cancer, cancer cell differentiation, and higher tumour
grade (Wilczynski et al, 1988/ Barnes et al, 1988/ Kurman
et al, 1988/ chapter 2 of this thesis).
In theory, it is possible to link reduced apoptosis with
a more rapid transition from CIN to cancer. If the lower
apoptosis and faster growth rate associated with HPV 18
in this fibroblast system, also occurred in cervical
keratinocytes in vivo, this would result in more rapid
production of CIN cells, which is likely to increase the
probability of further genetic changes required for
transition to malignancy. Furthermore, selection
pressures may be different, in that reduced apoptosis may
allow survival of genetically altered variants which
might otherwise die in a population of tumour cells more
prone to apoptosis. This raises the question of how viral
and cellular oncogenes regulate tumour cell apoptosis.
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4.3 REGULATION OF TUMOUR CELL APOPTOSIS BY RAS, MYC AND
HPV E6 AND E7 GENES
A. RAS
Suppression of tumour cell apoptosis by activated ras has
been shown in this thesis to produce faster population
expansion in culture and contribute towards larger tumour
size. Increased production of cells is likely to
influence the degree of aggression of neoplasms. A key
difference between ras and my c tumour behaviour
investigated by Wyllie et al ( 1 9 8 7 ), was the
aggressiveness of the tumours that they formed: the T24-
ras expressing cells produced a higher primary tumour
take rate, a higher proportion of test mice with
metastasis at 14 days, and a higher cytological grade of
fibrosarcoma, compared with c-mvc expressing cells.
Carcinogen-induced mutation of ras followed by loss of
the normal ras allele is associated with progression of
established squamous carcinomas to more aggressive
spindle cell cancers (Brown et al, 1986/ Buchmann et al,
1991). Activation of ras also occurs in premalignant
lesions, such as colorectal adenomas (Williams et al,
1990), and atypical hyperplasia of breast (Going et al,
1992). Faster population expansion of precursors in these
circumstances may be important in increasing the risk of
malignant transformation.
Ras-mediated inhibition of apoptosis is further supported
by two other findings. Ki-ras expression decreases in
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association with the onset of apoptosis in rat
chloroleukaemic cells (Rytomaa and Servomaa, 1987). The
ras oncogene has also been implicated in suppression of
cell death of mouse mast cells. An immortalised
interleukin-3 dependent mouse mast cell line (BB-3c) was
transfected with the human activated Ha-ras oncogene
under the transcriptional control of the mouse mammary
tumour virus long terminal repeat that contains a
steroid-responsive enhancer element (Andrejauskas and
Moroni, 1989). Steroid treatment produced expression of
ras p21 protein which was associated with progressive
growth of the transfectants in the absence of exogenous
interleukin-3. On withdrawal of steroid, p21 ras protein
expression decreased and this was associated with rapid
cell death. Expression of the Ha-ras oncogene induced
the cell line to produce autocrine interleukin-3 and
granulocyte macrophage colony stimulating factor,
suggesting a complex mechanism of growth control
implicating ras stimulation of autocrine growth factor
secretion and suppression of cell death. Interleukin-3
has also been shown to rescue other leukaemic cell lines
from apoptosis (Lotem et al, 1991).
The mechanism by which ras may inhibit apoptosis is
unknown, but one possibility is the prevention or
reversal of the priming stage for apoptosis (see below),
which may be an essential step prior to triggering of
apoptosis by specific or non-specific stimuli.
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The ras product is not the only oncoprotein implicated in
suppression of apoptosis. The bcl-2 gene product has also
been demonstrated to inhibit apoptosis. It was first
identified through gene mapping of the t (14;18)
chromosomal translocation of human follicular B-cell
lymphoma, which juxtaposes the bcl-2 gene on chromosome
18 with the immunogloblin heavy chain locus on chromosome
14. The be1-2-immunoglobulin fusion gene is markedly
deregulated resulting in inappropriately elevated levels
of bcl-2 RNA and protein (Cleary et al, 1 9 8 6 ) .
Follicular lymphoma is typically an indolent disease
comprising small resting B-cells, which frequently
develops into a high grade lymphoma.
Bcl-2 encodes proteins of 22-26 kDa (Haldar et al,
1 9 8 9 ) , that have been localised to the inner
mitochondrial membrane (Hockenbery et al, 1990).
Overexpression of bcl-2 has been shown to block apoptotic
cell death of a pro-B lymphocyte cell line (Hockenbery et
al, 1 9 90 ) . Moreover, deregulated bcl-2 extends the
survival of certain haematopoietic cell lines following
growth factor deprivation (Vaux et al, 1988/ Nunez et al,
1990). Transgenic mice bearing a be1-2-immunoglobulin
fusion minigene showed polyclonal expansion of resting
IgM-IgD B cells which display prolonged cell survival but
no increase in cell proliferation (McDonnell et al,
1989), and following a long latency there was progression
from polyclonal to monoclonal disease, in which half of
the tumours were immunoblastic high grade lymphomas with
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a rearranged c-myc gene, suggesting that prolonged B
cell life increased tumour incidence (McDonnell and
Korsmeyer, 1991) .
The bcl-2 protein was expressed in variety of cell
lineages in transgenic mice, including but not exclusive
to those with a high incidence of cancer in man, such as
skin, colon, breast, prostate and pancreas, raising the
possibility that be1-2-induced extended survival of such
cell types may contribute to their predisposition to
malignancy (Hockenber y et al, 1991) .
The effects on tumour cell apoptosis have also been
studied in Epstein-Barr virus containing tumours. EBV-
positive BL cell clones expressing only one virus latent
protein (EBNA-1) have been shown to be extremely
sensitive to apoptosis, whereas isogenic clones
expressing all 8 EBV latent proteins were considerably
more resistant to the induction of apoptosis, suggesting
enhancement of B cell survival by EBV-induced suppression
of apoptosis, and this may contribute to either B cell
infection or neoplasia (Gregory et al, 1991) . The latent
membrane protein LMP-1 mediates this suppression of
apoptosis in transfected human B cells, and is associated
with upregulation of bcl-2 (Henderson et al, 1991).
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B. MYC
In marked contrast to rescue from apoptosis induced by
ras or bcl-2 genes, c-myc increased tumour cell apoptosis
in vitro and in vivo. This correlated with low population
expansion rates and small tumour sizes. Experimental
modulation of c-myc activity has also been used to
demonstrate that myc stimulates apoptosis in Rat-1
fibroblasts transfected with a construct encoding a mvc-
oestrogen receptor (MYC-ER) fusion protein which only
shows myc activity in the presence of oestrogen (Eilers
et al, 1989; Evan et al, 1992) . This experimental system
showed that the degree of apoptosis was related to the
levels of myc protein in cells, and that constitutive myc
expression induced apoptosis in cells growth arrested by
various means including serum deprivation. The regions of
the myc protein required for apoptosis were studied using
a range of mutants, and these were the same as those
required for cotransformation, autosuppression and
inhibition of differentiation (Evan et al, 1992) .
Increased expression of c-mvc has been found during
apoptosis of rat prostate epithelium following castration
(Buttyan et al, 1 9 8 8) . Thus, myc is associated with
induction of apoptosis in mesenchymal and epithelial cell
types.
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C. HPV E6 AND E7 GENES
The c-myc oncogene is associated with high levels of
apoptosis, and high risk HPV genomes are associated with
moderate levels. It is possible that this similarity of
effect may be due to common mechanisms of action. HPV E7
transforming gene products (of high risk types 16 and 18)
have been demonstrated to bind the retinoblastoma protein
pl05 (Phelps et al, 1988/ Munger et al, 1989b and 1991) .
Functional inactivation of retinoblastoma gene products,
by binding with viral transforming proteins, has been
shown to lead to release of TGF-betal inhibition of c-myc
transcriptional activity within keratinocytes (Pietenpol
et al, 1990).
There is evidence of direct binding in vitro of c-myc
protein to Rb protein, through a common Rb "pocket". This
"pocket" also mediates Rb binding to the cellular
transcription factor E2F, several other cellular nuclear
proteins, and the DNA tumour virus oncoproteins SVLT,
AdElA, HPV 16 E7 and HPV 18 E7 (Wagner and Green, 1991).
The N terminal domain of c-myc protein contains the
binding site for Rb and competes directly with HPV E7
(Rustgi et al, 1991), whereas the DNA binding and protein
dimerisation motifs are situated in the C terminus of c-
mvc (Cole, 1991). Furthermore, the c-myc promotor
sequence contains many protein binding motifs including
E2F-binding sites (Chittenden et al, 1991), and this
promotor site is involved in Rb-mediated repression of c-
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mvc (Moses et al, 1990). The retinoblastoma protein can
also repress c-fos expression by an effect on its 5' cis-
acting promotor element ("Rb control element" or RCE,
which contains sequence similarities to the E2F binding
site) (Robbins et al, 1990).
Thus, HPV 16 and 18 E7 proteins inactivate Rb protein and
may release repression of c-f o s as well as c-my c
transcription, and release c-myc protein from Rb-myc
complexes. Both myc and f o s are associated with
stimulation of apoptosis as well as proliferation. C-fos
and c-myc (along with hsp 70) have increased expression
during apoptosis of rat prostate epithelium (Buttyan et
al, 1988) . It would be possible in future to investigate
the levels of expression of myc and fos proteins in the
HPV transfected cell lines.
Both c-fos and c-myc oncoproteins bind DNA and have been
implicated in regulating gene expression, but there are
few examples of direct effects on specific genes,
particularly for c-myc. C-myc forms dimers with max,
which bind the sequence CACGTG present in the plasminogen
activator inhibitor-1 promotor that is deregulated in
myc-immortalised fibroblasts (Cole, 1991). However, the
region of the c-myc protein involved in binding to the Rb
"pocket" is also a weak transcriptional activation domain
and contributes to transformation (Cole, 1991) .
The effects of the p53 tumour suppressor gene on tumour
cell apoptosis have been investigated using a temperature
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sensitive p53 mutant introduced into a murine myeloid
leukaemic cell line. The Val-135 mutant behaves like
other oncogenic p53 mutants at 37.5°C, but like wild-type
p53 at 32.5°C. No effects on myeloid differentiation were
observed, but wild-type p53 activity resulted in
induction of apoptosis, not found with mutant p53
activity (Yonish-Rouach et al, 1991) . The possibility
that wild-type p53 has similar effects on other cell
types has still to be studied. The actions of high risk
HPV 16 and 18 transforming E6 proteins include binding
cellular p53 protein (Werness et al, 1990), and producing
increased p53 protein degradation (Scheffner et al,
1991) . If wild-type p53 induces apoptosis in
keratinocytes and fibroblasts, then E6 would be expected
to counteract this, producing relative downregulation of
apoptosis.
HPV E7-mediated inactivation of Rb may induce
transactivation of both mvc and fos. and HPV E6 produces
degradation of wild-type p53. This combination of
activities is likely to have pleiotropic effects. These
may include effects on differentiation, proliferation and
apoptosis, although this is likely to depend on other
intracellular signalling activities, such as the presence
or absence of ras activation. Inactivation of Rb may also
release other cellular factors from complexes with Rb,
such as E2F, which subsequently alter gene expression
relevant to controlling cell turnover. The net effects on
apoptosis are likely to result from the summation of the
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predicted activities of E7 (stimulation of apoptosis
via Rb effects on myc and fos) and E6 (suppression of
apoptosis via p53), and this will be affected by the
comparative levels of expression of E7 and E6, and their
relative efficiencies in terms of protein function and
stability, both of which may differ between HPV types.
Overall, the moderate levels of tumour cell apoptosis
observed in this study are consistent with a combination
of positive and negative influences on tumour cell
apoptosis.
HPV genomes may also exert an influence on tumour cell
apoptosis by mechanisms independent of E7 and E6 effects.
Other HPV genes, present in the transfected plasmids, may
have effects that can not be excluded by these
experiments: HPV E2 and El-related gene products have
also been demonstrated to bind DNA and influence viral
gene expression, although there is little information
available about their effects upon cellular genes. BPV1
also has transforming properties, but E5 functions in
HPV 16 and 18 are unclear. Interestingly, few differences
have been shown between the El, E2 and E5 protein
functions of low and high risk HPV types. These sequences
can be deleted during viral genome integration, which is
a key early event in cervical neoplasia. Thus, their
effects on apoptosis, if any, in human cervical cancers
may not be as significant as those of E6 and E7.
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The dual binding of Rb and p53 is a common mechanism for
three classes of DNA tumour viruses: SV40, adenovirus,
and high risk HPVs. The Ela protein of adenovirus binds
Rb and has been reported to have a "cytotoxic" effect on
cells of unexplained mechanism (Whyte et al, 1988 ) .
Apoptosis was not investigated in this report. This
commonality of viral protein function emphasizes the
importance of the cellular targets, and suggests that
there is a common pathway for transformation of a variety
of cell types from several species. This provides some
support for extrapolation of data from rat fibroblasts
to human cervical cells.
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4.4 TWO CLASSES OF EVENT ARE REQUIRED FOR APOPTOSIS
Apoptosis depends upon the availability of certain key
proteins. These include the calcium-magnesium sensitive
endonuclease (Wyllie, 1980; Arends et al, 1990), and the
glutamyl transferases (Fesus et al, 1989). It is probable
that there are several more. Neither the endonuclease nor
the transglutaminases are normally present in every cell
in a tissue; they accumulate before apoptosis takes
place. Their coordinate expression is presumably
regulated by specific controller genes. In the paragraphs
to follow, a model is proposed, in which this coordinate
expression is referred to as priming for apoptosis
(figure 4.1).
Some tissues include a high proportion of primed cells
(eg thymus cortex) (Van Haelst, 1967a and 1967b), but in
most (eg liver) (Zajicek et al, 1985) they normally
represent a small minority. Only within the primed
subpopu1 ation can apoptosis occur. In these, the
initiation of apoptosis is the result of a distinct set
of events, referred to as triggering. Triggering
mechanisms include the controlled influx of calcium into
the cell, and cause activation of the endonuclease,
transglutaminases, and other putative effectors of
apoptosis. It is probable that triggered cells proceed
inevitably into apoptosis, but priming may be reversible.
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Figure 4.1
Two stage model for induction and activation of the
effectors of apoptosis. Cells become primed for
apoptosis, presumably in response to cell type-specific
signals, by expression of inactive precursor effector
proteins, such as the endonuclease (E), transglutaminases
(T), and other putative effectors (?). Effector
expression may be coordinately regulated by specific
controller genes. Apoptosis is initiated in primed cells,
through activation of effector molecules, by triggering
mechanisms. In thymocytes, these include the controlled
influx of calcium, without activation of protein kinase
C, and occur in response either to specific stimuli, such
as glucocorticoid or CD3 ligands, or to non-specific
stimuli, such as calcium ionophore, TCD-dioxin or low to
moderate doses of irradiation. Both endonuclease and
transglutaminase require calcium ions for activation.
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One of the actions of the activated ras oncogene, in this
scenario, may be to prevent or reverse the priming of
cells. Whereas, c-myc and high risk HPV E7 genes
(possibly via c-myc) may stimulate both priming, perhaps
by activating the putative controller genes.
This is supported by the presence of calcium-magnesium
sensitive endonuclease activity in viable c-myc
transfectants Ml, M7 and M8, but not in the parent 208F,
or T24-ras transfectant T1 cells. The serum sensitivity
of expression of the endonuclease in the transfectants T2
and T3 may reflect the levels of ras protein within the
cells following growth factor withdrawal. The level of
p21ras protein has been shown to decrease moderately in
T1 cells, and markedly in T2 and T3 cells (to
unmeasurable levels using a crude serial dilution
immunocytochemical method) when cultured in conditions of
serum deprivation, and this correlated inversely with an
increase in apoptosis (N. Toft, personal communication).
One of the interesting implications of this distinction
between priming and triggering, is that triggering
stimuli need not be as specific as those involved in
priming. Apoptosis may be triggered by activation of
specific surface receptors such as the T cell receptor
(see below), APO-1 or the very similar fas molecule
(Trauth et al, 1989/ Itoh et al, 1991), and also by mild
cellular injury capable of generating a temporary influx
of calcium ions. This could constitute a triggering
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stimulus to a primed cell, although it would have no such
effect on an unprimed one.
Two predictions follow: primed cells should be vulnerable
to apoptosis in response to a wide variety of minor
injury stimuli, and apoptosis of this sort should occur
exclusively in those regions of tissues in which primed
cells lie. In fact, there is evidence supporting both
these predictions. Thymocytes undergo apoptosis in
response to specific stimuli as diverse as
glucocorticoid or CD3 ligands, and to non-specific
stimuli such as low to moderate doses of ionising
radiation, TCD-dioxin or calcium ionophore (Van Haelst,
1967b; Umansky et al, 1981; Wyllie et al, 1984b; Yamada
and Ohyama, 1988; Smith et al, 1989; McConkey et al,
1988, 1989a and 1989b). The death is always in the thymus
cortex, not in the medulla (Van Haelst, 1967a).
Intestinal mucosal cells in the lower third of the crypt
(but not including the stem cells near the crypt base)
occasionally undergo apoptosis spontaneously (Searle et
al, 1975), and so are presumptively "primed". These are
also the main targets for death by apoptosis in response
to a diverse range of chemotherapeutic agents, ionising
radiation and zinc deprivation (Ijiri and Potten, 1983
and 1987; Elmes, 1977) .
Adrenal cortical epithelial cells of the innermost region
of the gland, the zona reticularis, are exclusively the
cells sensitive to apoptosis in response to ACTH
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withdrawal (Wyllie et al, 1973a and 1973b), and low doses
of the toxic carcinogen 7,12 DMBA (Currie et al, 1962).
The zona reticularis includes the oldest post-mitotic
cells in the adrenal cortex.
Spontaneous apoptosis is seen in late foetal and neonatal
kidney cells in the rapidly proliferating nephrogenic
zone in the outer renal cortex, but not in the zone of
slow cell turnover in the medulla. Greatly increased cell
deletion by apoptosis occurs in response to low to
moderate doses of irradiation and follows the same
spatial distribution (Gobe et al, 1988) .
When antibodies become available for the proteins
characteristic of primed cells, such as the endonuclease,
it should be possible to visualise their distribution
within tissues, and test these predictions more directly.
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4.5 MYC AND RAS CONTROL CELL FATE
Data from this thesis and from published studies on other
experimental systems may be combined in a hypothetical
model of genetic control of cell fate (figure 4.2). This
scheme proposes that certain critical gene products
regulate transit between states of growth arrest, rapid
turnover of cells (both high proliferation and
apoptosis), and population expansion. Gene products are
positioned at sites of key action, however this does not
exclude relevant effects at other sites. This scheme was
developed together with Dive and Wyllie (1992) from a
similar theme originally proposed to illustrate genetic
control of B cell maturation in germinal follicles in
lymph nodes with bcl-2 acting at the same site as ras.



















Hypothetical model that compounds data from a number of
different cell systems, to illustrate potential
regulation by certain genes of transit between stable
states of growth arrest, rapid turnover of cells (high
proliferation and high apoptosis), and population
expansion. Some genes may act at other points as well as
their key sites of action shown here. Other genes, not
shown, may also act at these transition control points.
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Cell transit between these states has been thoroughly
researched. Growth arrest can be induced in cells by
transfection with Rb (Huang et al, 1988). Growth arrest
after treatment with TGF-beta is mediated by activation
of Rb (Pietenpol et al, 1990/ Moses et al, 1991) . Exit
from growth arrest to a state of proliferation is
associated with activation of the immediate early
response genes, which include the transiently expressed
c-f o s and egr-1, and persistently expressed c-mvc
(Sukhatme et al, 1988/ Waters et al, 1990/ Waters et al,
1991). Conversion of temperature sensitive p53 protein
from mutated to wild type conformation induces
proliferating fibroblasts to enter a high apoptotic state
(Yonish-Rouach et al, 1991).
This thesis presents the association of c-myc with
induction of priming for apoptosis within a population
that is rapidly turning over. This is shown by expression
of nuclear calcium/magnesium sensitive endonuclease
activity that ladders chromatin, in a pattern
characteristic of apoptosis. Triggering of apoptosis in
these circumstances appears to be due to cell cycle block
in the presence of mvc activation. This is shown in rat
fibroblasts containing a MYC-ER fusion protein vector
that allows experimental manipulation of myc activity in
cells arrested by a variety of means, including serum
deprivation (Evan et al, 1992). Growth in very low serum
of myc transfectants studied in this thesis (M7 and M8),
also triggers high levels of apoptosis (E. Brown,
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personal communication). It is possible that myc may
have an independent role in triggering apoptosis, as
there is a higher rate of apoptotic death in these myc
transfectants, compared with the parent control, in the
presence of high serum, but this requires further
investigation. Experiments reported in this thesis
strongly suggest that activated ras mediates transit of
cells into the population expansion state by suppressing
or reversing priming for apoptosis.
The diagram emphasises the pivotal role of c-myc in
directing the rapid turnover state, which is the key
control point of the pathway. C-myc drives the two
coupled functions of proliferation and apoptosis.
Downregulation of myc is required for growth arrest or
differentiation (Evan et al, 1 9 92) . In contrast,
population expansion requires the active suppression of
apoptosis by a further signal, such as ras, which
overrides myc. In the HPV transfectants studied in this
thesis, E7 binding of Rb (possibly with consequent
indirect myc activation) may stimulate transit to the
rapid turnover state, and E6 mediated degradation of p53
may induce transit to the population expansion state, in
a manner analagous to the function of ras in this
pathway. In other cell systems bcl-2, the EBV gene LMP-1,
SV40 large T antigen (LT), and adenovirus Elb may also
act to directly suppress apoptosis or bind p53.
Similarly, SV40 LT and adenovirus Ela bind Rb, and are
predicted to stimulate transit to the rapid turnover
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state.
The ability of ras to override myc, may explain the
intermediate levels of apoptosis and population expansion
of the combined myc plus ras cotransfectants MT9 and
MT10. Precise rates of apoptosis may depend on the
relative levels of the two proteins. Introduction of myc
into an established ras transfectant (Tl) to produce MT7
made little difference to its phenotype. The only
exception was MT4, which was constructed by transfecting
ras into the established myc transfectant Ml. This would
be predicted to suppress apoptosis. However, MT4 may
express ras at a level too low to effectively reverse
priming for apoptosis, as MT4 shows many phenotypic
similarities to Ml, its immediate parent line, including
high apoptosis. These hypotheses could be tested by
measurement of oncoprotein levels by ELISA.
Thus, myc appears to be the central regulator of cell
fate, its downregulation influencing growth arrest and
differentiation, and its expression inducing
proliferation and apoptosis. However, the stimulus for




To rationalise clinical and experimental data on tumour
aggression, a small number of genes were selected for
investigation of their relationships with neoplastic
progression in the cervix and parameters of tumour
growth.
1. There is a more rapid transition from CIN to cancer
associated with HPV 18, indicated by higher CANCER/CIN
prevalence ratios, compared with HPV 16. This may be
partly explained by the lower levels of tumour cell
apoptosis of HPV 18 transfectants, compared with those of
HPV 16 transfectants. Lower apoptosis permits faster
population expansion, thus increasing the risk of
progression from precursor to malignancy.
2. Apoptosis appears to occur in two independent stages:
priming and triggering. The induction of the effector
proteins for apoptosis constitutes priming. The 3 myc
transfectants express at least one of these, the nuclear
calcium/magnesium sensitive endonuclease. In contrast,
the parent cell, and one ras transfectant do not show
this activity, whereas two other ras transfectants do so
in a manner dependent on serum concentration. Induction
of priming may explain the higher intrinsic rates of
apoptosis of myc transfectants.
351
3. Constitutive expression of c-myc appears to regulate
both proliferation and apoptosis, maintaining a stable
state of rapid turnover. The suppression of apoptosis by
activated ra s produces transition to a state of
population expansion. This contributes directly to
formation of larger tumours by ras transfectants, and
indirectly increases the risk of metastasis. HPV E6 and
E7 proteins may influence transition between different
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